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Alzheimer’s disease (AD) is a chronic disease marked by progressive loss of 
mental function resulting in perturbation of normal behaviour and an inability to 
perform daily tasks. It is estimated that the number of AD cases globally will triple by 
2050. The origin of beta-amyloid (Aβ), the key protein found in cerebral plaques 
associated with AD, has not been established, however the expression of amyloid 
precursor protein (APP) ubiquitously throughout the body suggests that Aβ could 
originate from the brain itself, or the periphery, or a combination of different 
locations.  
 
The aetiology of AD remains unclear due to uncertainty as to where the 
majority of plaque Aβ originates. Most research has been focussed on the brain as 
the primary source of Aβ (local production) as the blood-brain barrier (BBB) 
prevents the entry of most peripheral macromolecules and proteins (including Aβ) 
into the brain. However, brain samples from deceased AD patients show damage to 
cerebral blood vessels, increased haemodynamics and the presence of Aβ within 
the layers of cerebral vessels which is suggestive of possible contribution from 
peripheral organs.  
 
The increased incidence of AD is predominately related to the ageing 
population which may or may not have cardiovascular disease, diabetes, insulin 
resistance and obesity. The second most influential risk factor (after aging) for AD is 
the presence of an apolipoprotein (apo) E 4 allele. Approximately half of all AD 
sufferers have one or two apo E4 alleles and more than a quarter of all apo E4 
carriers have AD. Apolipoprotein E4 is also implicated in vascular disorders and the 
presence of such disorders as well as cardiovascular disease increases the 
likelihood of developing vascular dementia (vAD) and AD.  
 
Compared to the pre-agricultural period (or Paleolithic period), there has 
been substantial changes in the intake of high calorie foods, sugar, carbohydrate, 
protein, fat, cholesterol, fibre, dairy, antioxidants and micronutrients (Eaton et al. 
2010). The changes in diet being most widely observed in developed or westernised 




degenerative diseases such as obesity, cardiovascular disease and diabetes (Eaton 
et al. 2010). The prevalence of AD is also positively influenced by greater 
urbanisation and a growing shift toward western diet and lifestyle patterns. 
Furthermore diets high in total calories leading to obesity, IR and diabetes are also 
implicated in AD development and increased incidence of AD may be associated 
with programming of central hypothalamic energy metabolism.  
 
Epidemiological studies are consistent with the notion that AD is a disease of 
lipid metabolism and is significantly influenced by dietary fat type as well as the 
quantity consumed. Grant et al. (2014) found that the higher prevalence of AD in 
western countries compared to Asia and Africa correlated with increased caloric 
intake and increased intake of saturated and trans fatty acids. Some middle chain 
triglycerides however have been shown to have beneficial health effects in terms of 
CVD and diabetes which are risk factors for AD (St-Onge et al. 2008). Albanese et 
al. (2009) showed in middle and low-income countries (South America, China and 
India) that increased fish consumption was associated with a decreased risk of 
dementia and that dementia was associated with higher intake of meat. Fatty meat 
as opposed to lean meat is a term used to define cuts of meat which have greater 
fatty acid content. The distribution of fat in meat commodities includes (intradermal, 
interdermal or subdermal fats, and in muscle connective tissue and adipose tissue). 
Fat stored in adipose cells contains mostly triglycerides which contain fatty acids in 
particular, higher levels of saturated fatty acids (SFAs). The Honolulu-Asia Aging 
Study showed that Japanese men who migrated from Japan to Hawaii had a much 
greater risk of developing AD and similar research indicates a greater risk of AD 
amongst Japanese people living in America compared to those living in Japan. 
Increased intake of fatty meat and dairy products such as cream and butter that is 
high in SFAs can increase the risk of AD whilst a Mediterranean diet rich in olive oil 
that is monounsaturated fatty acid (MUFAs)-rich and fatty fish that is rich in omega 3 
(n-3) polyunsaturated fatty acids (PUFAs) can reduce AD risk. Consistent with 
epidemiological findings, animal models show increased SFA and CH consumption 
accelerates Aβ production whilst addition of oleic acid (MUFA) and fish oil (n-3 
PUFA) to diets reduces the rate of Aβ deposition into cerebral plaques. Cell studies 
also support these findings and provide additional insight into the intracellular 





Triglycerides (TGs) are the major type of lipid absorbed by the small 
intestinal epithelial cells called enterocytes. Within enterocytes, assembly of nascent 
chylomicrons (CMs) occurs from the addition of TGs, CH, CH esters and 
phospholipids to apo B48 within endoplasmic reticulum (ER) and Golgi apparatus. 
Nascent CMs are then transported via the Golgi apparatus to the basolateral 
membrane and secreted into mesenteric lymph where they enter the circulation via 
the subclavian vein. Hydrolysis by lipoprotein lipase (LPL) results in the formation of 
smaller TG-poor and CH and apo E rich CM remnants. These apo E-rich CM 
remnants participate in rapid clearance by the liver which is mediated by receptor-
specific processes (Hussain et al. 1996). 
 
There is evidence that AD and mild cognitive impairment (MCI) patients have 
greater concentration of Aβ in triglyceride-rich lipoproteins (TRLs) fraction including 
CM (Mamo et al. 2008). Several studies which measure plasma lipids in AD patients 
show a significant increase in apo B levels in fasting and non-fasting states and 
clinical studies show higher levels of apo B in AD patients compared to controls. 
One study showed in probable AD patients (determined by ICD 10 criteria) who had 
intake of breakfast (after 24 hour [h] fast) containing 20 g of dairy fat had 
significantly greater postprandial level of apo B48, a marker for CM. Levels of apo 
B48 was shown to increase by 400 % in probable AD subjects compared to age-
matched controls (Mamo et al. 2008). There is some evidence to suggest that 
metabolism of Aβ occurs parallel to the metabolism of intestinally derived CM 
(Mamo et al. 2008). Firstly, there is an increased secretion of soluble amyloid 
precursor protein (APP) following the ingestion of a fatty meal in healthy individuals; 
this is consistent with the possibility that dietary fats can influence APP processing, 
Aβ production and the postprandial Aβ response (Boyt et al. 1999). Secondly, 
secretion of CM has been shown to be principally enhanced by a fatty meal; there is 
a transient increase in plasma CM-TG levels which peaks 2-3 h after ingestion 
(Dubois et al. 1994). The relationship between Aβ metabolism and dietary fat and 
lipoprotein metabolism provides intriguing evidence that cerebral Aβ plaque could 
be wholly or in part derived from the small intestines.  
 
A fatty meal contains higher than normal recommended (NH&MRC 2006) 
dietary intake of less than 35 % total fat (kilojoules) and less than 10 % saturated fat 




kilojoules (to maintain weight), according to the guidelines, should consume less 
than 18.6 g total fat and less than 5.4 g saturated fat. For an average man’s 
recommended intake of 2500 kilojoules (to maintain weight), the intake of total fat 
should be kept within 23.3 g and for saturated fat less than 6.6 g.  
 
The Australian Bureau of Statistics (ABS) reported that 300,000 people were 
affected with AD in 2011, and global statistics showed that in 2010, 35 million 
people were affected. Based on current trends, the number of people living with AD 
will triple by 2050 (ABS 2008, ABS 2012). Urgency is required for the better 
understanding of AD disease mechanisms in order to prevent the development of 
AD and delay the disease progression in AD affected persons. Currently the origin 
of cerebral plaque Aβ is unclear however several key articles suggest plasma Aβ 
influx in sporadic AD could contribute to cerebral Aβ load. Therefore, the broad aim 
of this thesis is to elucidate if Aβ can be expressed in the small intestine and if Aβ 
associates with intestinal lipoproteins. If this is found, the objective to follow would 
be to determine if intestinal Aβ can be regulated by dietary fat types or influenced by 
absence of the apo E gene. We hypothesize that Aβ will be present in the 
enterocytes; at the site of protein synthesis and be associated with intestinal apo B. 
Consistent with the association of Aβ with lipids, we further speculate that apo E, 
which can regulate lipoprotein metabolism, may influence intestinal Aβ abundance. 
Lastly, compared to unsaturated fatty acids, saturated fat diet can contribute to 
development of AD via greater abundance of intestinal Aβ.  
 
Chapter 1 (literature review) provides a review of the current understanding 
surrounding pathological mechanisms, epidemiology and risk factors for AD and 
proposes possible avenues for future research. We hypothesize that the small 
intestine contributes significant Aβ to the plasma load; a process regulated by 
dietary fat intake. The small intestine may be the initial organ involved in Aβ 
production and be of interest in therapeutic interventions in relation to AD. Chapters 
2, 3, 4 and 5 are aimed at exploring this idea further.  
 
Chapter 2 (article 1) includes a study aimed to determine the presence of Aβ 
in the small intestine using wild-type mice fed either low or high SFA diets. Using 
immunohistochemistry (IHC) approach, this study was the first to locate in situ Aβ 




effects of dietary SFAs and suppressive effects of fasting on enterocytic Aβ-
lipoprotein homeostasis. Furthermore, Aβ expression was shown to occur in the 
perinuclear location of enterocytes; the location of protein synthesis and lipidation of 
apo B. Therefore, based on the results that are presented in chapter 2, it is 
conceivable that the homeostasis of enterocytic Aβ-lipoprotein is influenced by the 
availability of lipids from dietary sources. 
 
Individuals heterozygous or homozygous for apo E4 are more susceptible to 
developing AD by 17 % and 43 % respectively compared to apo E2 or apo E3- 
individuals. The role of apo E isoforms in AD has been extensively reviewed in the 
literature and the mechanisms of action can include decreased ability to bind Aβ, 
increased cleavage of APP, increased inflammation and oxidation and increased 
permeability of the blood-brain barrier (BBB) (Donahue and Johanson 2008, Fryer et 
al. 2005, Irizarry et al. 2004, Jofre-Monseny et al. 2008, LaDu et al. 1997, Mahley 
and Huang 1999, Poirier et al. 1993, Refolo and Fillit 2004). Notionally, compared to 
apo E2 and E3 individuals, apo E4 carriers exhibit altered metabolism of Aβ which 
increases the propensity for cerebral Aβ toxicity and formation of amyloid plaques. 
Isoforms of apo E can also be implicated in the transport of lipoproteins derived from 
the small intestine and liver, which have both been shown to produce Aβ under 
physiological conditions. Chapter 3 (article 2) discusses the role of apo E in 
enterocytic Aβ abundance. This study used C57BL6J apo E null (-/-) mice and wild 
type mice fed either low fat diet containing 4 % (w/w) fat or high fat and CH diet 
containing 20 % (w/w) fat (predominantly palmitic and stearic acid) and  2 % (w/w) 
CH for 12 weeks (w). Semi-quantitative IHC was used to quantify and compare the 
difference in Aβ abundance between groups. The study found high fat + CH feeding 
significantly increased enterocytic Aβ abundance in both apo E null mice and wild-
type mice. In addition, apo E null mice had increased villi height compared to wild-
type mice on a low fat diet whilst no effect on villi height was observed under high fat 
and CH feeding. The findings of this study indicate the presence of apo E can 
influence the absorption and availability of lipid substrate for maturation of 
lipoproteins and therefore may modulate enterocytic Aβ via indirect mechanisms.  
 
The current mechanisms of enterocytic Aβ association with postprandial 
lipoproteins are unclear. Previous observations (chapters 2 and 3) that show Aβ 




Aβ can interact with primordial lipoproteins during the lipidation of apo B during 
synthesis. Apolipoprotein B is an obligatory component of postprandial lipoproteins 
derived from the enterocytes. Research presented in chapter 4 (article 3) uses 3-D 
double immunofluorescence (IF) to investigate the co-association of Aβ with apo B 
within Golgi apparatus of enterocytes. Colocalization of Aβ with apo B was 
determined with Manders Overlap coefficient and Pearson’s coefficient was used to 
determine correlation of fluorescent intensities. A significant proportion of Aβ 
colocalized with intestinal apo B within the perinuclear location and lacteals. Under 
the influence of high fat diet, colocalization of Aβ with apo B was enhanced 
consistent with increases in both Aβ and apo B expressions. However, there was no 
observed relationship between relative abundance of Aβ and apo B with either low 
fat or high fat diets. The findings presented in this chapter support the notion that Aβ 
associates with apo B and becomes incorporated into postprandial lipoproteins 
within enterocytes, and that high fat feeding could exacerbate this process. 
 
It is unknown how the structural differences between fatty acid types affect 
pathological processes underlying the development of AD. Current evidence in 
transgenic animal models suggests that differences between fat types can affect 
rate and severity of amyloidosis in the brain by altering the rate of Aβ production and 
secretion from cells. For example, palmitic acid and stearic acid (both SFA’s) have 
been shown to increase proteolytic processing of APP leading to an increase Aβ 
production, whilst oleic acid (MUFA) and DHA/EPA (n-3 PUFA) reduce Aβ 
production from APP. Palmitic and stearic acids are two saturates that behave quite 
differently in vivo in many different ways, from digestion to various metabolic 
pathways. In fact most stearic acid is poorly absorbed and that which is absorbed is 
largely converted to oleic acid. Whether they give the same result in terms of AD is 
also debatable and requires greater investigation. Current literature does not 
address the effect of fatty acid type on enterocytic Aβ-lipoprotein abundance, which 
may be significant in AD and similar disorders. In the article presented in chapter 5, 
wild-type mice were fed high fat diets (20 % w/w) containing predominantly SFA, 
MUFA, PUFA or a low fat standard diet and small intestines were collected for 
immunofluorescence (IF) analysis of Aβ. Results showed diets high in fat increased 
enterocytic Aβ abundance and effects were not specific to fatty acid type. In 
summary, the findings presented in chapter 5 indicate SFA, MUFA and PUFA all 





Alzheimer’s disease patients exhibit cerebrovascular disturbances such as 
sequestration of Aβ within the blood vessels of the brain, proliferation of vascular 
cells and inflammation. Moreover, plasma-derived proteins are increasingly 
identified in AD brains. These observations are consistent with the notion of 
damaged BBB and underlying vascular pathology in AD. The role of dietary fatty 
acids (SFA, MUFA and PUFA) on BBB integrity was explored in article 4 (appendix 
B). Interestingly, high SFA feeding caused increased leakage of the BBB 
demonstrated by increased bi-directional transport of proteins such as S100B and 
apo B/Immunoglobulin (IgG) which are known to be exclusively present in the brain 
or blood respectively (Takechi et al. (2010b). Collectively, chronic high SFA feeding 
results in increased permeability of the BBB and increased sequestration of apo B 
with Aβ within the arterial walls of cerebral blood vessels (Takechi et al. (2010b). 
Coupled with previous findings, these results suggest that in the presence of 
damaged BBB, high SFA feeding increases production and cerebral influx of 
enterocytic Aβ-apo B-lipoprotein complex. Indeed, co-localization of apo B with 
cerebral amyloid plaques has been demonstrated in humans and transgenic mouse 
models of AD (Takechi et al. 2009) which strengthens the possibility of the role of 
peripheral transport of Aβ-apo B-lipoprotein complex in AD pathology.  
 
 Findings presented in the review article (Takechi et al. 2008) as well as in 
chapters 2 and 3 provide novel insight into the effects of dietary regulation of 
enterocytic Aβ and the role of lipid substrate availability in enterocytic Aβ-lipoprotein 
abundance and elucidate an intracellular association between Aβ abundance and 
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The post-mortem presence of cerebral amyloid plaques is diagnostic of AD. 
Beta-amyloid is the key protein in amyloid plaques and is regarded as the main 
pathological protein involved in initiation and pathological sequelae of AD. The 39-
43 amino-acid length Aβ protein is derived from enzymatic slicing of a large 
precursor molecule, APP. Production and secretion of Aβ into plasma has been 
shown to occur as a normal process in cell metabolism (Seubert et al. 1992). 
Amyloid plaques are produced chronically over time and the deposition of amyloid in 
plaques is considered a concentration dependent process (Barrow et al. 1992, 
Wisniewski et al. 1997). Chronic over-production of Aβ from APP results in 
exacerbated cerebral amyloidosis which can result in an early (< 65 years) and 
severe form of AD (early onset AD or familial AD). Although increased Aβ 
production has not yet been linked to the more common form of AD (late onset or 
sporadic AD), the prevailing theory in AD research suggest a likely involvement of 
Aβ metabolism (Haass and Selkoe 2007). 
 
The origin of Aβ found in cerebral amyloid plaque is unknown and current 
knowledge suggests that it could be derived from the brain or periphery or a 
combination of both. Empirical evidence shows that peripheral Aβ can cross the 
BBB and contribute to cerebral Aβ load. Although the degree of contribution is 
uncertain, precipitation and IF of amyloid plaques shows the presence of peripheral 
proteins in cerebral amyloid plaques. Several studies postulate that plasma proteins 
have a chaperone role in Aβ transport. In plasma, Aβ has a high tendency to bind to 
large hydrophobic molecules due to its amphiphilic properties. Kuo et al. (1999) 
identified that the majority (94 %) of Aβ binds to lipoproteins with high affinity and 
previous studies show that the binding of free Aβ in the brain is protective against 
deposition (Wisniewski and Sadowski 2008). Decreases in association of free Aβ 
with albumin in plasma can contribute to pathology (Yamamoto et al. 2014). In the 
brain, conversion of monomeric Aβ to an oligomeric form (more prone to 
aggregation) can be prevented by binding of Aβ to chaperone proteins (Goldgaber 




important and changes in diet or genetics could alter the chaperoning ability of 
lipoproteins for Aβ. Thus, changes in lipoprotein homeostasis can contribute to 
pathology of AD by binding to Aβ and thus limiting the deposition of Aβ into amyloid 
plaques. 
 
In addition, an association between lipid metabolism and AD was discovered 
when an isoform of apo E, E4 was implicated in a more than doubling of AD risk. 
Apolipoprotein E is found on low-density lipoprotein (LDL), high-density lipoprotein 
(HDL) and TG-rich CM and remnant lipoproteins. Apolipoprotein E has several roles 
in lipid metabolism but its primary role involves transport and clearance of TG and 
CH from CM remnants by interacting with LDL receptor, LDL-receptor related 
protein and apo E receptor. Individuals with apo E4 have an altered lipid profile 
including greater levels of LDL, CH and apo B and less apo E and TG compared to 
apo E3 and apo E2 containing individuals (Gregg et al. 1986). The increased risk of 
developing AD associated with apo E4 allele could be linked to the influence of apo 
E4 on plasma lipid profile.  
 
Moreover, an apo E4 paradox exists: increased intake of SFAs in apo E4 
individuals increases AD risk whilst low intake of SFAs in apo E4 individuals 
decreases AD risk (Petot and Friedland 2004). This study shows that the increased 
risk of developing AD that is associated with apo E4 can be modified by saturated 
fat intake. An accumulation of studies has established the significant role of dietary 
fats and Aβ metabolism in AD risk; however, the precise mechanisms remain 
elusive.  
 
A group of studies show that dietary fatty acid type can modulate the risk of 
AD (Barberger-Gateau et al. 2002, Eskelinen et al. 2008, Feart et al. 2009, Freund-
Levi et al. 2006, Jick et al. 2000, Kalmijn et al. 1997, Kivipelto et al. 2001, Kivipelto 
et al. 2002, Luchsinger et al. 2002, Scarmeas et al. 2007, Solfrizzi et al. 1999). 
Several epidemiological findings (Eskelinen et al. 2008, Kalmijn et al. 1997, Kivipelto 
et al. 2001, Kivipelto et al. 2002, Luchsinger et al. 2002, Morris et al. 2003, Wolozin 
et al. 2000) can increase the risk of developing AD and animal models show a diet 
high in SFAs can increase beta-amyloid production and exacerbate AD pathology 
(Ho et al. 2004, Refolo et al. 2000, Shie et al. 2002, Sparks et al. 1994). However, in 




the risk of developing AD (Feart et al. 2009, Scarmeas et al. 2007) which is thought 
to be linked to decreased production of Aβ (Amtul et al. 2010). Studies involving 
consumption of diets high in fish intake (Barberger-Gateau et al. 2002, Freund-Levi 
et al. 2006, Kalmijn et al. 1996) or low n-6/n-3 PUFA ratio have found such diets 
(Conquer et al. 2000, Gonzalez et al. 2010) to be associated with enhanced 
cognitive function and a lowered risk of AD development. The benefits of n-3 PUFA 
and low n-6/n-3 ration of PUFA in diet was also attributed to decreased production 
of Aβ (Arsenault et al. 2011, Julien et al. 2010, Lim et al. 2005, Oksman et al. 2006). 
This thesis addresses the possibility that dietary fats implicated in AD pathology 
could be a consequence of differential roles of fatty acids in regulating intestinal Aβ.  
 
The hypothesis of this thesis is derived from the host of studies that suggest 





The small intestine, a lipogenic organ can produce and secrete Aβ, the key 
protein implicated in AD. Secondly, that intestinal Aβ protein can be regulated by 
dietary fat, and if so, metabolism of intestinal Aβ is likely to be associated with 
intestinally derived lipoproteins.  
 
The intended hypothesis addresses the initial part of a broader concept that 
proposes the possible implications of intestinally and/or hepatically secreted Aβ-
lipoproteins in AD pathology; specifically, addressing disruption of the BBB and 
initiating an inflammatory cascade. Although the content of thesis does not provide 
empirical evidence that intestinal Aβ is a source of cerebral Aβ, causal links 
between intestinally derived Aβ and cerebral plaque load will be provided in the 












Objective 1:  To critically review and summarize literature and empirical 
evidence relating to links between dietary fats, lipid metabolism 
and AD. (Chapter 1) 
 
Objective 2: To determine whether or not Aβ is expressed in small intestinal 
enterocytes and if this expression can be modified by a high fat 
and CH diet. (Chapter 2)   
 Hypothesis: Aβ is found in the small intestinal epithelial cells 
(enterocytes) that produce postprandial lipoproteins. 
 
Objective 3: To determine if apo E deletion in the presence of high fat feeding 
would have an effect on intestinal Aβ in wild-type and apo E gene 
knockout mice. (Chapter 3) 
 Hypothesis: Apolipoprotein E can modulate enterocytic Aβ 
expression and this can be influenced by changes in dietary fat 
content.    
 
Objective 4:  To ascertain whether intestinal Aβ associates with apo B within 
the enterocytes of the small intestines. Secondly, to further 
determine if high fat feeding can modulate the degree of 
association between intestinal Aβ and apo B. (Chapter 4) 
 Hypothesis: High fat feeding will increase the association 
between Aβ and apolipoprotein B in enterocytes. 
 
Objective 5: To investigate if fatty acid types (saturated fat, monounsaturated 
fat or polyunsaturated fat) can differentially regulate intestinal Aβ 
expression and plasma abundance of apo B and Aβ. (Chapter 5) 
Hypothesis: Dietary saturated fat will increase enterocytic Aβ, whilst 










Chapter 1 –  Literature review  
 
This chapter provides a comprehensive review of past and current literature 
regarding the aetiology of AD in relation to the metabolism of lipid and dietary fatty 
acids. The review contains a collection of key publications which are considered to 
be “high-impact” in the area and provide a basis for my hypothesis and objectives.   
 
Objectives addressed: 
Objective 1:  To critically review and summarize literature and 
empirical evidence relating to links between dietary fats, 
lipid metabolism and AD. 
 
Chapter 2 –  Determining enterocytic Aβ expression  
 
The content of this chapter is covered by article 1:  
 
Galloway S, Jian L, Johnsen RD, Chew S, Mamo JCL. (2007) B-amyloid or its 
precursor protein is found in epithelial cells of the small intestine and is stimulated 
by high fat feeding. J Nutr Biochem. 18, 279-284. 
 
Objectives addressed:  
Objective 2:  To determine whether or not Aβ is expressed in small 
intestinal enterocytes and if this expression can be 
modified by a high fat and CH diet. 
 
Chapter 3 – Effect of apo E knockout on enterocytic beta-amyloid expression 
 
The content of this chapter is covered by article 2:  
 
Galloway S, Pallebage-Gamarallage MM, Takechi R, Jian L, Johnsen RD, Dhaliwal 
SS, Mamo JC. (2008) Synergistic effects of high fat feeding and apolipoprotein E 





Objectives addressed:  
Objective 3:   To determine if apo E deletion in the presence of high fat 
feeding would have an effect on intestinal Aβ in wild-
type and apo E gene knockout mice. 
 
Chapter 4 – Colocalization of enterocytic beta-amyloid with apolipoprotein B 
 
The content of this chapter will be covered by article 3: 
 
Galloway S, Takechi R, Pallebage-Gamarallage MM, Dhaliwal SS, Mamo JC. (2009) 
Amyloid-beta colocalizes with apolipoprotein B in absorptive cells of the small 
intestine. Lipids Health Dis. 8, 46. 
 
Objectives addressed:  
Objective 4:    To ascertain whether intestinal Aβ associates with apo B 
within the enterocytes of the small intestines. Secondly, 
to further determine if high fat feeding can modulate the 
degree of association between intestinal Aβ and apo B. 
 
Chapter 5 –  Effect of differential fatty acids on enterocytic beta-amyloid 
abundance 
 
Objectives addressed:  
Objective 5:   To investigate if fatty acid types (saturated fat, 
monounsaturated fat or polyunsaturated fat) can differentially regulate 
intestinal Aβ expression and plasma abundance of apo B and Aβ. 
 
Chapter 6 – General discussion 
 
The discussion chapter includes several co-authored articles, which 
discusses the implication of findings, as well as limitation and future direction. In 
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Chapter 1: LITERATURE REVIEW 
 
This chapter provides a detailed review of past and current literature 
regarding the aetiology of AD in relation to dietary fats and outlines the potential 
underlining mechanisms and the possible role that the small intestine plays in the 
regulation of intestinal lipoprotein absorption and secretion. The literature review 
references a collection of key publications which are considered “high-impact” in the 
area of AD research and a significant number of these have provided a foundation 
for the development our hypothesis and objectives 
 
My own assimilation of current knowledge contained in the literature leads 
me to believe that AD can be prevented, even amongst those in the population most 
at risk and that diet is the primary modifiable risk factor in relation to AD risk. 
Although ageing and the presence of the apo E 4 isoform are regarded as the two 
most significant risk factors in AD development, an accumulation of epidemiological, 
animal and cell studies show that ingestion of dietary fats strongly influences AD risk 
and that SFAs in particular can facilitate increased production and transport of Aβ 
leading to increased cerebral load. The mechanisms underlying dietary fat influence 
on AD risk have been thoroughly explored but remain unclear. 
 
 
1.1 Overview of Alzheimer’s disease  
 
1.1.1 Global prevalence of Alzheimer’s disease 
 
Dementia is a general term describing impairment in cognitive function and 
can be a consequence of a range of neurodegenerative disorders. Dementia is a 
disabling illness affecting a person’s ability to function normally on a day-to-day 
basis. On a global scale, dementia is the primary cause for disability in the elderly, 
contributing to 13.2 % of the total burden of disease compared with ischaemic heart 
disease at 14.1 %, lung disease at 12.5 %, glaucoma at 9.4 %, cerebrovascular 
disease at 7.1 % and rheumatoid arthritis at 4.7 % (World Health Organization 
2008). More than half of all dementia cases are clinically diagnosed as AD. The 




are currently living with AD globally and the number of people affected by AD is 
expected to triple by 2050. The most influential factor in the risk of developing 
sporadic or late onset (> 65 years) AD is aging and the prevalence of dementia is 
largely influenced by age.  
 
1.1.2 Dementia and Alzheimer’s disease in Australia 
 
In Australia, in 2011 there were 298,000 people living with dementia. 
Approximately 1 % of the Australian population, 9 % of persons over 65 years of age 
and 30 % of persons over 85 years of age had dementia. The majority were women 
(62 %), aged more than 75 years and lived in the community (70 %) as opposed to 
aged care facilities. Based on current trends, the Australian Bureau of Statistics 
(ABS) estimates, the number of people living with dementia in Australia in 2050 will 
triple to 900,000 (ABS 2008, ABS 2012). In 2010, dementia was the third leading 
cause of death in Australia after ischaemic heart disease and cerebrovascular 
disease, accounting for 6 % of all deaths and the number of deaths caused by AD 
was shown to have increased from 3,740 to 9,003 from 2001 to 2010 respectively. 
This represents a 200 % increase in the reported incidence of AD within a decade 
(Australian Institute of Health and Welfare 2012). 
 
In terms of costs to the Australian health care system, approximately 
552,000 general practitioner visits were related to dementia care in 2010-2011. In 
the previous year, dementia was diagnosed at a rate of 1 per 100 (or 83,226) 
hospitalisations with 392,796 dementia specific government funded prescriptions 
being made. In the same year, $4.9 billion was spent on dementia related health 
and aged care systems which included about $2 billion directly on dementia; $1.1 
billion in residential care facilities and $408 million for aged care services in the 
community (Australian Institute of Health and Welfare 2012).  
 
1.1.3 Alzheimer’s disease symptoms 
 
Alzheimer’s disease is a chronic and sinister disease characterised by 
gradual and progressive loss of cognitive function resulting in behavioral 




abilities. The disease, in most instances, results in accelerated death of the affected 
person.  
 
Alzheimer’s disease was originally described in 1906 by German physician 
Alois Alzheimer who was treating a 57-year old woman displaying a number of 
unusual cognitive and psychological abnormalities. Below are three short excerpts 
(translation with commentary) from Alzheimer’s report of the first patient diagnosed 
with AD -  
 
“[Auguste] was described as being jealous towards her husband and having  
‘reduced comprehension and memory, as well as aphasia, disorientation, 
unpredictable behaviour, paranoia, auditory hallucinations, and pronounced 
psychosocial impairment’ (Maurer et al. 1997) and “general loss in intelligence” 
(Strassnig and Ganguli 2005); 
 
“Although this was true, Auguste was physically functioning: ‘The gait is 
undisturbed; she uses her hands both equally well. The patellar reflexes are 
present. The pupils react. Slightly rigid radial arteries, no enlargement of cardiac 
dullness, no protein” (Strassnig and Ganguli 2005); and 
  
Deterioration of her condition as described by Alzheimer - “The patient was 
eventually completely dull; lying in bed with legs pulled up; had let go under her and 
developed decubitus despite all care.” (Strassnig and Ganguli 2005). Auguste D was 
admitted to hospital on November 25 1901 and died on April 8 in 1905.  
 
Episodic memory associated with the hippocampus and entorhinal cortex 
areas is normally the first cognitive skill to become affected in AD. The loss of 
episodic memory in AD could be due to improper consolidation or storage of new 
information, thus making learning of new information difficult (Chen et al. 2001, 
Lange et al. 2002, Small et al. 2000). The inability to “think”, for example: problem 
solving, working memory (focus and attention), concept formation and cue-directed 
behaviour also occur early in the disease process (Chen et al. 2001, Perry and 





It is important to note that decline in mental function is a normal physiological 
phenomenon in aging and is common amongst the elderly, but more rapid and 
severe rates of decline are evident in MCI and AD. There is currently no definitive 
diagnosis for AD apart from the post-mortem examination of the brain and 
confirmation of the presence of amyloid plaque, neurofibrillary tangles (NFTs) and 
other cerebral changes associated with cognitive impairment. 
 
Mini-mental state examination is a standard questionnaire for determining 
dementia however it does not differentiate dementia types. Mild cognitive 
impairment can predict the later development of AD however currently the early 
diagnostic markers for AD are lacking. Alzheimer’s disease is thought to be 
irreversible after a certain point in the disease thus early diagnosis of AD is critical in 
developing appropriate medical interventions and slowing the disease progression. 
Currently, markers and cognitive assessments to aid in the characterisation of a pre-
clinical phase of AD are being investigated with the aim of developing a screening 
tool for cognitively normal patients for the later development of AD (Lazarczyk et al. 
2012).  
 
The current enigma surrounding AD pathogenesis contributes to a lack of 
effective strategies for management and cure of AD. There is currently no cure for 
AD except for compensatory treatment with cholinesterase inhibitors and N-methyl-
D-aspartate receptor antagonists for synapse loss prevalent in AD and for 
symptomatic treatment with antipsychotics, antidepressants and anticonvulsants. 
Clinical trials of these treatments have shown mild to no improvement in cognition 
with little evidence of further efficacy past 12 months treatment duration. Proposed 
agents which can alter the course of the disease progression have been trialed but 
are currently inconclusive and some awaiting third phase results (Ballard et al. 
2011).  
 
1.1.4 Overview of Alzheimer’s disease pathology  
 
Hallmark AD pathology is characterised by post-mortem findings of amyloid 
or "senile" plaques, NFTs (figure 1), and accompanying microvascular changes 
(Mattson 2004). These pathological characteristics or ‘changes’ were first described 




examination observed brain atrophy, peculiar "stainable" lesions that were 
"refractory to dyes" (congophilic amyloid plaques) and Bielschofsky silver-positive 
neurofibrils. 
 
Alzheimer also noted atherosclerotic changes in the patient’s blood vessels 
and Strassnig and Ganguli (2005) described the vessel changes as "signs of excess 
proliferation in the endothelium here and there; also a neovascularization.", 
However, others report no significant signs of atherosclerosis in AD but "some 





Figure 1. Depiction of brain from individual without Alzheimer’s and individual with 
Alzheimer’s showing the abnormal presence of neurofibrillary tangles and amyloid 
plaques.  
 
Source: The medical illustration is provided courtesy of Alzheimer’s Disease 
Research, a BrightFocus Foundation program. 




1.1.4.1 Amyloid (senile) plaques  
 
Amyloid plaques are amorphous, insoluble and congophilic and contain an 
abundance of Aβ and other proteins. Amyloid plaques are 50-100 µm in diameter 
and are found surrounded by activated microglia, reactive astrocytes, and dystrophic 
axons and dendrites (Barnham et al. 2003). Two forms of amyloid plaques are 
characterised: diffuse plaques or semi-soluble oligomers which are the result of 
deposition of soluble Aβ onto extracellular brain matrices (Harper and Lansbury 
1997, Teplow 1998); and mature insoluble plaques which are thought to evolve from 
diffuse plaques (Blessed et al. 1968, Perry et al. 1978) and are considered the 
hallmark late-stage pathological indication of AD. The conditions under which 
conversion of diffuse plaques to mature plaques occurs is currently not well 
understood; however, an increase in soluble Aβ has been shown to result in 
concentration dependent deposition into the brain (Esler et al. 1996). 
 
Attachment and addition of soluble Aβ to the brain matrices forms insoluble 
fibrils and is considered to be a concentration dependent process (Nichols et al. 
2002). Morphologically, diffuse plaques contain less Aβ and appear as “partially 
amorphous pre-amyloid fibrils”, whereas the amyloid rich mature plaques have 
many thick bundles of apparent “amyloid fibrils” (Ikeda et al. 1990).  
 
Brain inflammation as evidenced by the presence of activated microglia, 
increased cytokines and acute phase and complement proteins has been found to 
be associated with amyloid plaque development (Akiyama et al. 2000) and the 
presence of amyloid plaques in the cortex and hippocampus areas responsible for 
memory and learning indicates that amyloid plaques are associated with 
neurodegeneration. Although diffuse plaques do not appear to trigger inflammation 
nor have they been associated with dystrophic neuritis compared to mature plaques 
which have been associated with a variety of inflammatory components and 
damaged neurons and neurites. Diffuse plaques are found in brains of cognitively 
intact individuals of varying ages and therefore are not considered a central 






Despite the pathological significance of Aβ, increased quantities of diffuse 
and mature plaques have not been shown to correlate with increased levels of 
cognitive decline (Lue et al. 1999); however, a correlation has been established 
between elevated levels of soluble Aβ in brain and cognitive decline (Naslund et al. 
2000). Levels of soluble Aβ versus insoluble Aβ distinguish AD from normal and 
pathological aging (Wang et al. 1999). Cognitive decline in AD may therefore 
function as a consequence of other pathological events other than from plaque 
number, at least in early disease process.  
 
Presentation of cerebral amyloid plaques may otherwise indicate that soluble 
Aβ concentration in the brain is higher than an amount that is metabolically 
sustainable. This idea is therefore controversial to the previous notion that mature 
plaques were pathogenic. Treusch et al. (2009) proposed another explanation and 
suggested that mature amyloid plaques may act as a “sink” for soluble Aβ and thus 
presence may indicate the extent of exposure to the brain rather than measure of 
neurodegeneration. Although insoluble Aβ plaques can confer protection via the 
proposed “sink” mechanism, exacerbated deposition of Aβ into diffuse plaques 
causes conversion of soluble oligomeric Aβ into insoluble amyloid fibrils which have 
been shown to initiate inflammation and therefore contribute to pathology via a 
separate pathway. It is reasonable to assume that the balance between cerebral 
soluble Aβ oligomers and Aβ in plaques is important in maintaining neuronal cells 
and synaptic function. Chronic over-exposure of the brain to soluble oligomeric Aβ is 
also likely to be realized as an increase in amyloid plaque burden.  
 
Changes in Aβ concentration in the brain may be caused by alternation of 
the balance between production, influx, efflux and degradation of Aβ. Therefore, 
elucidating possible mechanisms underlying Aβ metabolism in the context of 
oligomeric and plaque formation metabolism is potentially important for considering 
therapeutic targets and preventative interventions. 
 
1.1.4.2 Neurofibrillary tangles  
 
Neurofibrillary tangles are intraneuronal bundles of paired helical filaments 
caused by the hyper-phosphorylation of tau protein (Alonso et al. 1996). This 




damage and cell death (Arendt et al. 1998). Neurofibrillary tangles can also be 
triggered by Aβ via hyperphosphorylation of microtubular associated protein 
(Busciglio et al. 1995). Neurofibrillary tangles and cerebral inflammation occur in 
other neurological disorders and appear to be consequential and responsive to Aβ 
deposition in the brain and the maturation of amyloid plaques. Studies demonstrate 
that Aβ deposits in the brain early in the disease process and before the 
appearance of NFTs (Iwatsubo et al. 1994, Lippa et al. 1998, Rapoport et al. 2002, 
Younkin 1995), and NFT’s are thought to be triggered by Aβ (Hardy et al. 1998).  
 
 
1.2 Beta-amyloid protein in Alzheimer’s disease  
 
1.2.1 Overview  
 
Since Alois Alzheimer’s original observations, the understanding of the 
morphological and chemical processes involved in AD neuropathology has evolved 
considerably. In 1983, Aβ protein was identified as the main component of amyloid 
brain plaques and research has since determined Aβ protein as the main protein 
involved in AD pathology (Allsop et al. 1983, Glenner and Wong 1984, Haass and 
Selkoe 2007, Klein 2002, Masters et al. 1985, Salminen et al. 2009, Tanzi and 
Bertram 2005, Walsh and Selkoe 2007). Samples of AD affected brains show the 
widespread presence of Aβ in areas including in the cerebral cortex and the 
hippocampus as well as the cerebellum, brainstem, basal ganglia, amygdala and to 
a lesser extent, the diencephalon (Schmidt et al. 1994). 
 
The current dominating hypothesis regarding AD pathology is known as the 
‘amyloid cascade hypothesis’ and supports the key role of Aβ in AD (figure 2). The 
hypothesis postulates that an imbalance in the normal metabolism of Aβ causes 
increased cerebral amyloidosis triggering a number of cellular events that lead to 
cell stress, dysfunction or loss and subsequent cognitive decline (Selkoe 2001). 
Consistent in current literature is the idea that Aβ deposition occurs early on in the 
disease process, possibly decades before onset of symptoms. Therefore, 







Figure 2. According to The Amyloid Cascade Hypothesis, the sequence of events 
leading to Alzheimer’s disease is initiated by Aβ protein.  
 
Source: Adapted from Box 2, Haass and Selkoe 2007 (License number: 
3463090338026). 
 
1.2.2 Toxicity of soluble beta-amyloid 
 
In support of the possibility that soluble Aβ is neurotoxic, animal models 
show that soluble amyloid oligomers are toxic to synapses and directly cause losses 
in long-term potentiation in rodent hippocampus (Shankar et al. 2008). 
Oligomerization of Aβ into dimmers, trimers (Walsh et al. 2002), photofibrils (Harper 
et al. 1999) or insoluble fibrils (Lorenzo and Yankner 1994, Pike et al. 1993) can 
mediate the toxicity of Aβ. Oligomeric Aβ and not monomeric forms of Aβ have been 




show toxic effects of Aβ on long-term potentiation by causing endocytosis of NMDA 
receptors of postsynaptic membranes (Snyder et al. 2005).  
 
In addition, Aβ can also disrupt calcium homeostasis by causing an increase 
in influx and release from intracellular compartments (Demuro et al. 2005) causing 
intracellular damage of endoplasmic reticulum, synapse and calcium-related 
proteins. Extracellular Aβ deposits have shown to activate microglia via binding to 
scavenger receptors such as advanced glycation end products (RAGE). Formation 
of oligomeric Aβ, in particular the longer and more hydrophobic Aβ42, has been 
shown to nucleate and bind to extracellular matrices of the brain including heparin 
sulphate proteoglycans. In addition, mature amyloid plaques can activate 
complement pathway via binding to complement proteins (Eikelenboom et al. 2006) 
supporting the role of Aβ in initiating an inflammatory response.  
 
1.2.3 Origin of beta-amyloid 
 
Beta-amyloid peptide of 37-43 amino acids lengths are derived from 
proteolytic processing of 100-140 kDa APP (Kang et al. 1987). Amyloid precursor 
protein is a type-1 transmembrane protein that is embedded within the cell 
membrane with N-terminal tails protruding into the lumen and C-terminal within the 
cytosol (Kang et al. 1987). Amyloid precursor protein cleavage by α- or β-secretases 
and subsequently, γ-secretase (Sherrington et al. 1995, Sinha et al. 1999) produces 
soluble APPα and soluble APPβ respectively. Cleavage of APPβ by γ-secretase 
complex (containing presenilins) yields soluble oligomeric Aβ whereas cleavage of 
APPα produces a by product known as p3 and the latter pathway prevents Aβ 
production (figure 3). These are respectively designated amyloidogenic and non-
amyloidogenic pathways. Soluble Aβ forms are present at very low, but detectable 
levels in a normal brain (Tabaton et al. 1994). 
 
Following the amyloidogenic proteolysis of APP, Aβ40 and Aβ42 are 
secreted into extracellular space. Both Aβ40 and Aβ42 are pathological forms in AD 
during different stages of the disease progression. Immunopositive Aβ42 has been 
found in early diffuse plaques (while no Aβ40 was present) (Iwatsubo et al. 1994) 
whilst Aβ40 seems to be abundant in mature plaques. Soluble Aβ can be detected 




Koudinov et al. 1994, Koudinov et al. 1996b, Seubert et al. 1992, Shoji et al. 1992). 
Plaque and capillary deposits of Aβ are homologous to soluble Aβ (Busciglio et al. 
1993, Vigo-Pelfery et al. 1993) which indicates the soluble Aβ in plasma and 
cerebrospinal fluid (CSF) can both contribute to plaque Aβ. 
 
 
Figure 3. Production of beta-amyloid. Image shows the sequential cleavage of APP 
in membrane and intracellular compartments to produce Aβ in neuron.  
 
Source: Adaption from Figure 1, Mattson 2004 (License number: 3463110683913) 
 
The ubiquitous genetic expression of APP in various tissues including the 
brain, heart, kidneys, liver, intestines and adrenal glands and presence of Aβ in 
CSF, plasma and body fluids indicate plaque Aβ could originate from the brain or 
periphery or a combination of both (Davis-Salinas et al. 1995, Golde et al. 1990, 
Yasojima et al. 2001). The relative impermeability of the BBB (Clifford et al. 2007) 
and high expression of APP in brain (Yasojima et al. 2001) supports a primary 
cerebral source of plaque Aβ. Other evidence shows however that deposits of Aβ in 
plaques are located close to or directly on blood vessels which indicate a possible 





1.2.4 Over production of beta-amyloid in Alzheimer’s disease 
 
Neuronal cell production of Aβ is considered a normal and constant event 
and does not contribute to pathology when the balance between production and 
clearance of Aβ is well maintained (Selkoe et al. 1996). In cognitively intact 
individuals, brain soluble Aβ is present within neurons and, in lower concentrations, 
interstitial space (Andreasen and Blennow 2002, Seubert et al. 1992). Currently, the 
function of APP and Aβ is not known. There are many major theories includes 
functional involvement of APP in cell growth and proliferation, function as a cell-
surface or extracellular matrix receptor and in regulation of blood clotting (Dawkins 
and Small 2014). Functions of Aβ may include regulation of lipid metabolism 
(Kontush et al. 2004), neuronal physiology including cellular transport and apoptosis 
(Li et al. 2007), and feedback regulation of synaptic transmission (Esteban 2004). 
 
Genetic mutations of APP lead to an abnormal proteolysis of APP and 
increase in Aβ production resulting in an earlier onset (familial) and more severe 
form of AD (St George-Hyslop 2000). Conversely, a mutation in APP that causes 
decreased Aβ production is protective against AD development (Jonsson et al. 
2012). Overproduction of Aβ from APP is the key event causing familial AD but less 
likely in the more common late onset or sporadic form of AD that constitutes 99 % of 
AD cases (Bateman et al. 2012).  
 
On the contrary, production of brain Aβ in sporadic AD has also been studied 
and evidence shows little increase in Aβ40 and Aβ42 (Lewczuk et al. 2010) and β-
secretase (BACE-1) activity (Zetterberg et al. 2008) in proteolytic processing of APP 
meaning that other pathological mechanisms are likely to be implicated. Determining 
the processes of amyloid production from APP and the various pathways which 
guide the preference towards non-amyloidogenic processing of APP is of great 
interest in understanding mechanisms of Aβ production in relation to AD. 
 
1.2.5 Inadequate clearance of beta-amyloid from the brain in 
Alzheimer’s disease 
 
Rapid clearance of Aβ from the brain is indicative that high concentrations of 




induced neurotoxicity. It has been postulated that aberrant clearance of Aβ via 
transport across the BBB could contribute to accumulation of Aβ (Zlokovic et al. 
1993). Clearance of Aβ from the brain can take place from periarterial spaces and 
drain into venous circulation (Weller et al. 1998). However, a study showed that Aβ 
clearance from the brain is rapid. Injection of radio labelled Aβ40 into lateral 
ventricles of Sprague-Dawley rats showed rapid clearance of Aβ peptide, clearing 
30 % after 3 min and 70 % after 10 min (Ghersi-Egea et al. 1996). Considering the 
rate of CSF and Aβ removal from the brain, an aberration in Aβ clearance which 
causes AD pathology is less likely.  
 
Based on non-significant changes in Aβ40 and Aβ42 production and rapid 
clearance of Aβ and turnover of CSF, it is less likely that production and clearance is 
compromised in AD. However, it cannot be excluded either. Studies of CSF Aβ 
levels have been largely controversial and are complicated by a number of other 
factors. Firstly, production of Aβ increases during aging, but will decrease as Aβ 
nucleates in the brain during AD processes. A recent longitudinal study shows 
changes in CSF Aβ appears 25 years prior the onset of symptoms in AD cases. 
Levels of Aβ42 and Aβ40 increases with aging, whilst in subjects where cognitive 
impairment and AD eventuated, Aβ levels slowly decline (Bateman et al. 2012). 
Interestingly, Aβ42 declined earlier in the disease process and levels remained 
constant after onset of symptoms whilst Aβ40 declined later in the disease process 
and levels continued to decline after the onset of symptoms (Bateman et al. 2012). 
This study was done in familial AD cases; however, histopathological brain 
pathologies of sporadic and familial cases are virtually indistinguishable indicating 
similar pathologic processes.   
 
1.2.6 Section summary  
 
Presently, the origin of Aβ found in cerebral plaque has not been 
established; however, the presence of Aβ in body fluids including blood, CSF, blood 
vessels and cell supernatant suggests that plaque Aβ could originate from the brain, 
the blood or both. Beta-amyloid could cause cognitive decline in its soluble form 
and/or deposit in extracellular matrices of the brain and initiate a pathological 
cascade of events which have been described in the ‘amyloid cascade hypothesis’. 




development, which over time causes inflammation, oxidation and the appearance 
of NFTs. Formation of amyloid plaques is a chronic process which depends on a 
number of conditions including the overproduction of cerebral Aβ and/or inadequate 
clearance of Aβ from the brain. Production of cerebral Aβ does not increase 
significantly in sporadic AD but does in familial cases and together with evidence of 
rapid clearance of Aβ from the brain, suggests that cerebral Aβ could be due to 
accumulation from another source, notably from plasma. However, few have 
explored this possibility further as transport across the BBB is considered limited 
due to structural architecture of cerebral capillary vessels.  
 
 
1.3 Cerebral vascular and blood-brain barrier changes in Alzheimer’s 
disease 
  
1.3.1 Role of blood-brain barrier in bi-directional transport of beta-
amyloid 
 
The blood vessels which line the brain and spinal cord are different from the 
rest of the body as they are additionally lined by cells of the brain and together are 
collectively known as the BBB. The BBB is comprised of several cell types including 
endothelial cells of the capillaries (smooth muscle cells in arterioles and arteries), 
astrocytes, pericytes as well as basement membranes. Endothelial cells are the first 
line of defence and are structurally aligned very tightly. These cell to cell junctions 
are abundant in small units of tight junction proteins, occludin, claudins and 
junctional adhesion molecules (Abbott et al. 2010, Ballabh et al. 2004). In addition, 
astrocyte foot processes are involved in modulating endothelial tight-junction 
proteins and the structural integrity of the endothelium (Balabanov and Dore-Duffy 
1998, Zlokovic 2005); however, there is some evidence that pericytes may also 
influence endothelial cell function. 
 
The BBB is generally impermeable to many plasma proteins, 
macromolecules, peptides, pro-inflammatory molecules and neurotoxic products 
(Hawkins and Davis 2005, Mayhan 2001, Risau et al. 1998), allowing only selective 
influx of molecules via diffusion or active transport mechanisms. Capillary vessels 




transport occurs via RAGE (Kandimalla et al. 2005, Poduslo et al. 1999). 
Maintenance of barrier function for cerebral capillary vessels is pivotal for 
maintaining synaptic signal and neuronal plasticity (Nedergaard et al. 2003, 
Newman 2003, Zlokovic 2005). 
 
Studies of BBB in normal individuals show that under conditions where 
cerebral blood vessels are intact and functioning normally, plasma-derived Aβ 
relative to total cerebral load is probably low (Poduslo et al. 2001). However, an 
increasing number of studies show that BBB damage and altered haemodynamics 
in AD patients can contribute to an increased influx of plasma components including 
Aβ. Indeed, the aberration of cerebral blood vessels in AD was first observed and 
reported by Alois Alzheimer himself - "large vessels show atherosclerotic changes" 
and "some regressive alterations of the arterial wall" (initial reports of Alois 
Alzheimer (1907) and Perusini (1911) was translated from German to English by 
Maurer et al. (1997). 
 
Whilst current understanding of bi-directional transport of Aβ is limited 
(Deane et al. 2003, Shibata et al. 2000), entrance of Aβ into the brain can occur via 
endothelial cells protein RAGE (Deane et al. 2003, Donahue et al. 2006). Yan et al. 
(1996) found binding of RAGE to Aβ and that the binding site is dissimilar to 
advanced glycation end products (AGEs). This study also showed that the binding of 
Aβ to RAGE was inhibited in a concentration dependent matter by addition of AGE 
albumin or amphoterin. In addition, low-density-lipoprotein receptor-related protein-1 
(LRP-1) binds to Aβ within the junctions of endothelial cells of the capillaries of the 
brain. Transport via LRP-1 primarily mediates efflux rather than influx (Deane et al. 
2009, Deane et al. 2005, Donahue et al. 2006). Some consider the balance between 
RAGE and LRP-1 is indicative of the dominant brain-to-blood efflux of Aβ transport 
(Deane et al. 2009, Deane et al. 2008, Donahue et al. 2006, Ye et al. 2005). 
 
1.3.2 Role of vasculature disturbance in Alzheimer’s disease pathology 
 
The presence of underlying vascular risk factors and cardiovascular disease 
increases the likelihood of developing vAD and AD (Breteler 2000, Luchsinger and 
Mayeux 2004). Vascular risk factors include: hypertension, high CH, high TGs, 




syndrome (Kalaria et al. 2012), diabetes mellitus (Ott et al. 1999, Peila et al. 2002) 
diabetes, (Strachan 2003) and atherosclerosis. The presence of one or more risk 
factors can increase the risk of developing AD by between 1.2-4 times with the 
presence of three or more risk factors showing the greatest risk (Kalaria et al. 2012, 
Tschanz et al. 2013). Obesity alone has been shown to increase the risk of AD by 2-
5 times (Gustafson 2008). The emergence of vascular risk factors typically in mid-
life (Kivipelto et al. 2001) demonstrates the possibility for early onset of vascular 
changes that are present in AD. 
 
The clinical importance of blood vessel integrity and cerebral blood flow 
(haemodynamics) changes in AD pathology has been increasingly studied. Cerebral 
amyloid deposits or cerebral amyloid angiopathy is evident in 80 % of AD patients 
(Thal et al. 2008) and 30 % of AD subjects show evidence of cerebral haemorrhage 
or micro-emboli (Pettersen et al. 2008). Cerebral blood flow is altered in AD patients 
with some reporting hypoperfusion (Johnson et al. 2005) with lower blood flow 
velocity (Ruitenberg et al. 2005). Aberrant blood flow in AD could be caused by the 
presence of atherosclerotic lesions. Subjects with atherosclerosis are three times 
more at risk of developing dementia (van Oijen et al. 2007). Atherosclerotic plaques 
present in leptomeningeal arteries and the main arteries supplying blood to the brain 
(circle of Willis) are more severe in AD cases compared to nondemented controls 
(Beach et al. 2007, Kalback et al. 2004, Roher et al. 2003).  
 
1.3.3 Plasma beta-amyloid can damage cerebral vasculature including 
the blood-brain barrier 
 
Several studies show that circulating Aβ could compromise vascular and 
specifically BBB integrity (Jancso et al. 1998, Su et al. 1999), damaging vascular 
endothelium (Thomas et al. 1996) and smooth muscle cells (Crawford et al. 1998) 
and altering the vasoactivity of cerebral vasculature by increased blood pressure 
(Arendash et al. 1999), decreased blood flow and increased vascular resistance 
(Suo et al. 1998). The mechanisms behind Aβ ‘toxicity’ towards vascular integrity 
have been considered. The vasoactive property of Aβ was first demonstrated by 
Thomas et al. (1996) when addition of synthetic Aβ to the aorta enhanced 
vasoconstriction and decreased the relaxation response. Crawford et al. (1997) also 




dependent on free radical production. Indeed, decreased cerebral blood flow in 
frontal, temporal, parietal, and posterior parietal cingulated cortices was observed in 
AD patients compared to age matched controls (Alsop et al. 2000). A recent article 
attributed decreased cerebral haemodynamics to impairment of cerebral auto-
regulation of blood flow in a mouse model of AD (Claassen and Zhang 2011). The 
latter observation was confirmed in a human study where cerebral autoregulation 
was found to be less effective (greater amount of brain pressure fluctuation) 
compared to age-matched controls (Meel-van den Abeelen et al. 2014). Collectively, 
these studies indicate that Aβ could initiate cerebral vascular changes and altered 
brain haemodynamics contributing to the vascular changes observed in AD.   
 
1.3.4 Section Summary  
 
The ubiquitous genetic expression of APP in various tissues (Davis-Salinas 
et al. 1995, Golde et al. 1990) and high concentration of Aβ in blood (Seubert et al. 
1992) coupled with the presence of damaged cerebral blood vessels in AD 
individuals indicates that peripheral Aβ could contribute to brain Aβ load (Zlokovic et 
al. 1993). Taking into consideration these studies, it is possible to conclude that 
cerebral amyloidosis can be exacerbated under circumstance where the BBB is less 
intact and thus allowing a greater influx of peripherally derived Aβ.  
 
 
1.4 Lipid metabolism and Alzheimer’s disease 
 
1.4.1 Relationship between apolipoprotein E4 and Alzheimer’s disease 
risk 
 
The second most influential risk factor after aging for AD is the presence of 
an apo E, E4 allele. Apolipoprotein E4 allele has been associated with greater risk of 
both early onset (or familial) and late onset (sporadic) AD (Corder et al. 1993, Farrer 
et al. 1997, Saunders et al. 1993, Strittmatter et al. 1993a, Ye et al. 2005) and is 
present in half of all AD subjects (Farrer et al. 1997). 
 
Apolipoprotein E is a 35 kDa 299 aa long protein produced in the liver and 




1988, Mahley and Huang 1999, Mahley and Rall 2000). There are three main 
isoforms of apo E in humans differing in their primary structure: apo E2 (Cys112 and 
Cys158), E3 (Cys112 and Arg158) and E4 (Arg112 and Arg 158) (Weisgraber 
1994).  
 
Apolipoprotein E is critically involved in transport, redistribution and 
clearance of CH and TG from lipoproteins (Mahley 1988, Mahley and Huang 1999, 
Mahley and Rall 2000). Apolipoprotein E is found on all CM and CM-remnants and 
the level of apo E present on the molecules may vary from the fasted to fed state. 
More apo E is found on TG-depleted remnants of hepatically derived VLDL and 
postprandial lipoprotein CMs. Apolipoprotein E is a ligand for apo B100/E receptor 
and therefore modulates the binding of CM remnant or LDL remnant particles which 
contain CH and remaining TG after lipolysis. Individuals with apo E4 alleles have 
different lipid profiles including greater levels of LDL-CH and apo B and less apo E 
and TG compared to individuals with apo E3 and apo E2 (Gregg et al. 1986). 
Differences in plasma lipid profiles have been attributed to differences in apo E 
association clearance via apo E receptor (Gregg et al. 1986). 
  
Approximately 40-65 % of people with AD have one or two apo E4 alleles 
compared to 20 % among the non AD population and more than 25 % of people 
carrying the apo E4 allele have AD (Lindsay et al. 2002). The presence of the apo 
E4 allele and risk of developing AD have been found to increase in an apo E4 dose 
dependent manner. For example, the presence of one apo E4 allele increases AD 
risk by 3 times and two apo E4 alleles increase AD risk by 8 times. Conversely, the 
presence of apo E2 alleles (E2/E2) decreases the risk by half and apo E2 can have 
a protective role (Corder et al. 1994) against AD. It is interesting to note people with 
an allele combination of E2/E4 are at similar risk to people with an E3/E3 allele 
combination suggesting that the detrimental effects of apo E4 could be nullified by 
the protective effects of apo E2. Clinical studies and animal studies show the 
presence of apo E4 results in a greater number of amyloid plaques (Sparks et al. 
1996) in the brain compared to apo E3 (Carter et al. 2001, Gearing et al. 1996).  
 
The presence of apo E4 is associated with changes in lipid profile and 
disorders in lipid metabolism. Familial type V hyperlipoproteinemia (Ghiselli et al. 




(hypercholesterolemia) (Utermann et al. 1984) are commonly associated with apo 
E4. Increased plasma CH, LDL-CH and apo B, and decreased HDL-CH and apo AI 
(Caramelli et al. 1999, Kuo et al. 1998) are reported in AD patients. The increased 
AD risk associated with the apo E4 allele could notionally be linked to a genetic 
influence of apo E4 on plasma lipid profile.  
 
In addition, apo E4 can directly affect the development of amyloid plaques by 
influencing Aβ metabolism and/or other factors which influence plaque development; 
or indirectly, by decreasing choline acetyltransferase activity and nicotinic receptor 
binding sites (Poirier et al. 1995). The latter is implicated with treatment of AD by 
cholinesterase inhibitors but not involved in disease process (Poirier et al. 1995).  
 
1.4.2 Role of lipoproteins and apolipoprotein E4 in beta-amyloid 
pathology 
 
When Aβ bind with high affinity to lipoproteins and apolipoproteins they are 
referred to as lipidated Aβ, de-lipidated or free Aβ exists as well (Koudinov et al. 
1994). Lipidation of Aβ has been suggested to play a role in the pathology of AD. 
Greater amounts of de-lipidated Aβ40 and Aβ42 were found in patients with MCI 
and AD subjects (Hanson et al. 2013, Matsubara et al. 1999). It is interesting to note 
that Alzheimer-prone, apo E4-containing subjects have the most delipidated or lipid 
free apo E, compared to E3 or E2 containing individuals (Hanson et al. 2013). In 
addition, C-terminal of lipidated apo E4 binds substantially more Aβ than apo E3 
and apo E2 (Stratman et al. 2005). On the other hand, Tokuda et al. (2000) found 
greater association of lipid-bound apo E3 with Aβ compared to apo E4 subjects. In 
addition, the delipidation of apo E reduced its binding ability to Aβ by 5 to 10 fold. 
The reduced tendency for apo E to bind lipids may also affect its ability to sequester 
and clear Aβ, in turn, modulating the amount of free pathogenic Aβ. Apolipoprotein 
E4 individuals had the highest amount of de-lipidated or lipid-free apo E molecules 
compared to other isoforms (E4 >E3 >E2) (Hanson et al. 2013) which can impact on 
binding to Aβ. Takamura et al. (2011) found that dissociation of soluble Aβ from 
lipoproteins (de-lipidation) in CSF renders Aβ to a state that is more prone to 
oligomerization in the brain and soluble Aβ oligomers can directly cause synaptic 




relevant as sequestration of Aβ can prevent deposition and thus protect the brain 
from toxicity.  
 
1.4.3 Diet-genetic interaction of apolipoprotein E4 
 
The synergistic effects of diet and lifestyle on risk for chronic diseases such 
as AD have been increasingly realized. Although the risk of apo E isoforms in AD 
has been established in western countries, an apo E4 paradox exists. In some 
populations the presence of apo E4 genetics does not correlate to increased 
prevalence of AD. Nigerians for example have a high incidence of apo E4 yet a low 
incidence of AD (Hendrie et al. 1996, Ogunniyi and Osuntokun 1991, Osuntokun et 
al. 1992). In a review article by Petot and Friedland (2004) it was shown that the 
association of apo E4 with AD was weaker for Africans, African-Americans, Arabs 
and Indians in comparison to Caucasians. Africans, for example were shown to 
have high prevalence of apo E4 and low prevalence of AD, African-Americans: a 
high prevalence of apo E4 and high prevalence of AD, Arabs: a low prevalence of 
apo E4 and high prevalence of AD, and finally East Indians with a moderate 
prevalence of apo E4 and low prevalence of AD (Farrer et al. 2003). Petot and 
Friedland (2004) attributed the paradox to the differences in total fat consumption 
across the population groups. When apo E4 individuals consume a high fat diet (>35 
% kcal), the risk of developing AD is increased compared to a diet with less fat (<35 
% kcal). However, the results from this study were based on food consumption 
questionnaire and results did not make discrepancy between types of fat consumed.  
 
 
1.5 Dietary fat and Alzheimer’s disease  
 
1.5.1 Overview of dietary fat and Alzheimer’s disease risk 
 
Dietary fat is linked to both AD and other chronic diseases that are risk 
factors for AD. The prevalence of AD is positively influenced by increasing intake of 
calories and dietary fat. Caloric and dietary fat intake mid-life has been linked to 
developing AD in later life (Dosunmu et al. 2007). Excessive caloric intake and 
sedentary behaviour may directly influence AD risk (through unknown pathways) or 




diseases such as obesity (Brantley et al. 2005), cardiovascular disease and 
diabetes (Brookmeyer et al. 2007, Kivipelto et al. 2001).  
 
In addition, there has been some indication of a link between ketogenic diets 
containing low carbohydrate and high fat levels with neurological diseases such as 
AD. Brownlow et al. (2013) used transgenic APP + PS1 mice and Tg4510 which 
were fed either ketogenic diet or control diet for 16 w. The ketogenic diet consists of 
270 mg/kg of medium chain fatty acids as well as 70 g/kg of flaxseed oil and 60 g/kg 
of canola oil (compared to 0, 21 and 19 g/kg in control diets respectively). 
Carbohydrate was 62.2 g/kg in the control diet compared to 0.5 g/kg in the ketogenic 
diets and there was more fibre in the ketogenic diet (245.31 g/kg) compared to the 
control diet (40 g/kg). Following blood tests, results showed significantly greater 
levels of β-hydroxybutyrate and less glucose after 4 w of dietary regime. No 
changes in amyloid plaques or tau proteins were observed between control and 
ketogenic diets for all mice groups. In addition, there were no significant differences 
between the diets for open field test, radial arm water maze however there was a 
slight improvement of rotarod test for the ketogenic diets. The results from this study 
do not establish any specific link between the benefits of ketogenic diets in wild-type 
and transgenic mice with Alzheimer-like pathology.  
 
The review by Stafstrom and Rho (2012) outlines the literature and provides 
an overview of ketogenic diets on a range of neurological disorders. This paper 
concludes that neurological disorders in general can be caused by an imbalance of 
energy metabolism, which can possibly be regulated by dietary therapy which 
favours a ketogenic diet. Interestingly, the author also notes that ketogenic diets can 
mimic the mechanisms and health benefits of caloric restriction by reducing glucose. 
The link between increased calorie intake and AD has been mentioned several 
times in the literature review chapter. 
 
1.5.2 Effect of dietary fat on brain structure and function 
 
Dietary nutrient intake is important for optimal brain function and evidence 
shows that SFAs affect neuronal function and may lead to neurological diseases 




structure, neuronal plasticity and memory (Greenwood and Winocur 2001, Molteni et 
al. 2002, Molteni et al. 2004, Winocur and Greenwood 1999).  
 
Fats derived from dietary sources can be characterized as either SFAs or 
unsaturated fatty acids (UFAs) and are differentiated based on chain length and the 
presence of double bonds. Saturated fatty acids contain no double bonds whereas 
UFAs contains one or more double bonds. Unsaturated fatty acids containing one 
bond are known as MUFAs and those with more than one bond are referred to as 
PUFAs.  
 
Diets high in SFAs have been reported to have detrimental effects on 
cognitive performance in humans, rats and mice (Sartorius et al. 2012, Winocur and 
Greenwood 1999) by altering neurobiology of the hippocampus (Davidson et al. 
2012, Freeman and Granholm 2012) and hippocampus associated functions (review 
by Kanoski and Davidson 2011). Sartorius et al. (2012) uses milk fat and canola oil 
which as high in long chain SFA (predominantly palmitic acid 2.38 % and stearic 
acid 0.74%) and MUFA (Oleic acid 5.1 %), respectively. Male C57BL/6J mice were 
fed milk fat (3.3 % fat), canola oil (3.3 % fat) or standard chow (5 % fat – 
predominantly PUFA linoleic acid 3.51 %) for 8 weeks. Wincur and Greenwood 
(1999) also used diets which contained either 20 % (w/w) of soybean oil, or 18 % 
(w/w) beef tallow, 1% (w/w) soybean oil and 1 % (w/w) safflower oil or standard low 
fat diet containing 4.5 % (w/w) of fat. The diet containing beef tallow contains 
predominantly SFA (5.72 % palmitic acid and 4.1 % stearic acid), some MUFA 
(7.36% Oleic acid) and PUFA (2.02 % n-6) this dietary information was available in 
their previous publication by McGee and Greenwood (1990). The high energy diets 
used by Davidson et al. (2012) to feed the rats for 21 days included 17 % (w/w) as 
lard and 1.5 % (w/w) as safflower oil. Although the specific components of fatty 
acids were not provided in this study, lard contains 56-62 % UFA and 38-43 % SFA. 
The diet used by Freeman and Granholm (2012) uses 10 % hydrogenated coconut 
oil and 2 % cholesterol. Although coconut oil is known to contain high levels of SFA, 
the percentages of fatty acids were not provided and a search for custom diet “D2-
AIN93” did not return any results on the manufacturer’s website (BP Biomedicals). 
Diets high in SFAs reduce levels of brain derived neurotrophic factor (BDNF) which 
protects neurons from toxicity and mice maintained on a SFA rich diet for 4 w 




high SFA diet on BDNF (Molteni et al. 2002, Molteni et al. 2004, Wu et al. 2003). 
Studies by Molteni et al. (2002), Molteni et al. (2004) and Wu et al. (2003) have all 
used a similar diet to Davidson et al. (2012) using lard as their primary source of 
SFA. Diets high in SFAs promote oxidative stress by increasing free radical 
production which could be detrimental to brain function (Greenwood and Winocur 
1990, Greenwood and Winocur 2001, Molteni et al. 2002, Kaplan and Greenwood 
1998, Wu et al. 2003).  
 
Conversely, MUFAs and PUFAs have been shown to be protective against 
(Hooijmans et al. 2009, Naqvi et al. 2011) or reverse cognitive decline (Morris 2004). 
In the study by Hooijimans et al. (2009), the PUFA diet contained 0.4% DHA, long 
chain PUFA with low n-6/n-3 ratio compared to SFA diet a with high SFA (type not 
specified) and low amount of long chain PUFA and high n-6/n-3 ratio. Naqvi et al. 
(2011) conducted a food frequency questionnaire on 441 women over the age of 60. 
These women completed both initial and follow-up cognitive assessments and had 
complete data. Data collected from the questionnaire were used to estimate the 
frequency and amount intake of each fatty acid from diet history in the past 3 years. 
This study found that high intake of MUFA was linked to reduced declines in 
cognitive performance. Longitudinal human studies show that PUFA and MUFA 
containing foods regulate neuronal transmission for healthy brain function (Solfrizzi 
et al. 2005) and are protective against neurodegeneration (Kalmijn et al. 1997, 
Morris 2004). There have also been important findings in experimental models that 
show rats fed PUFA perform better in Morris Water Maze assessment (Greenwood 
and Winocur 1990) and spatial tasks (Winocur and Greenwood 1999) compared to 
rats fed a high SFA diet or control diet. Saturated fat diet fed transgenic APP and 
wild-type mice show increased markers of astrocyte activiation (GFAP) expression, 
a marker of neuroinflammation (Julien et al. 2010). 
 
It is important to consider other physiological or pathological consequences 
(such as glucose metabolism, cognitive decline and neurotoxicity) of high fat diets 
which can be independent of Aβ metabolism and AD pathology. Therefore, it is 
important to distinguish between direct and indirect influences of diet on AD 
pathology when assessing the literature and to focus specifically on Aβ metabolism 





1.5.3 Global pattern of Alzheimer’s disease and dietary fat intake 
 
Global variations in diet and lifestyle have been linked to the incidence and 
prevalence of AD (Grant 1998, Grant 2014). Geographically, AD is not uniform and 
there is a significantly lower prevalence in developing countries in comparison to 
developed countries (Chandra et al. 1998, Hendrie et al. 1995, Prince et al. 2004). 
The variation in AD incidence between countries has been linked to the cultural and 
dietary variations between countries (Grant 1998, Grant 2014). Countries with a high 
incidence of AD have higher average animal product, processed food and calorie 
intake than countries exhibiting a low incidence of AD. Moreover, increasing 
prevalence of AD in developing countries is thought to reflect increased urbanisation 
and a transition to western diet and lifestyle patterns. 
 
In North and Latin America, the total percentage of the population with AD is 
higher (5.4 %) compared with Europe (4.4 % West > East), Africa (3.6 % North and 
Middle East), developed pacific regions (4.3 % Australia, Japan, South Korea and 
Singapore), developing western pacific regions (4.0 % China and Vietnam), and less 
developed regions (2.7 % Indonesia, Thailand and Sri Lanka; 1.9 % India and South 
Asia; 1.6 % South Africa) (Ferri et al. 2005).  
 
Grant (2014) found that total caloric intake and intake of saturated and trans-
fatty acids correlated with an increase in AD in Western countries compared to Asia 
and Africa (Kalmijn et al. 1997). Albanese et al. (2009) showed in middle and low-
income countries (South America, China and India) that increased fish consumption 
was associated with a decreased risk of dementia and that dementia was 
associated with higher intake of meat. The author acknowledged that there was a 
potential lack of other relevant information such as the type of meat consumed, 
method of preparation and size of portions of meat. 
 
The Honolulu-Asia Aging Study showed that when Japanese men who 
migrated from Japan to Hawaii had a much greater risk of developing AD (Havlik et 
al. 2000, Shadlen et al. 2000) which is consistent with research indicating a greater 
risk of AD among Japanese living in America compared to Japanese living in Japan 
(Graves et al. 1999). The cross-cultural study highlights the importance of 




habits which increase the intake of fat and protein are linked to greater risk of 
developing AD (Shadlen et al. 2000). 
 
1.5.4 Effects of different dietary fats on cognitive decline and 
Alzheimer’s disease 
 
Although general trends are suggestive that total fat and caloric intake are 
positively correlated with increasing prevalence of AD, epidemiological studies are 
consistent with the notion that AD can be a disease of lipid metabolism and is more 
significantly influenced by dietary fat type rather than quantity consumed.  
 
1.5.4.1 Dietary saturated fat and cholesterol and Alzheimer’s disease 
risk 
 
1.5.4.1.1 Epidemiological evidence 
 
An accumulation of epidemiological studies show that high dietary intake of 
SFA and CH is linked with increased prevalence of AD. Eskelinen et al. (2008) 
surveyed the participants of CAIDE and a random sample of 2000 individuals (aged 
65-79). Total number of 1,449 participants completed the follow up tests (mean 
follow up time 4.9 years). Individuals diagnosed with dementia and those who did 
not complete the examination were excluded from the analysis, leaving a cohort of 
1,341 individuals. Dietary intake was analysed by semi-frequency food 
questionnaire, identification of type and amount of fat intake was determined by 
questions which asked for amount of fat intake. In addition, the fatty acids types and 
quantities of SFA, MUFA and PUFA were calculated based on types of spreads and 
milk was ingested, as well as the fats used in cooking and baking. Results from this 
study showed that increased dietary SFA (from dairy) in midlife was associated with 
poorer cognitive function and MCI. Another study of 815 people aged 65 and over 
with 4 years follow-up showed that intake of SFA and trans-UFAs was positively 
associated with AD risk (Morris et al. 2003). Increased dietary intake of CH and high 
serum CH levels midlife has also been implicated in development of AD (Kivipelto et 
al. 2001, Kivipelto et al. 2002). In the Rotterdam Study of 5386 people over the age 




follow-up (Kalmijn et al. 1997). Other large epidemiological studies show that high 
intake of SFAs and calories increase the risk of AD (Luchsinger et al. 2002).  
 
The effect of dietary intake on the development of AD on the elderly 
partipants from the Chicago Health and Aging project was further examined by 
Morris et al. (2003). Out of the available cohort of 8501 subjects over the age of 65, 
815 subjects were selected based on participation and cognitive state at the 
beginning of the experiment. Similar to the study by Eskelinen et al. (2008), this 
study has uses food-frequency questionnaire to evaluate the frequency and types of 
dietary fats ingested which allows analysis of SFA, PUFA and MUFA intake from 
dairy including spreads, chocolate; cooking/baking oil; fish oil supplement; eggs; 
meat and seafood. These choices presumably will give an accurate representation 
of frequency and types of fat ingested. Although limitations of these methods can 
include memory (questionnaire in the past year) and comprehension of the test, also 
test does not differentiate between the types of meat – for example, no option to 
select short cut or normal bacon (more fat) or grass fed or grain fed beef. These 
may impact on the type and content of fat ingested so some caution can be 
exercised whilst interpreting results.  
 
Consistent with a positive association between elevated serum CH and AD 
risk, the use of CH lowering statins has been shown to decrease the prevalence of 
AD (Jick et al. 2000, Wolozin et al. 2000). However, the effectiveness of statins for 
use in dementia has been questioned. The meta-study by Ott et al. (2015) 
examines 25 articles (out of 5823 identified relevant articles from 2007 examining 
for the effective use of statins for dementia) and shows that statins can sometimes 
have adverse effects but only when the dose is used above the recommended 
limits. This study does not otherwise infer that the long term use of statins cause 
adverse effects on cognition. Statins can reduce levels of CH by inhibiting 3-
hydroxy-3-methylglutaryl coenzyme A reductase, the rate limiting step in CH 
biosynthesis pathway (Hamelin and Turgeon 1998). However, statins can also 
influence AD risk including suppression of the isoprenoid pathway (Bellosta et al. 
2000), which has been implicated in AD (Cole and Vassar 2006). Statins are 
conventionally prescribed for vascular disease because high CH is a risk factor in 
atherosclerosis. However, the putative mechanisms as to how CH and statins can 




membrane CH dynamics which can affect processing of membrane protein APP 
resulting in an aberrant increase in Aβ production (Eckert et al. 2005). 
 
1.5.4.1.2 Animal models 
 
Experiments in both wild type and transgenic animal models are supportive 
of the regulatory role of dietary fats in metabolism and cerebral deposition of Aβ 
protein. In adult New Zealand rabbits fed 2 % CH, both hypercholesterolemia and 
time-dependent increases in immunopositive cerebral amyloid deposits were noted 
after 4, 6 and 8 w of dietary intervention (Sparks et al. 1994). Intake of 5 % CH and 
10 % fat in young APP Tg2576 transgenic mouse models for 7 w exhibited 
increased Aβ production and cerebral amyloidosis (Refolo et al. 2000). These 
results were replicated in another transgenic AD mice (TgAPPsw) fed high fat and 
CH chow for 7 or 10 months which induced significant increases in plasma lipids 
(VLDL and TGs) which correlated with increases in Aβ40 and Aβ42 plasma 
abundance (Shie et al. 2002). A similar experimental approach was explored by Ho 
et al. (2004) who used Tg2576 mice fed a high fat diet (60 % calorie intake from fat) 
compared with a low fat diet group (10 % calorie intake from fat). The study showed 
a 2-fold increase in amyloid 40 and 42 levels in the hippocampus, determined by 
sandwich ELISA in mice fed the high fat diet.  
 
1.5.4.1.3 Cell models 
 
Further evidence of the role of dietary fats in influencing intracellular APP 
processing has been established by a number of cell studies. In one study, the 
addition of SFAs; palmitic acid and stearic acid to a conditioned medium of APP 
transfected COS-7 cells significantly enhanced secretion of Aβ40 and Aβ42 whilst 
incubation with oleic acid and palmitoleic acid reduced secretions (Amtul et al. 
2011a). In agreement with these results, Patil et al. (2006) also found direct 
stimulatory effects of palmitic acids and stearic acid on increased β-secretase 








1.5.4.2 Dietary monounsaturated fat and Alzheimer’s disease risk 
 
1.5.4.2.1 Epidemiological evidence  
 
An accumulating body of evidence suggests a protective and beneficial role 
of dietary MUFA in relation to AD risk. The classical Mediterranean diet is 
characterised by high levels of olive oil (predominantly MUFA), as well as fish, fruit, 
vegetables, legumes, cereals, moderate intake of dairy and lower intake of meat and 
SFAs. Although the Mediterranean diet can vary, the focus is on limited intake of 
processed foods and inclusion of nuts/seeds and whole grain cereals;  moderate 
intake of dairy, eggs, fish and poultry, with lower intake of red meat; and moderate 
intake of red wine. The Mediterranean diet is 25-35 % dietary lipids and 
approximately 8-10 % can be calories from SFA from the above mentioned sources. 
However, not all Mediterranean diets are supportive of the beneficial diet in AD. 
Katsierdanis et al. (2013) examined a population of 557 elderly subjects with a food 
intake questionnaire and a cognitive assessment. Subjects showed no relationship 
between intakes of various dietary components (meat, vegetables, grains, sugar 
etc.) with mental performance. There was a non-significant increase in saturated fat 
intake among subjects (both men and women) who scored less in the cognitive 
tests. This cross-sectional study does not conclude if the Mediterranean diet per se 
contributes to the cognitive state but rather whether intake of specific components of 
the diet and lifestyle can influence cognitive decline among elderly individuals in the 
Mediterranean region.  
 
Studies of dietary habits in the United States (Feart et al. 2009, Scarmeas et 
al. 2007), France (Tangney et al. 2011), Southern Italy (Solfrizzi et al. 1999) and 
more recently Australia (Gardener et al. 2012), suggest that increased intake of 
MUFAs can lower the risk of cognitive decline and presumably AD. Feart et al. 
(2009) studied in a sample of 9294 elderly subjects found that consuming 
Mediterranean diet over time was associated with slower rate of cognitive decline. 
Scarmeas et al. (2007) also conducted a longitudinal study in 192 individuals pre-
diagnosed with AD found when subjects take in more “Mediterranean-type” foods, 
there were significantly linked to a reduced in rate of mortality. Tangney et al. (2011) 
also used a longitudinal study design; this study was performed on 3790 individuals 




This study also concluded that adherence to Mediterranean diet was more 
associated with reduced rate of cognitive decline. In addition to oleic acid, other 
components of olive oil such as vitamin E (La Fata et al. 2014) and oleocanthal 
(Abuznait et al. 2013) have also been proposed to have beneficial effects on AD.  
 
1.5.4.2.2 Animal models 
 
Amtul et al. (2011) examined the effects of addition of oleic acid (MUFA) to a 
low fat chow diet in order to determine if oleic acid alone can influence Aβ levels in 
the brain. Transgenic mice (TgCRND8) mice were fed from 3 w to 20/21 w of age 
before they were sacrificed. The oleic acid diet contained the addition of oleic oil 
(2% w/w) to control low fat diet containing 1 % w/w soybean oil) and no cholesterol. 
Quantitative immunological analysis of brain tissue samples showed a significant 
decrease in Aβ42 levels in the hippocampus and lowered plaque in the 
hippocampus, amygdale and neurocortex compared to control low fat chow fed mice 
(Amtul et al. 2011b). The author concluded that this was linked to increased sAPPα 
and a decrease in β-secretase processing of APP in intracellular and membrane 
compartments which contain secretases.  
 
1.5.4.2.3 Cell models 
 
The addition of 0.1 µm oleic acid to transfected COS-7 cells transfected with 
APP695 decreased both Aβ40 and Aβ42 in conditioned medium compared to BSA 
controls (Amtul et al. 2010). Further investigation showed stimulatory effects of oleic 
acid on nonamyloidogenic pathway (increased soluble APPα by 50 %) and 
decreased amyloidogenic processing of APP (lower β- and γ-secreatase by 20 %). 
These results were comparable to animal studies where dietary administration of 
oleic acid resulted in a significant reduction in Aβ plaque in the neocortex, amygdale 










1.5.4.3 Polyunsaturated fat and Alzheimer’s disease risk 
 
1.5.4.3.1 Omega-3 polyunsaturated fatty acids  
 
There is increasing interest in the beneficial role of n-3 PUFA in chronic 
illnesses including AD. Consumption of ‘oily fish’ has been shown to be protective 
against cardiovascular disease, cognitive decline and AD (Barberger-Gateau et al. 
2002, Freund-Levi et al. 2006, Kalmijn et al. 1997, Morris et al. 2003, Morris et al. 
2006, Schaefer et al. 2006, van Gelder et al. 2007). Oily fish is a major source of n-3 
PUFAs, mainly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), 
both of which are important for brain structure and function (Freund-Levi et al. 2006, 
Yurko-Mauro 2010). Docosahexaenoic acid is anti-oxidative and improves learning 
ability in animals (Calon et al. 2004, Gamoh et al. 2001, Lim and Suzuki 2000) and 
has also been shown to decrease Aβ secretion from neuronal cells (Lukiw et al. 
2005). As the body can only synthesize small amounts of EPA and DHA from α-
linolenic acid (Pawlosky et al. 2001), dietary intake of n-3 PUFA forms the major 
source. Despite findings that establish the benefits of PUFAs, some studies show no 
benefit of fish intake on dementia risk (Engelhart et al. 2002, Laurin et al. 2003). 
Studies show outcomes are also dependent on level of cognitive decline, presence 
of other chronic diseases, background dietary factors such as n6 PUFA, caloric 
intake and Devore et al. (2009) attributes the discrepancy between such findings as 
a result of different stages of AD progression. 
 
1.5.4.3.2 Omega-6 polyunsaturated fatty acids 
 
The main dietary source of n-6 fatty acids is vegetable oils but sources also 
include eggs, nuts, cereals and poultry. Linoleic acid and arachidonic acid are main 
types of n-6 and both can be converted to pro-inflammatory eicosanoids and 
prostaglandins. A Japanese study shows that increased n-6 PUFA intake is 
associated with increased risk of developing AD and vAD (Otsuka et al. 2002). To 
support this, Sanchez-Mejia et al. (2008) found greater n-6 and by-product of n-6 
arachidonic acid was present in hippocampus of Alzheimer’s hAPP mouse models 
indicating possible oxidative or inflammatory processes involved with presence of n-




responsible for oxidation and conversion of n-6 PUFA to pro-inflammatory oxidative 
derivates have also been implicated in AD (Klegeris and McGeer 2002).  
 
1.5.4.3.3 Ratio of omega-6/omega-3 fatty acids 
 
It is unknown how the ratio of n-3 or n-6 can be related to dementia and AD. 
A cross sectional study in 304 elderly patients showed a relationship between a high 
n-6/n-3 ratio and cognitive decline (Gonzalez et al. 2010). Another study found 
increased n-6/n-3 ratio in AD cohorts compared to non-demented controls (Conquer 
et al. 2000). There are numerous reports of the benefits of n-3 PUFA (Cole et al. 
2010, Fotuhi et al. 2009) and the pro-inflammatory factors of n-6 PUFA (Kuehl and 
Egan 1980). Although metabolic pathways of n-3 and n-6 are independent from 
each other, both n-3 and n-6 use the same enzymes and compete for 
cyclooxygenase, 5- lipoxygenase, elongase, delta-5-desaturase and delta-6-
desaturase (Lewis et al. 1990). An imbalance in the n-3 and n-6 ratio, rather than 
total amount of n-3 and n-6 intake could therefore be of a greater relevance to AD 
pathology.  
 
1.5.4.3.4 Animal models 
 
Increases in dietary n-6 (safflower oil) in AD transgenic models increase 
synaptic loss (Calon et al. 2005, Calon et al. 2004, Cole et al. 2010). A direct 
relationship between dietary n-6/n-3 has been demonstrated in transgenic APP mice 
that showed that a DHA enriched diet (low n-6/n-3 ratio) compared to a DHA 
depleted diet (high n-6/n-3 ratio) reduced cortical Aβ burden by 70 % and reduced 
cerebral plaque burden by 40 % (Lim et al. 2005). A similar study conducted by 
Oksman et al. (2006) using transgenic APPswe/PS1dE9 mice on a diet with different 
n-6/n-3 ratios showed a significant reduction in Aβ42 levels in the hippocampus for 
diet with 1.4 n-6/n-3 ratio compared to their respective diets with higher proportions 
of n-6 relative to n-3 (ratios 8 and 70) (Oksman et al. 2006). The same study 
showed that 4 month 40 % SFA + 1 % CH feeding induced a non-significant 
increase in hippocampal Aβ40 and Aβ42 (Oksman et al. 2006). However, 
intervention with a diet containing 5 % DHA and 15 % SFA feeding reduced Aβ40 
and Aβ42 in the hippocampus (Oksman et al. 2006). Another study in amyloid 




levels increased but non-significantly with greater n-6/n-3 ratios (10.3 vs 2.8) 
compared to controls (Arsenault et al. 2011). Additive effects of PUFA with or 
without SFA have also been studied in transgenic amyloid mice models. A study by 
Julien et al. (2010) showed that a high ratio of n-6/n-3 (77) paired with low fat 
feeding (making up 5 % fat w/w) reduced cortical Aβ40 and Aβ42, whilst the same 
ratio with high SFAs derived from lard (35 % w/w) increased both soluble and 
insoluble Aβ after nine months feeding (Julien et al. 2010). The author concluded 
that dietary fat increased in cerebral amyloidosis was not linked to increase in total 
APP or APP processing products in brain and alteration of brain Aβ42/40 ratio was 
more likely (Julien et al. 2010).  
 
1.5.4.3.5 Cell models 
 
Cell studies relating to PUFAs and Aβ have mainly focused on the individual 
effects of n-6 or n-3 rather than the effects of changes to n-6/n-3 ratios. Amtul et al. 
(2010) showed that the addition of n-3 and n-6 PUFAs (EPA and AA) to APP 
transfected COS-7 cells resulted in an increase in secretion of Aβ40 and Aβ42 
compared to DHA which showed a significant decrease in secretion in a 
concentration dependent manner. The author concluded that the concentration of 
DHA can modulate Aβ secretion via γ- and β-secretases (Amtul et al. 2010). Taken 
together, these studies suggest that intracellular changes in fat concentration and 
ratio can change production and secretion of APP.  
 
 
1.6. Beta-amyloid production from lipogenic organs 
 
1.6.1 Metabolism of exogenous and endogenously derived fats 
 
Following the ingestion of a fatty meal and entrance into the stomach, bile 
emulsifies dietary fats in the small intestine. TGs are the major type of lipid 
absorbed from the diet. Pancreatic lipase hydrolyses TG to monoacylglycerol and 
fatty acids that can be readily absorbed by the small intestinal epithelial cells called 
enterocytes. Within enterocytes, assembly of nascent CMs occurs from the addition 
of TGs, CH, CH esters and phospholipids with apo B48 (Hussain et al. 2001, van 




TG and also endogenous synthesized or new TG for obligatory incorporation into 
CM. A number of proteins are reported to associate with nascent CMs prior to 
secretion, including apo A-I, A-IV, apo J, apo D, apo E and small molecular weight 
proteins such as apo C-II. Nascent CMs are then transported via the Golgi 
apparatus to the basolateral membrane and secreted into mesenteric lymph and 
transported to the thoracic duct from which they enter the circulation via the 
subclavian vein. Circulating CMs interact with plasma HDL and receive apo CII and 
apo E. Apo CII on the surface of CMs can activate LPL which catalyse the 
hydrolysis of TGs from CMs for tissue use (predominantly liver, adipose and 
skeletal tissue). Hydrolysis by LPL results in the formation of smaller TG-poor and 
CH and apo E rich CM remnants. These apo E-rich CMs remnants participate in 
rapid clearance by the liver which is mediated by LDL-R and apo B100/E receptor-
specific processes (Hussain et al. 1996). Please see other articles by Hussain 
(2014 review) for more detail regarding CM production. 
 
Hepatocytes are the major liver cell type responsible for clearance of 
postprandial CMs. Dietary-derived substrate and endogenous biosynthesis of TG 
are secreted by hepatocytes as nascent VLDL. The physiochemical properties of 
VLDL are similar to CMs in that they are enriched in TG and comprise a large 
structural protein (apo B100). Like CMs, apo CII-activated hydrolysis of VLDL-TG by 
capillary lipases progressively hydrolyze TG, resulting in a lipid depleted VLDL 
remnant particles or intermediate density lipoprotein IDL. The remnant VLDL 
particles share clearance pathways with remnants of postprandial lipoproteins and 
to a large extent are cleared, however approximately half are hydrolyzed further by 
hepatic lipases resulting in CH-rich LDL. Circulating LDL interacts with LDL-
receptors (via apo B) and is internalized via a classical endocytotic pathway 
involving lysosomal degradation.  
 
In humans and some other species, CMs are distinguished from hepatically 
derived VLDL in that they contain a truncated variant of apo B100, a consequence 
of messenger ribonucleic acid editing.  Enterocytic apo B48 is approximately half the 
amino acid length of apo B100, but serves the same principal function of providing 
structural integrity to relatively large macromolecules. Whilst metabolism of CMs and 




the catabolic cascade is much quicker for CMs, a consequence of stereotactic 
interactions of apo E (the primary ligand for clearance) with apo B48.  
1.6.2 Association between plasma triglycerides and Alzheimer’s 
disease 
 
There is accumulating evidence that disturbances in the metabolism of TRLs 
may be associated with increased risk for AD (Altman and Rutledge 2010). A cross-
sectional study (Suryadevara et al. 2003) showed that probable AD patients had 
greater plasma levels of LDL and TG which was present irrespective of pre-existing 
vascular disease. A similar study (Sabbagh et al. 2004) of lipid levels in elderly 
population with probable AD shows increased TG levels in this group compared to 
healthy standard levels. Contrary to these findings, Presecki et al. (2011) reported a 
decrease in TG in subjects with MCI and a significant decrease in TG levels in 
subjects who performed worse in mental function exams. Whilst others found no 
significant association between fasting TG levels in AD and control subjects 
(Adunsky et al. 2002, Mamo et al. 2008, Merched et al. 2000, Reitz et al. 2004). 
Further evidence comes somewhat surprisingly from studies in amyloid transgenic 
mice. Burgess et al. (2006) reported that onset and progression of disease was 
associated with increased plasma Aβ and increased secretion into blood of TRL-Aβ. 
 
1.6.3 The relationship between post-prandial lipid metabolism, beta-
amyloid and Alzheimer’s disease 
 
A reason for discrepancy in findings could be the time of blood collection, as 
food intake and duration since last feed can impact on levels of TG. This information 
was not indicated by Adunsky et al. (2002), Reitz et al. (2004) and Sabbagh et al. 
(2004), where fasting was indicated, the duration was not mentioned by 
Suryadevara et al. (2003) and only Mamo et al. (2008) and Merched et al. (2000) 
stated respective overnight and 12 h fast prior to blood collection. The inconsistency 
in method makes it difficult to interpret plasma TG changes in AD. Disturbances in 
the metabolism of TRLs may be associated with increased risk for AD (Altman and 
Rutledge 2010). One study shows that postprandial lipoprotein metabolism is 
compromised in subjects with probable AD (Mamo et al. 2008). This study analysed 
both fasting (12 h fast) and post-absorptive (4 h fast after consuming meal 




chemiluminescence methods. Results show a 3-fold increase in apo B48 levels 
compared to age-matched control subjects indicating greater plasma concentration 
of TRL in blood. Perhaps it would be more clinically relevant to test post-prandial 
level of TRLs in probable AD rather than fasting lipid levels since this study shows 
that probable AD subjects would have a disturbance in postprandial lipoprotein apo 
B48 concentration. 
 
1.6.4 The distribution of beta-amyloid and plasma lipoproteins 
 
Pathogenic relevance of TRLs in AD might be linked to the ability of 
lipoprotein to bind hydrophobic Aβ in plasma (James and Mamo 2005). A significant 
portion (95 %) of Aβ40 was found to be associated with lipoproteins in pooled AD 
plasma (Kuo et al. 1999). Inadvertently, this association makes detection of 
lipoprotein-bound Aβ more difficult for immunodetection due to lipid masking of 
epitopes (James and Mamo 2005). The plasma Aβ-lipoprotein distribution profile 
between probable AD, and control subjects were explored in one study. Despite 
showing non-significant changes in fasting plasma lipids, Mamo et al. (2008) 
reported that a significant amount of plasma Aβ was found with TRL (57-60 %) 
compared to LDL (12-29 %) and HDL (3.9-5.6 %). The association of plasma Aβ 
with lipoproteins, in particular TRLs indicates the possible role of Aβ in transport and 
metabolism of lipoproteins. Triglyceride-rich lipoproteins (density ≤ 1.019 g/mL) 
detected in this study includes CMs and VLDLs of intestine and liver origin. Although 
it is not possible to deduce the relative abundance of Aβ in CM or VLDL, a previous 
study found an avid association between Aβ and CMs (James et al. 2003) and the 
production and secretion of Aβ-lipoproteins within hepatocytes has also been 
reported (Koudinov et al. 1997).  
 
 Kontush (2004), in a review article proposes that Aβ could be an apo 
component of lipoproteins and the physiological role of Aβ is to regulate lipoprotein 
metabolism. As mentioned above, Aβ peptide has hydrophobic C-terminus which 
allows it to bind to hydrophobic substances such as lipids; the more pathologenic 
Aβ42 being more hydrophobic than the shorter Aβ40. Studies including those 
mentioned in this literature review indicate that Aβ binds with strong affinity to 




underlines that Aβ, as a component of lipoproteins, could function in several ways 
including as an antioxidant, in synaptic activity and in regulation of lipid metabolism.  
 
1.6.5 The association of apolipoprotein B with Alzheimer’s disease 
 
Apolipoprotein B is an apolipoprotein that is present on TRLs and is 
synthesized in the small intestine and the liver. Several clinical studies show that 
disturbances in apo B levels are detected in AD subjects. An increase in apo B 
levels is found in fasting and non-fasting states in AD patients compared to controls 
(Caramelli et al. 1999, Giubilei et al. 1990). In particular, apo B48, an obligatory 
marker for CMs, was shown to increase by 400 % in AD subjects compared to age-
matched controls (Mamo et al. 2008). The relationship of Aβ with dietary fat and 
lipoprotein metabolism provides intriguing evidence that Aβ could be derived from 
lipogenic organs. The small intestine and liver are responsible for production of 
exogenous and endogenously derived fats respectively. Increased plasma TGs and 
apo B in AD subjects, coupled with specific increases of CMs in response to dietary 
fats suggests that Aβ pathology can be associated with post-ingestion kinetics of 
dietary fats.  
 
1.6.6 Beta-amyloid production from lipogenic cells 
 
Given that Aβ in plasma readily binds with avidity to lipoproteins derived from 
the small intestine or liver, the Aβ could also be produced and secreted from 
enterocytes and hepatocytes which synthesize apo B containing TRLs. A study 
using human liver carcinoma (HepG2) cells, which are common model to study 
human hepatocytes with great morphological and functional similarities, show 
presence of soluble Aβ40 within cell medium and cell lysates (Koudinov and 
Koudinova 1997). Analysis of conditioned cell medium revealed secretion of Aβ 
occurs under physiological conditions. Interestingly, secreted Aβ was recovered in 
complex 200-300 kDa with a diverse range of lipids (TG, CH, CH esters, 
phospholipids and apos) which are normally present on lipoproteins. In addition, 
intracellular Aβ associated with Golgi apparatus did not pass through the 30 kDa 
filter. Taken together, the author concluded that Aβ becomes incorporated into 
lipoproteins within the Golgi apparatus and Aβ is secreted in complex with 




possibility that liver hepatocytes can contribute a large portion of plasma Aβ-
lipoproteins. Although this study does not evaluate intestinal/enterocytic Aβ 
abundance, the enterocytes and hepatocytes share similar roles in production and 
secretion of apo B-containing lipoproteins and therefore, may also contribute to Aβ-
lipoproteins in blood.  
 
1.6.7 Plasma chylomicrons- beta-amyloid and Alzheimer’s disease risk 
 
The mechanism(s) underpinning the association of Western styled diets with 
increased risk for AD are not known. Like hepatocytes, some dietary fats may 
stimulate the production of CMs or CM-Aβ complex. Increased hepatic synthesis 
and secretion of VLDL-Aβ complex may synergistically exaggerate plasma 
lipoprotein-Aβ. Mamo et al. (2008) reported that plasma TG and CM concentrations 
were similar in fasted AD versus age matched controls. However, in response to 
ingestion of a mixed lipid meal, the post-absorptive plasma concentration of apo B48 
(CMs) was remarkably four-fold higher in AD subjects compared to controls. The 
latter suggests dietary induced hyer-amyloidemia is not evident when fasted.  
 
Transient postprandial elevations in the plasma concentration of soluble APP 
were reported in otherwise healthy subjects (Boyt et al. 1999) and in kinetic tracer 
studies, James et al. (2003) showed that Aβ may serve as an apolipoprotein of 
CMs. This study examined the possibility that Aβ can bind and follow the metabolic 
pathway of CMs throughout the transport and clearance of the particles. Using a 
synthetic model of Aβ bound to CM (synthetic Aβ was incorporated into an artificial 
lipoprotein molecule which is similar to chylomicrons [density = 1.006 g/ml]) and 
injected into the ear vein of new Zealand white rabbit, the particle was traced and 
identified in major organs – spleen, brain, liver, adipose tissue, muscle, bone 
marrow, lung and kidney. This study found iodine 125 radiolabelled Aβ took on 
similar metabolic pathway as cholesterol ester and transported primarily to fatty-rich 
tissues (adipose tissue [22.4 ng], liver [12.0 ng], bone marrow [8.0 ng] and muscle 
[2.6 ng]). In addition, the Aβ-CM like molecules was cleared at a strongly 
comparable pace as cholesterol esters over 30 min indicating that Aβ does not alter 
the kinetics of lipoprotein clearance. The association of Aβ with lipids supports the 
possibility that altered lipid metabolism, for example in cases where aberrations in 




plasma Aβ homeostasis and therefore AD risk. This study also supports that this 
lipoprotein-Aβ complex can attach to vasculature in particular BBB via receptor-
mediated processes.  
 
1.6.8 Plasma beta-amyloid and postprandial lipoproteins contribute to 
cerebral pathology  
 
 Plasma lipid levels and also Aβ have been previously shown to be 
responsive to intake of dietary fats, although the causative reasons are currently not 
well understood. Postprandial lipemia refers to a period of time where changes in 
plasma lipids and lipoproteins occur after the ingestions of a high fat meal. This 
postprandial state is largely reflected by the increase in CMs, VLDL and remnant 
particles as well as a decrease in LDL and HDL (Vigna et al. 1999). This increase in 
CMs, VLDL and their respective remnants can play a role in the development of 
atherosclerosis by ineffective catabolism (Mamo et al. 1998) and the retention of 
these apo B-containing lipoproteins by endothelial cells (Proctor et al. 2002).  
 
Numerous studies support increased dietary SFAs increase APP (Amtul et 
al. 2011a, Ho et al. 2004, Patil et al. 2006, Shie et al. 2002) processing which 
contributes to increased risk of developing AD (Julien et al. 2010, Koudinov and 
Koudinova 1997, Mamo et al. 2008, Olsson et al. 2003). Given that consumption of 
a fatty meal in humans can induce post-prandial lipidemia and high levels of apo B 
and TG, it is reasonable to assume that there is an increased amount of atherogenic 
CMs with Aβ and remnant particles present in plasma. It is possible to assume that 
an increase in plasma CMs can also mean increased levels of CM-Aβ in plasma as 
well under the postprandial state as there is clear evidence to suggest that AD 
patients could have aberrant postprandial lipoprotein metabolism including a build 
up of atherogenic remnant particles (Mamo et al. 1998). In addition, damage to the 
BBB and vasculature is frequently reported in AD patients and damaged BBB can 
mechanistically cause an increase in Aβ influx (refer to section 3). There is evidence 
that apo B, the obligatory apolipoprotein of intestinal and liver lipoproteins VLDLs 
colocalizes with cerebral amyloid plaques in humans and transgenic mouse models 






1.7 Section summary 
 
The gradual “loss of mind” associated with AD is undoubtedly the most 
devastating consequence for individuals suffering with the disease. The Aetiology of 
the disease is unknown and there is presently no cure. Currently 300,000 people in 
Australia and 35 million people world-wide have AD and numbers are expected to 
triple by 2050. AD is a chronic disease of insidious nature followed by gradual and 
progressive loss of cognitive function which results in behavioral disturbances to 
episodic memory, language, executive function and visuospatial abilities. Abnormal 
deposits of insoluble amyloid protein and tau are visualised in post-mortem brain 
examinations of AD patients and are considered to be hallmark features of AD; 
however there is no explanation for the sporadic form of AD which constitutes about 
99% of all cases. 
 
An accumulating body of epidemiological, animal and cell research verifies 
the role of dietary fats in the pathogenesis of AD including a direct link between the 
amount and type of fat consumed and the production of Aβ, which has been 
identified as the main pathological protein in AD. Dietary fats can influence the risk 
of AD via regulation of the key steps of Aβ metabolism including production, 
transport/clearance and deposition.  
  
Currently there is no direct evidence for the origin of cerebral plaque Aβ; 
however several key articles suggest plasma Aβ influx in sporadic AD could 
contribute to cerebral Aβ load. Dietary fat intake and CH can modulate this process 
possibly by altering BBB integrity, modulating the availability of Aβ chaperone 
proteins (including TRLs) and/or increasing the production of Aβ from APP.  
 
Despite the use of compensatory treatments which offer some delay in the 
disease progression, AD progressively destroys cognitive function leading to 
eventual complete impairment and death of the affected person. Urgency is required 
for the better understanding of AD disease mechanisms in order to prevent the 
development of AD and delay the disease progression in AD affected persons. 
Current literature summarises that irreversible neurotoxicity in AD can be 




























Chapter 2 – Intestinal Aβ expression and effects by high fat 
feeding 
 
The content of this chapter is covered by article 1:  
 
Galloway S, Jian L, Johnsen RD, Chew S, Mamo JCL. (2007) B-amyloid or its 
precursor protein is found in epithelial cells of the small intestine and is stimulated 




Objective 2: To determine whether or not Aβ is expressed in small intestinal 
enterocytes and if this expression can be modified by a high fat and CH diet. 
 
Hypothesis: Aβ is found in the small intestinal epithelial cells (enterocytes) 




Cerebral deposition of Aβ peptide is causally associated early onset type 
AD, it is currently not known whether if Aβ plaques occur as a secondary event in 
late onset form of AD. The prevalent paradigm suggests that accumulation of Aβ in 
the brain initiates a cascade of events which leads to Aβ-induced synaptic toxicity 
and neuronal cell loss. Cerebral Aβ protein could be derived from the brain, the 
periphery, or a combination of both; the origin of Aβ remains unclear. Local and 
peripheral contributions are both possible considering that APP is ubiquitously 
expressed throughout the body; Aβ is produced under physiological conditions and 
is normally present in cells, interstitial fluid, plasma and CSF. In blood and CSF, Aβ 
associates with chaperone molecules and significant Aβ preferentially binds to 
lipoproteins. The presence of apo E, E4 is present in half of AD cases, and apo E is 





Epidemiological studies which show the risk of developing AD increases 
with high consumption of dietary fats, in particular SFAs and CH. This was 
additionally confirmed in animal models. High fat and CH feeding in animal models 
results in exacerbated cerebral Aβ plaque load compared to low fat feeding. There 
is intriguing evidence to suggest that Aβ can be involved in the metabolism of 
dietary regulated lipoprotein CMs. Chylomicrons are lipoproteins produced in the 
small intestinal epithelial cells and are secreted in response to high fat feeding. It is 
not known however whether or not the small intestine also produce Aβ. This study is 
aimed at investigating this possibility by using wild-type mice fed high fat CH diet. 
Beta-amyloid and/or APP were determined by semi-quantitative 
immunohistochemistry, the antibody AB5076 detects Aβ isoforms (includes 40 and 
42) as well as APP. The expression of Aβ/APP was found within epithelial cells or 
enterocytes of the small intestine under low fat feeding. In addition, high fat CH 
feeding significantly increased enterocytic abundance of Aβ. 
 
The findings are consistent with the possibility that Aβ could be a regulatory 
apolipoprotein of CMs. In addition, pathology of diet-induced cerebral amyloidosis 
can be linked to intestinal Aβ production and abundance. Chapter 2 will discuss 






















































The content of this chapter is covered by article 2:  
 
Galloway S, Pallebage-Gamarallage MM, Takechi R, Jian L, Johnsen RD, Dhaliwal 
SS, Mamo JC. (2008) Synergistic effects of high fat feeding and apolipoprotein E 
deletion on enterocytic amyloid beta peptide abundance. Lipids Health Dis. 7, 15. 
 
Objective addressed:  
 
Objective 3: To determine if apo E deletion in the presence of high fat 
feeding would have an effect on intestinal Aβ in wild-type and apo E gene knockout 
mice. 
 
Hypothesis: Apolipoprotein E can modulate enterocytic Aβ expression and 
this can be influenced by changes in dietary fat content.    
 
Article summary:  
 
We have previously determined the presence of Aβ within the small intestinal 
absorptive epithelial cells with specific immunological methods. Our observations 
showed that whilst high fat (HF) feeding increased abundance of enterocyte Aβ 
dramatically, fasting resulted in abolishment of Aβ expression. An allelic variation of 
apo apo E, apo E4, increases the risk of developing AD by modulating production, 
transport/solubility and clearance of Aβ. Apolipoprotein E is involved in redistribution 
of CH in the body and in the presence of apo E4, there is an accumulation of CH. 
High dietary fat-induced hypercholesterolemia in wild-type (WT) and transgenic AD 
animals resulted in greater levels of cerebral Aβ compared to low fat (LF) chow fed 
controls.  
 
To investigate the role of apo E in intestinal Aβ abundance, genetically 




synergistic effect of HF feeding was determined by feeding apo E knockout (KO) 
mice on HF and CH diets. Immunohistochemistry was used to determine semi-
quantitative abundance of Aβ. We found increased intestinal Aβ under HF feeding 
compared to LF fed apo E KO mice. In addition, plasma CH was significantly 
enhanced in apo E KO mice compared to WT controls. Intestinal villi height 
increased with HF feeding in WT mice, whilst remained unchanged in apo E KO 
mice.  
 
The mechanism by which HF feeding increases enterocytic Aβ abundance in 
apo E KO mice is unclear. However, some studies show apo E can interact with γ-
secretase activity and modulate proteolysis of Aβ from APP. High fat feeding 
increases absorption of lipids and synthesis of CMs and Aβ via greater availability of 

























































Chapter 4 – Colocalization of intestinal Aβ with apo B 
 
 
The content of this chapter will be covered by article 3: 
 
Galloway S, Takechi R, Pallebage-Gamarallage MM, Dhaliwal SS, Mamo JC. 
(2009) Amyloid-beta colocalizes with apolipoprotein B in absorptive cells of the small 
intestine. Lipids Health Dis. 8, 46. 
 
Objective addressed:  
 
Objective 4: To ascertain whether intestinal Aβ associates with apo B within 
the enterocytes of the small intestines. Secondly, to further determine if high fat 
feeding can modulate the degree of association between intestinal Aβ and apo B. 
 
Hypothesis: High fat feeding will increase the association between Aβ and 
apolipoprotein B in enterocytes. 
 
Article summary:  
 
It is clear from previous studies that intestinal expression of Aβ is regulated 
by dietary fat intake. We have previously shown high fat feeding increased Aβ 
abundance compared to low-fat groups whilst fasting abolished expression. 
Immunolocalisation of Aβ expression within enterocytes occurs specifically above 
the nucleus in “perinuclear” location, at the site of proteins and CM synthesis. 
Several lines of evidence suggest that Aβ can bind to and behave as a regulatory 
apolipoprotein component of CMs. There exists a possibility that Aβ can form a part 
of primordial lipoprotein during the process of lipidation, however it is not currently 
known if this happens and if so, to what extent. This study utilizes 3D double IF to 
determine if enterocytic Aβ associates with intestinal lipoprotein CMs. 
 
A significant abundance of apo B (an obligatory component of CMs) and Aβ 
was found within the perinuclear location of enterocytes. Both apo B and Aβ co-
localised with the Golgi apparatus. Patterns of Aβ and apo B remained essentially 




for high fat groups. Co-localization studies show that 73 % of Aβ associates with 
apo B increasing to 87 % under high fat feeding. This study provides in vivo 
evidence that Aβ is secreted as a CM complex within enterocytes and explores the 
plasma kinetics of plasma Aβ-lipoprotein in context with the association between 













































































5.1 Introduction and background:  
 
5.1.1 Global variation in Alzheimer’s disease prevalence  
 
Global variations in diet and lifestyle and in particular dietary fat intake have 
been linked to the incidence and prevalence of AD (Grant 1998). Geographically, 
AD is not uniform and there is a significantly lower prevalence in developing 
countries in comparison to developed countries (Prince et al. 2004, Chandra et al. 
1998, Hendrie et al. 1995). A meta-study (Ferri et al. 2005) shows that AD incidence 
is highest in North and Latin America (5.4 %), followed by Europe (4.4 %) and 
developed pacific regions including Australia, Japan, Singapore and South Korea 
(4.3 %). Developing west pacific regions (China and Vietnam (4 %)), Africa (3.6 %), 
Indonesia (2.7 %), Thailand (2.7 %), Sri Lanka (2.7 %) and India (1.9 %) have lower 
AD prevalence.  
 
Countries with a high incidence of AD generally have higher fat intake than 
countries exhibiting a low incidence of AD. Moreover, accelerated rates of 
prevalence of AD in developing countries are thought to reflect in part, a transition to 
western diet and lifestyle patterns. The Honolulu-Asia Aging study showed that 
when Japanese men migrated to countries with greater dietary saturated fat intake 
(than Japan), these men were at greater risk of developing AD (Shadlen et al. 2000, 
Havlik et al. 2000, Graves et al. 1999). 
 
5.1.2 Fatty acid types differentially regulate risk of developing 
Alzheimer’s disease 
 
Although general trends are suggestive that total fat and caloric intake are 
positively correlated with increased prevalence of AD, epidemiological studies are 
consistent with the notion that the AD-dietary fat nexus principally reflects fat-type. 




demonstrating an association between dietary SFAs intake and chronic vascular-
disorders such as cardiovascular disease (CVD), diabetes, obesity and AD (Morris 
et al. 2003). Conversely, a Mediterranean diet rich in olive oil (MUFA-rich) and ‘oily 
fish’ rich in n-3 PUFAs can be protective against AD (Scarmeas et al. 2007, 
Scarmeas et al. 2009). 
 
5.1.3 Saturated fatty acids and cholesterol in Alzheimer’s disease risk  
 
A number of epidemiological studies show that high dietary intake of SFAs 
and cholesterol is linked with increased prevalence of AD. A longitudinal cohort 
study of 1449 subject based CAIDE (Cardiovascular risk factors, Aging and 
Dementia) study with median follow-up time of 21 years, showed that dietary SFAs 
during midlife was associated with poorer cognitive function and mild-cognitive 
impairment (Eskelinen et al. 2008). Similarly, another study of 815 subjects aged 65 
and over with 4 year follow-up showed that intake of SFAs was positively associated 
with developing AD (Morris et al. 2003). In the Rotterdam Study of 5386 subjects 
over the age of 55, increased SFAs and cholesterol intake was were linked to 
increased risk for dementia after just a 2 year follow-up (Kalmijn et al. 1997) and in 
another large epidemiological study, Luchsinger et al. (2002) also reported that high 
intake of SFAs increase the risk of AD. Dietary cholesterol and high serum 
cholesterol levels mid-life may have synergistic effects with SFAs for increasing AD 
risk based on observations reported by Kivipelto et al. (2001, 2002). 
 
5.1.4 Unsaturated fatty acids in Alzheimer’s disease risk 
 
Studies of dietary behaviour in the United States of America (Scarmeas et al. 
2007, Feart et al. 2009), France (Tangney et al. 2011), South Italy (Solfrizzi et al. 
1999), and more recently, Australia (Gardener et al. 2012) suggest that increased 
intake of MUFAs can be protective against cognitive decline and by extension AD. In 
addition, a number of epidemiological studies show that frequent consumption of oily 
fish has been shown to be protective against cardiovascular disease, cognitive 
decline and AD (Barberger-Gateau et al. 2002, Morris et al. 2003, Morris et al. 2006, 
Freund-Levi et al. 2006, Schaefer et al. 2006; Kalmijn et al. 1997, van Gelder et al. 
2007). Oily fish is a major source of n-3 PUFAs, mainly eicosapentaenoic acid 




structure and function. Docosahexaenoic acid improves learning ability in animals 
(Lim and Suzuki 2000, Gamoh et al. 2001, Calon et al. 2004) and DHA has also 
been shown to decrease Aβ secretion from neuronal cells (Lukiw et al. 2005). As the 
body can only synthesise a small amount of EPA and DHA from α-linolenic acid 
(ALA) (Pawlosky et al. 2001), dietary intake of long chain n-3 fatty acids forms the 
major brain source. Despite these findings that support the benefits of PUFAs in 
dementia prevention, other studies have shown no benefit of fish intake on dementia 
risk (Laurin et al. 2003, Engelhart et al. 2002). Devore et al. (2009) attributes the 
discrepancy between such findings to be a result of the different stages of AD 
progression, heterogeneity in risk factors and complexity of the pathophysiological 
evolution of the disorder. 
 
5.1.5 Vascular changes and origin of beta-amyloid in Alzheimer’s 
disease pathology 
 
A significant body of research has investigated factors regulating central 
biosynthesis, secretion and oligomerisation of cerebral Aβ. However, the exact 
origin of Aβ deposits in amyloid plaque or precursor cerebral amyloid angiopathy is 
presently not established. Since plaque and capillary deposits of Aβ are 
homologous to soluble Aβ found in blood and CSF (Busciglio et al. 1993, Vigo-
Pelfery et al. 1993), the exact source/s of cerebral insoluble Aβ cannot be 
distinguished. Therefore, it is reasonable to assume brain Aβ can be derived from 
peripheral sources in addition to the central nervous system per se. There are 
several lines of evidence that support the notion that peripheral (blood-derived) Aβ 
may contribute to cerebral Aβ pathology (Zlokovic et al. 1993). Clifford et al. (2007) 
showed that 19 out of 21 AD brains showed extravasation of plasma proteins and in 
the same study, venous injection of fluorescence labelled Aβ into BBB damaged 
mice (induced by pertussis toxin) showed leakage of Aβ40 and Aβ42 in brain 
arterioles and parenchyma. Perfusion of synthetic Aβ40 and Aβ42 in neck blood 
vessels of guinea pigs has also been shown to cause BBB sequestration and 
transport of Aβ40 and Aβ42 into the brain (Martel et al. 1996). There is evidence 
that soluble Aβ travels bilaterally from the blood to the brain via non-specific and 
active pathways and via specific transporters, carriers or receptors and that plasma 
soluble Aβ can contribute to cerebral pathology (Zlokovic 2005) (refer to Chapter 1, 





5.1.6 High fat diets; lipogenic organs and Alzheimer’s disease risk 
 
The functional units of lipogenic organs, the small intestine (Galloway et al. 
2007, Pallebage-Gamarallage et al. 2009) and liver (Koudinov and Koudinova 1997, 
Galloway et al. Unpublished observations) can synthesize and secrete hydrophobic 
Aβ complexed to lipoproteins. Galloway et al. (2009) reported that absorptive 
epithelial cells of the small intestine showed increased enterocytic abundance of A 
in response to a well tolerated diet that was enriched in SFA and cholesterol. 
Conversely, fasting abolished enterocytic A suggesting a postprandial lipid 
regulatory pathway of enterocytic Aβ secretion (Galloway et al. 2007). Consistent 
with these findings, Boyt et al. (1999) reported increases in soluble APP following an 
oral mixed meal challenge containing significant dietary lipids. Moreover, James et 
al. (2003) showed that Aβ can bind and is metabolised when complexed with 
triglyceride-rich lipoproteins. These findings are consistent with the notion that 
lipoprotein-Aβ production and secretion into plasma is a postprandial phenomenon 
and are the first in the literature to suggest novel and alternative mechanisms of 
action concerning dietary fat induced increases in peripheral Aβ-lipoproteins post 
meals.  
 
In a physiological context, metabolism of postprandial lipoproteins has been 
linked to initiation of an inflammatory cascade of events in atherosclerosis and 
arterial entrapment of apo B-containing lipoproteins (including CMs) in the intimal 
arterial wall (Proctor et al. 2003). Interestingly, in cases of probable AD and 
cognitive impairment, subjects also have exhibited delayed responses to oral fat 
loading test. Mamo et al. (2008) suggested that late-onset AD could in part be 
consequence of delayed apo B-Aβ-lipoprotein clearance. Indeed, plasma Aβ has 
been shown to negatively affect the integrity of the BBB by damaging endothelial 
and smooth muscle cells resulting in altered blood flow and increased vascular 
resistance (Thomas et al. 1996, Crawford et al. 1998, Arendash et al. 1999, Suo et 
al. 1998, Jancso et al. 1998). These findings led to the hypothesis that exaggerated 
vascular exposure to post-prandial lipoprotein A may compromise cerebral 
capillary function with subsequent parenchymal extravasation of blood-derived apo 
B-lipoprotein A. This hypothesis is consistent with previous findings on intestinally 





Although the differential regulation of SFAs (Galloway et al. 1997) and 
cholesterol (Pallebage-Gamarallage et al. 2009) has been previously reported, 
the effect of UFAs in enterocytic Aβ has not been previously studied. As dietary 
fats can differentially regulate metabolism of exogenously derived lipids by 
modulating the production and secretion of intestinal apo B-containing 
lipoproteins, they can by extension also regulate the apo B-Aβ-lipoprotein 
complex which is implicated in AD. A primary objective of this candidacy was to 
determine the effects of diets containing predominantly SFA, MUFA or PUFA on 
enterocytic Aβ abundance.  
 
The objective of this study is to investigate if fatty acid types (saturated 
fat, monounsaturated fat or polyunsaturated fat) can differentially regulate 
intestinal Aβ expression and plasma abundance of apo B and Aβ. We 
hypothesize that saturated fat will increase, whilst unsaturated fatty acids will 
decrease enterocytic Aβ. To test the hypothesis, we used wild type mice fed 
different either low 4 % w/w fat diet or 20 % w/w diet as predominant SFA, 
MUFA or PUFA.  
 
 
5.2 Materials and methods 
 
5.2.1 Animals and maintenance 
 
Six week-old female wild-type C57BL/6J mice weighing approximately 16g 
were obtained from the Animal Resources Centre (ARC, Perth, Western Australia). 
Animals were randomly divided into groups (n=12 per group): LF (low fat), SFA 
(saturated fatty acid), MUFA (monounsaturated fatty acid) or PUFA (polyunsaturated 
fatty acid) group. Animals were contained in an environment which was controlled 
for temperature, air pressure and lighting (12:12 h light/dark cycles). Mice had 
access to food and water ad-libitum and remained on diets for periods of 19 w and 
38 w, the latter to explore potential duration effects. The body weight of mice and 
the amount of food and water ingested were recorded weekly to ensure adequate 
food consumption and growth. Procedures relating to mice handling and sacrifice 




were approved by a National Health and Medical Research Council (NH&MRC) of 
Australia accredited ethics committee (Curtin University ethics approval no. R 02-
07).   
 
5.2.2 Dietary intervention in C57BL6J mice 
 
Experimental diets were manufactured by Specialty Feeds (Glenn Forest, 
Perth, Western Australia) and were supplied in 5 kilogram vacuum sealed (under 
nitrogen) air tight bags. Standard low fat (LF) rodent laboratory chow (AIN93M, 
Specialty Feeds, Western Australia) contained 4 % fat (w/w) and high fat (HF) chow 
contained 20.3 % (w/w) (or 40 % digestible energy) as fat. The low fat diet consisted 
of 4 % (w/w) total fat of which 2.4 % was oleic acid (18:1 n-9). High fat (HF) diets 
were made by replacing canola oil of LF chow with cocoa butter (SFA group), 
Sunola oil (MUFA group) and NUMEGA fish oil (PUFA group). The SFA chow 
(SF07-050, Specialty Feeds, Western Australia) predominantly contained 5.16 % 
palmitic acid (16:0) and 7.31 % stearic acid (18:0) and also 6.62 % 
monounsaturated fat as oleic acid. The MUFA chow (SF07-051, Specialty Feeds, 
Western Australia) contained 15.7 % oleic acid, 2.4 % linoleic acid (18:2 n6) and 
trace amounts of other fats. The PUFA chow (SF07-049, Specialty Feeds, Western 
Australia) was enriched with fish oil and contained 8.2 % docosahexaenoic acid 
(DHA 22:6 n3), 2.0 % eicosapentaemoic acid (EPA 20:5 n3) with a high n-3/n-6 ratio 
of 13.4. The PUFA diet also contained 3.26 % palmitic acid and 2.25 % oleic acid 

















Table 1: Fatty acid composition of dietary groups (given as % of total weight) 
Diet LF SFA MUFA PUFA 
Fat added Canola oil Cocoa butter  Sunola oil NUMEGA fish oil 
Total fat 4 20.30 20.30 20.30 
SFA 0.30 12.99 1.74 5.12 
Saturated fatty acids C12 
and less n/a 0.1 
not 
detected n/a 
Myristic acid (14:0) trace 0.05 0.02 0.54 
Pentadecanoic acid (15:0) n/a 0.01 n/a 0.16 
Palmitc acid (16:0) 0.2 5.16 0.85 3.26 
Magaric acid (17:0) n/a 0.05 n/a 0.18 
Stearic acid (18:0) 0.1 7.31 0.87 0.92 
Arachidic acid (20:0) n/a 0.24 n/a 0.06 
Behenic acid (22:0) n/a 0.04 n/a n/a 
Tetracosanoic acid (24:0) n/a 0.03 n/a n/a 
MUFA 2.4 6.69 15.79 3.19 
Palmitoleic acid (16:1) n/a 0.05 0.02 0.66 
Heptadecenoic acid (17:1) n/a 0.01 n/a 0.1 
Oleic acid (18:1 n-9) 2.4 6.62 15.7 2.25 
Gadenoic acid (20:1) n/a 0.01 0.07 0.18 
PUFA 1.2 0.72 2.83 11.38 
n-6/n-3 ratio 1.20 13.40 12.48 0.07 
Linoleic acid (18:2n-6) 0.8 0.67 2.42 0.23 
a-linoleic acid (18:3n-3) n/a 0.05 0.13 0.09 
y-linoleic acid (18:3n-6) 0.4 
not 
detected n/a 0.08 
Stearidonic acid (18:4n-3) n/a n/a 0.08 n/a 
Arachidonic acid (20:4n-6) trace 
not 
detected 0.2 0.46 















n/a, data not available 
Table 1 summarizes fatty acid compositions of chow diet of each group: LF, SFA, MUFA and 
PUFA. Proteins, carbohydrates, minerals and vitamins were comparable between groups. 
 
LF low-fat, SFA saturated fatty acid, MUFA monounsaturated fatty acid, PUFA 






5.2.3 Sample collection 
 
Mice from each dietary group were randomly selected for sacrifice at 19 w 
and the remainder were sacrificed at 38 w. Mice were anaesthetized with an 
intraperitoneal injection of Phenobarbital (45 mg/kg). Blood and tissue collection 
methods were as described previously (Galloway et al. 2007, Pallebage-Gamallage 
et al. 2009). Briefly, blood was collected by cardiac puncture into ethylene-diamine-
tetracetic acid (EDTA)-tubes in ice. For intestinal Aβ immunofluorescence, the 
digestive tract was removed and small intestinal length measured from the pyloric 
sphincter to ileocecal valve and recorded. Thereafter the length of the small 
intestines were flushed with chilled phosphate buffered saline (PBS, pH=7.4) and 2 
cm was cut and removed for fixation in 4 % paraformaldehyde. Tissues were fixed 
for 24 h and processed and longitudinal sections were embedded into paraffin wax 
blocks. Sections were trimmed to where all villi were exposed. Five-micron serial 
sections were cut and mounted on silanised-coated slides for immunostaining and 
histology.  
  
5.2.4 Plasma beta-amyloid analysis 
 
Plasma Aβ was measured using a commercially available Biosource ELISA 
kits which detects mouse Aβ40 (KMB3481; Invitrogen, Carlsbad, CA USA) and Aβ42 
(KMB3441; Invitrogen, Carlsbad, CA USA) with rabbit monoclonal antibody raised 
C-terminus of mouse Aβ42. ELISA immunodetection method was performed as per 
the instructions of the manufacturer and as previously described (Takechi et al. 
2010). The standard provided for Aβ40 is detectable from 0 – 500 pg/ml and Aβ42 
detection range is from 0-200 pg/ml. Manufacturers claim Aβ40 antibody does not 
recognise Aβ42 or Aβ43 and Aβ42 antibody does not detect Aβ40 or Aβ43.  
 
5.2.5 Plasma lipid analysis 
 
Plasma lipids were measured using absorbance based assays which are 
commercially available. Total plasma triglycerides were determined by 
measurement of surrogate marker glycerol produced from triglyceride hydrolysis (TR 
1697, Randox laboratories, U.K). Cholesterol esterase/oxidase technique was used 





5.2.6 Plasma apolipoprotein B analysis 
  
Plasma apo B was determined in mouse plasma by Western blots and 
quantified by densitometry as previously described (Galloway et al. 2009).  
 
5.2.7 Immunofluorescent detection of enterocytic beta-amyloid 
 
Analysis of intestinal Aβ using immunofluorescent microscopy was done as 
previously described (Takechi et al. 2008b, Pallebage-Gamarallage et al. 2012). In 
brief, tissue sections (5 μm thick) were deparaffinised and rehydrated and then 
placed in boiling deionised water for 15 mins to retrieve antigens and for a further 10 
mins in PBS to permeabolise tissues before blocking in 20 % goat serum. Rabbit 
anti-human Aβ (AB5076, Chemicon Temecula, CA) was diluted to 1:1000 in PBS 
and then added to slides and allowed to incubate overnight at 4 °C followed by 1 h 
incubation in goat anti-rabbit IgG (1:200) (E0432, DAKO, Carpentaria, CA) at room 
temperature. Immunofluorescence was visualised with addition of anti-rabbit IgG 
with Alexa488 (1:100). Cell nuclei were labelled with DAPI (1:1000) (Invitrogen, 
Victoria, Australia) and sections were mounted on anti-fade mounting medium and 




Immunofluorescent digital images of X 100 magnification (Plan Neofluar x20 
objective, 1.3 numerical aperture) for photomicroscopy were acquired by AxioCam 
HRc camera (Zeiss, Germany) using AxioVert 200 M inverted microscope (Zeiss, 
Germany). Identical conditions were used to simultaneously capture fluorescent 
images. Assessment of pixel intensity for Aβ measurements were done using 
version 5.5 of AxioVision software. Filters used for excitation and emission were 
determined based on individual characteristics of fluorophores. Filter 38 (Ex 
BP470/40, beam splitter FT495 and Em BP525/50) and 49 (Ex G365, beam splitter 
FT395 and Em BP445/50) were used selectively for Alexa488 and DAPI stains 
respectively. Detection of emission from Alexa488 did not overlap fluorescent 
emission from DAPI staining. In addition, images were analysed in a darkroom and 




5.2.9 Quantification of intestinal beta-amyloid abundance  
 
Quantification of fluorescence was performed as previously described 
(Pallebage-Gamarallage et al. 2012). In brief, approximately 40-50 2-dimensional 
(1388 x 1040 pixels) images were captured per treatment group with each image 
containing 4 or more villi. The densitometric sum of Aβ was calculated and villus 
nuclei were counted for each image using automatic measurement tool in 
Measurement module (AxioVision software version 4.7.1, Carl Zeiss, Germany). For 
each image, hue, saturation and threshold was standardised and image modification 
was limited only to removal of auto fluorescent debris of intestinal lumen. 
Quantification of enterocytic Aβ was determined by analysis of overall pixel intensity 
(densitometry) and dividing by the total number of cells counted per field of view. 
 
5.2.10 Statistical analysis  
 
The effect of HF feeding on A abundance, body weight gain, plasma Aβ 
and plasma lipids were assessed by univariate analysis. Outliers were removed 
using Post-hoc comparisons of means were performed and if equal variance was 
not found, then Mann-Whitney test was used to compare the difference between 
individual groups. Correlation studies were performed using Pearson’s correlation if 
data was considered normal; otherwise, Spearman’s correlation was used. A P-
value < 0.05 was considered a statistically significant. Data was analysed and 
graphs were generated using GraphPad Prism version 6, Microsoft Excel 2007 and 
SPSS version 17.0. If data was not considered normally distributed (column 
statistics tool, GraphPad Prism), then data was presented with histogram showing 
min to max; alternatively, bar graph exhibiting mean plus standard error of mean 













5.3.1 Body weight and plasma lipids  
 
Body weight and plasma lipids were determined to monitor animal wellbeing 
and tolerance to diets. All mice gained weight consistently each week throughout the 
course of experiment. There were significant increases in body weight in all 
treatment groups at 19 and 38 w compared to initial weight at the commencement of 
dietary regimen (Fig. 1). At the end of the experiment (38 w), the MUFA group 
gained significantly greater weight than other treatment groups. Conversely, the 
PUFA treated mice gained significantly less weight than other fat supplemented 
treatment groups at the end of the dietary regimen (Fig. 1).  
 
Despite a more modest weight gain in mice maintained on a PUFA enriched 
diet, these mice were moderately hypercholesterolemic compared to control mice 
maintained on the LF chow diet. The mean plasma cholesterol concentration in mice 
maintained on an SFA or MUFA enriched diet was approximately 25 % greater than 
the LF-treated mice. Plasma triglycerides were not significantly different between 
different treatment groups.  
 
In mice, the liver produces apo B48 in addition to apo B100 so there is no 
equivocal marker of intestinal versus hepatic TRLs (Greeve et al. 1993). Therefore, 
total apo B-containing lipoproteins were determined by Western blot analysis. In the 
C57BL/6J mice used in this study and consistent with the plasma lipid data 
suggesting that the diets were well tolerated, chronic maintenance of mice on diets 
enriched in either SFA, MUFA or PUFA had no significant effect on the plasma 











Figure 1: The effect of dietary fats on body weight and weight gain in wild-type 
C57BL6J mice 
 
Figure 1 Data indicated as mean body weight ± standard error of the mean (S.E.M). Change 
in mean body weight of mice maintained on LF, SFA, MUFA and PUFA diets were recorded 
over the duration of the experiment where 0 weeks indicate the commencement of feeding. 
Weight of mice (all groups) was significantly higher than commencement weight (week 0). 
 
LF low-fat, SFA saturated fatty acid, MUFA monounsaturated fatty acid, PUFA 
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Table 2: The effect of various dietary fats on plasma lipid concentration in 
wild-type C57BL6J mice 
 
 Cholesterol (mM) Triglyceride (mM) 
LF 1.84 ± 0.075 0.64 ± 0.056 
SFA 2.23 ± 0.274 0.72 ± 0.125 
MUFA 2.30 ± 0.312 0.67 ± 0.095 
PUFA 2.57 ± 0.164 0.74 ± 0.105 
 
Table 2 Data indicated as mean ± standard error of mean. Univariate ANOVA test was used 
to determine differences between plasma lipids and dietary groups. Single-factor ANOVA 
shows no difference between plasma cholesterol and triglyceride between groups at 19 
weeks.  
 
LF low-fat, SFA saturated fatty acid, MUFA monounsaturated fatty acid, PUFA 






















Figure 2: The effect of various dietary fats on plasma apolipoprotein B 
concentration in wild type C57BL6J mice 
 
Figure 2 Histogram for plasma concentrations of total apolipoprotein B (Fig. 2) indicated as 
mean ± standard error of mean.
 a 
No significant difference was determined between dietary 
LF, SFA, MUFA and PUFA groups (P < 0.05). 
LF low-fat, SFA saturated fatty acid, MUFA monounsaturated fatty acid, PUFA 















5.3.2 The effect of duration of feeding on intestinal abundance of beta-
amyloid in C57BL6J mice 
 
The abundance of intestinal Aβ in response to dietary intake of various fatty 
acids in C57BL6J wild-type mice was assessed with immunofluorescent microscopy 
and protein abundance quantified by calculating fluorescent pixel intensity per cell 
nuclei (Fig. 4). We confirm previous studies that Aβ immunofluorescence (yellow) 
was evident within the mucosal layer of the duodenum comprised principally of non-
ciliated columnar epithelial cells or enterocytes and lamina propria. The distribution 
of Aβ along the villi is more prominent on the body and tips of villi compared to basal 
located and crypt villi cells. Within enterocytes, the location of Aβ is consistent with 
intracellular transport of synthesized proteins from Golgi apparatus and endoplasmic 
reticulum towards secretion on basolateral surface in polarised enterocytes. In 
addition, Aβ was visible particularly within the capillaries and lacteals of the lamina 
propria as evidence of the secretory pathway. 
 
The overall effects of diets enriched in fatty acids (all fatty acid treatment 
groups combined) compared to LF-controls on enterocytic-specific beta amyloid. 
Enterocytic Aβ was increased approximately 6-fold in the fat-supplemented mice 
compared to mice maintained on the LF diet (Fig. 3: LF versus HF). Duration of 
feeding effects was considered to exclude potential confounding effects of dietary 
acclimatization. Without discrimination of fatty acid treatment types, the data 
suggests sustained amplification effects over a 38 w intervention period of fatty acid 
dietary enrichment on enterocytic abundance of Aβ compared to LF fed controls 
(Fig. 3). A comparison of 38 w fed versus 19 w control mice did however suggest 
the possibility of a modest age-associated effect on enterocytic Aβ; however, the 
magnitude of this putative age-associated effect was relatively small compared to 
the effects of fat supplementation per se.  
 
Figure 3 shows HF feeding significantly increased enterocytic abundance 
with no distinguishable difference between 19 w and 38 w durations. Similarly, the 
LF feeding showed no difference between both durations. Based on the lack of 
















Figure 3 Quantitative analysis of enterocytic Aβ between low fat (LF) and high fat (HF: SFA + 
MUFA + PUFA) diets and comparison of enterocytic Aβ expression at 19 w and 38 w of 





duration of feeding did not significantly increase the expression of enterocytic Aβ. High fat 
feeding significantly increased the expression of enterocytic Aβ compared to LF for 19 w and 
38 w using (P < 0.05) 
LF low-fat, SFA saturated fatty acid, MUFA monounsaturated fatty acid, PUFA 

















5.3.3 The effect of dietary fats on intestinal abundance of beta-amyloid 
in C57BL6J mice 
 
The pattern of Aβ fluorescence was detected along the villi and in the 
perinuclear location of all dietary groups; however, the abundance of Aβ was 
different between groups. All HF fed groups (SFA, MUFA and PUFA) exhibit 
significant increase in enterocytic Aβ (pixel area of staining and pixel intensity per 
cell) compared to LF fed controls (Fig. 4). High magnification depicts Aβ is abundant 
within the perinuclear location and traces of Aβ is also evident in the basolateral 
location of enterocytes under SFA feeding (Fig. 4a: SFA frame). In comparison to 
SFA group, unsaturated fatty acid (UFA) feeding showed a similar pattern of Aβ 
immunofluorescence within the absorptive villi of the small intestine. Both MUFA and 
PUFA had relatively greater abundance of Aβ immunofluorescence in perinuclear 
and basolateral areas of enterocytes (Fig. 4a: MUFA and PUFA frames).  
 
5.3.4  Quantitative evaluation of enterocytic beta-amyloid and fatty 
acid effects 
 
Equal caloric diets composed of 20.3 % (w/w) of fats were incorporated into 
the low fat chow containing 4 % (w/w) of fats. The SFA diet contained 65 % total 
SFAs (predominantly palmitic and stearic) significantly enhanced enterocyte 
expression of Aβ by 3.5-fold in comparison to LF group (Fig. 4b). In comparison, 
feeding of 77 % is oleic acid (MUFA) and 56 % n-3 PUFAs also increased intensity 
of Aβ immunofluorescence by 5.4-fold and 7.5-fold respectively compared to LF 
(Fig. 4b). Quantitative evaluation shows that fatty acid and increase calorie intake 










Figure 4a: The effect of dietary fatty acids on beta-amyloid abundance in small 
intestinal villi 
 
Fig. 4a Immunofluorescent images representative for each group showing small intestinal Aβ 
(yellow) and enterocyte cell nuclei (blue). Top row of images shows low-magnification and 
bottom row shows magnified portion of villi (red box) indicating cellular abundance of Aβ in 
enterocytes. The villus consists of a single outer layer of which the predominant cell type is 
enterocytes (mucosa). The lamina propria form the centre of the villi and consist of lacteals, 
blood vessels, lymphatics, and connective tissue. Presence of Aβ is concentrated in the 
perinuclear region of enterocytes with some Aβ evident towards the basal location of cells 
and within the lacteals. The pattern of staining is consistent in each group. Abundance of Aβ 
is increased in high fat (HF) feeding which was specific to the type of fat ingested. Scale bar 
= 40 µm (top row) 10 µm (bottom row).  
LF low fat, SFA saturated fatty acid, MUFA monounsaturated fatty acid, PUFA 





Figure 4b: Quantification and analysis of the effect of dietary fatty acids on 
enterocytic beta-amyloid. 
 
Figure 4b bar graph and table presents histogram of median with min, max and quartiles for 
optical density value of enterocytic Aβ immunofluorescence between LF control, SFA, MUFA 
and PUFA groups. Optical density per cell = [mean OD x pixel area] / total number of cells 
counted. 
b
 Indicates significant difference compared to 
a 
LF group (P < 0.05). 
LF low fat, SFA saturated fatty acid, MUFA monounsaturated fatty acid, PUFA 

















5.3.5 Effect of dietary fats on plasma beta-amyloid 40 and beta-amyloid 42 
 
Increased enterocytic abundance of Aβ may translate to increased secretion 
into lacteals and blood. Plasma Aβ40 and Aβ42 were measured and having 
confirmed no duration-of-feeding effects within treatments (19 w versus 38 w), 
therefore pooled data is presented. Irrespective of treatment group, there was 
approximately an 8-fold greater concentration of Aβ40 in plasma compared to Aβ42. 
The potential differential effects of dietary fat supplementation on plasma Aβ 
isoforms are indicated in Figure 5. There was no substantive effect of dietary fatty-
acid treatment on plasma Aβ40 concentration compared to LF-controls. However, 
the median plasma Aβ42 appeared markedly greater in fat supplemented mice with 
MUFA > PUFA > SFA > LF. However, significant within fatty-acid treatment group 
variability did not realize statistically significant differences (Fig. 5a and 5b). 
Consistent with the notion of greater Aβ42 relative to Aβ40, the plasma ratio was 
significantly greater in mice on fatty acid enriched diets compared to LF-controls 
















Figure 5a: The effect of dietary fats on plasma beta-amyloid 40 
 
 
Figure 5b: The effect of dietary fats on plasma beta-amyloid 42 
 
Figure 5c: The effect of dietary fats on plasma beta-amyloid 42/40 ratio 




Figure 5 Data shows plasma Aβ40 (5a), Aβ42 (5b) and Aβ42/Aβ40 ratio (5c) measurements 
for LF, SFA, MUFA and PUFA groups. Plasma Aβ40 and Aβ42 are indicated by histogram 
(median, min, max and quartiles) and Aβ42/40 ratios are indicated as mean ± standard error 
of mean 
a 
No significant difference was found between dietary groups (P > 0.05).  
 
LF low fat, SFA saturated fatty acid, MUFA monounsaturated fatty acid, PUFA 
polyunsaturated fatty acid. 
 
5.3.6 Association between plasma beta-amyloid and plasma 
apolipoprotein B 
 
Figure 4 in this chapter indicates that diets enriched in dietary TG enhance 
Aβ abundance within enterocytes and this observation was independent of the TG 
fatty-acid isoforms of SFA, MUFA and PUFA. Chapter 4 (Galloway et al. 2009) 
demonstrated the colocalisation of enterocytic apo B with Aβ and degree of 
association determined by Manders Overlap Coefficient was significantly enhanced 
in SFA fed group. These observations are consistent with the possibility of increased 
chylomicron biogenesis and secretion occuring in association with increased 
enterocytic Aβ abundance, although the abundance of Aβ and apo B were not 
dependent (chapter 4) suggesting that the relative abundance of Aβ per CM may 
also differ between dietary treatment groups.  The relative ratio of plasma Aβ to apo 
B lipoproteins may therefore provide some insight into relative enrichment as a 
consequence of fatty acid feeding. Figure 6a shows no significant difference 
between fatty acid treatment groups in the concentration of Aβ40 relative to the LF 
group, however there was significant inter-group variability and therefore statistical 
significance was not realized. Some evidence of increased enrichment with Aβ42 of 











Figure 6a: fatty acid diet effects on ratios of beta-amyloid 40 to apolipoprotein B 
  
Figure 6b: fatty acid diet effects on ratios of beta-amyloid 42 to apolipoprotein B 
 
 
Figure 6 Ratios of Aβ40 and Aβ42 to plasma apo B are shown as histograms in figure 7a 
and 7b respectively. 
a
 Indicates significant difference compared to LF control group (P < 
0.05). 
 
LF low fat, SFA saturated fatty acid, MUFA monounsaturated fatty acid, PUFA 







This study utilized wild-type C57BL/6J mice that are widely used for studying 
lipid disorders such as atherosclerosis. Experimentally, these mice have 
demonstrated good tolerance to high SFA and CH diets, with a similar degree of 
enrichment as indicated in this study (Pallebage-Gamarallage et al. 2009, 
Pallebage-Gamarallage et al. 2012). The aetiology of AD is unknown, however the 
presence of an isoform of apo E, E4 (allele) in up to 50 % of AD cases has led to the 
notion that AD could be a result of a disorder in lipid metabolism (Lindsay et al. 
2002). However, some dietary fats especially SFAs have been increasingly reported 
to be associated with increased prevalence of AD in large multi-nation 
epidemiological studies (Grant 1998, Morris et al. 2003, Shadlen et al. 2000, Havlik 
et al. 2000, Graves et al. 1999). However, the link between AD and postprandial 
lipoproteins, including apo B-containing lipoproteins, which are produced and 
secreted in response to exogenous availability of dietary fatty acids is not well 
understood. We previously hypothesized that dietary fat induced stimulation of CM’s 
enriched in Aβ, might increase AD risk as a consequence of exaggerated 
cerebrovascular exposure to lipoprotein associated Aβ (Takechi et al. 2008a). 
Consistent with this hypothesis, we reported that C57BL/6J mice maintained on an 
SFA diet for 12 w had BBB dysfunction and blood-to-brain delivery and retention of 
apo B associated lipoproteins (Takechi et al. 2010b). However, mice maintained on 
diets enriched with MUFA or PUFA did not demonstrate brain parenchymal 
extravasation of apo B lipoprotein associated Aβ. Therefore, a primary objective of 
this candidacy was to explore the hypothesis that diets enriched in saturated or 
unsaturated fatty acids, differentially modulate Aβ biogenesis. 
 
Immunofluorescent microscopy captured images showed expression of Aβ 
within the proximal small intestine of C57BL/6J mice and specifically on the mucosal 
layer and confined to simple epithelium containing enterocytes as well as lacteals. 
Within polarized enterocytes, the presence of Aβ was visible within the perinuclear 
location, the site of ER and Golgi apparatus. The pattern and location of staining is 
consistent with previous demonstrations of intestinal Aβ abundance using IHC 
(Galloway et al. 2007, Galloway et al. 2008, Galloway et al. 2009, Pallebage-
Gamarallage et al. 2009). The pattern of staining remained consistent across groups 




Quantification of enterocytic Aβ was done by image capture and measurement of 
fluorescent intensity or pixel density with automatic measurement software. Pixel 
density was then divided by the number of cells counted to determine mean Aβ 
intensity per cell. High SFA, MUFA and PUFA diets all led to significant increase in 
enterocytic abundance of Aβ compared to LF controls (P < 0.05). This data indicates 
that HF feeding increased enterocytic Aβ without discrimination for fatty acid 
treatment group. In contrast to the hypothesis suggesting that SFA specifically 
would increase enterocytic Aβ relative to equicaloric diets enriched in MUFA or 
PUFA, there was no difference on enterocytic Aβ between fatty-acid treatment 
groups per se. An increase in Aβ staining observed under HF feeding was evident 
within the perinuclear region of the cytosolic compartment suggesting direct effects 
on Aβ biogenesis. 
 
The distribution of Aβ was primarily evident in the perinuclear region and not 
identified at the cell membrane. This observation is consistent with earlier findings 
that 90 % of APP is found to be present in the Golgi apparatus and the trans-Golgi 
network (Haass et al. 1992). In addition, the polarized enterocytes (columnar ciliated 
simple epithelial cells) are structurally built for absorption at the apical surface and 
secretion at the baso-lateral surface. One study of APP production in polarised 
kidney cells found that a large amount of sAPPα is produced in the trans-Golgi 
network (Haass et al. 1995) and a small amount on plasma membrane. 
Colocalization of Aβ with apo B within enterocytes (Chapter 4), is consistent with 
previous findings in cultured liver cells (HepG2 cells) where intracellular Aβ was 
recovered with components of lipoproteins including phospholipids, TG, CH (and CH 
esters) and apolipoproteins (Koudinov and Koudinova 1997). Like hepatocytes, it is 
conceivable that within enterocytes, Aβ is also processed in a similar manner. This 
led to the conclusion that enterocytic Aβ might be involved with the apo B lipidation 
process and CM maturation and thereafter secreted associated with CMs (Galloway 
et al. 2009).  
 
The current chapter identified that both enterocytic Aβ and apo B can be 
strongly stimulated by dietary fatty acids, but as findings of Chapter 4 suggests, the 
synthesis of Aβ and apo B occur independently. Although literature on the effect of 
fatty acids on APP processing is limited, there are some studies of fatty acids effects 




induced an increase in Aβ production by up regulate β-secretase processing of APP 
in primary rat cortical neurons and Lui et al. (2004) demonstrated that oleic acid 
treatment in PSwt1 CHO cells increases APP expression and Aβ abundance. 
However, Lim et al. (2005) showed that DHA up-regulates α-secretase and reduced 
β-secretase therefore reducing Aβ synthesis. It is possible that fatty acids may also 
modulate amyloidogenic or non-amyloidogenic processing of APP within the 
enterocytes.  
 
The abundance of enterocytic Aβ could reflect a balance of production and 
section. A limited number of cell culture studies suggest that SFA increase whilst 
MUFA and PUFA decrease secretion of Aβ in neurons and Chinese hamster ovary 
cell culture medium compared to BSA controls (Oksman et al. 2006, Amtul et al. 
2011b). Although these observations may provide some relevant details regarding 
the fatty acid effects on Aβ metabolism, we show secretion of Aβ occurs in 
association with apo B-lipoproteins and therefore findings cell culture models may 
be considered less physiologically relevant in context of current findings. An earlier 
study in our laboratory reported high-SFA feeding (with similar SFA content to this 
study) and 1 % CH for 32 d increased the intracellular abundance of Aβ in mouse 
enterocytes, however did not markedly increase lacteal abundance compared to 
controls (Pallebage-Gamarallage et al. 2012). Due to similarity in animal model and 
diet, it is reasonable to assume that SFA-induced increases in enterocytic Aβ in this 
current study is probably a consequence of heightened synthesis rather than 
decreased secretion.  
 
The findings in chapter 4 and in other studies (James et al. 2003, Koudinov 
and Koudinova 1997) demonstrate that Aβ directly associates with lipids and apo B 
in Golgi and is secreted in a complex with lipoproteins. In cell culture studies using 
transformed colonic enterocytes (CaCo2 cells), the addition of SFA (palmitic acid), 
MUFA (oleic acid) and n-6 PUFA (linoleic acid) were shown to increase secretion of 
TG and apo B48 comparably (van Greevenbroek et al. 1996). In addition, the total 
number of secreted apo B molecules was doubled compared to controls, but did not 
differ between media of fatty acid treatment group per se (van Greevenbroek et al. 
1996). The findings reported by van Greevenbroek et al. (1996) are broadly 
consistent with the primary findings reported here, in that enterocytic abundance of 




treatment groups. However, the in vivo model utilized in this study found no 
evidence of accumulation of lipoprotein associated Aβ within plasma. In this study, 
the fat-enriched diets were well tolerated with no evidence of dyslipidemia. Hence, a 
notional increase in secretion of postprandial lipoprotein-Aβ as a consequence of 
fatty acid feeding, may have been accommodated within the ordinary metabolic 
pathway, that being hydrolysis by endothelial lipases and thereafter, clearance by 
high affinity (receptor-mediated) pathways. Chronic excessive ingestion of SFA 
ordinarily suppress apo B/E receptor abundance, the primary pathway by which apo 
B lipoproteins including CM-remnants are cleared (Dane-Stewart et al. 2003). 
However, there was no evidence of apo B lipoprotein accumulation in the SFA 
treated mice in this study.  
 
The experimental design adopted is in the context of a post-prandial state so 
the time of sacrifice was restricted within a 2 h time frame following the ordinary 
feeding (dark room) feeding period.  It is possible that variability in the absorptive 
state masked and an adequate clearance pathway masked a transient state of 
postprandial hyperamyloidemia. To consider this possibility directly, in vivo fat 
loading studies are required or alternatively collection of lymph via cannulation 
techniques. The latter however is difficult technique to achieve in murine models due 
to size.  
 
In the absence of direct assessment of secretion, it is notionally also possible 
to assume that enterocytic accumulation of Aβ is indicative of reduced lipoprotein 
assembly and secretion into lacteals and lymph. However, this explanation is 
unlikely given a number of studies in vivo and in vitro which uniformally 
demonstrates that dietary fatty acids and in particular fatty acids stimulate assembly 
of large TRLs within enterocytes (Field et al. 1988, Williams et al. 2004, van 
Greevenbroek et al. 1996). In addition, the abundance of Aβ relative to apo B 
generally tended to be greater in the fat-treated mice compared to controls. The 
latter was particularly indicated for the Aβ42 isoform.  
 
The relevance of these findings in the context of AD risk is unclear. The SFA 
diet utilized in this study has equivocally been demonstrated to compromise BBB 
integrity, resulting in brain parenchymal retention of lipoprotein associated-Aβ which 




Compromised capillary integrity may be a consequence of increased exposure to 
post-prandial lipoprotein-Aβ; however frank accumulation of lipoproteins was not 
indicated in mice maintained on SFA treatment. On the other hand, there was 
evidence of increased enterocytic abundance of Aβ and apo B that may be 
indicative of heightened secretion during the absorptive phase. Rather, mice fed an 
equicaloric diet relative to SFA but enriched in MUFA or PUFA also were consistent 
with increased production of CM-associated Aβ. On the basis therefore that vascular 
exposure to lipoprotein-Aβ is not profoundly similar between fatty acid treatment 
groups, it would suggest that capillary dysfunction is a consequence of the fatty acid 
phenotype and not vascular exposure per se. Thereafter however, the metabolic 
lipoproteins cascade that occurs as a consequence of extracellular retention may be 
exacerbated as a consequence of the Aβ enrichment. If this were the case, the 


















































Chapter 6: General discussion 
 
This chapter will present a general discussion for the findings presented in this 
thesis. Chapter 2 identified the presence of Aβ within intestinal lipogenic enterocytes 
and in conjunction with chapter 3 and 5 showed that enterocytic Aβ abundance can 
be regulated by the ingestion of dietary fats. Chapter 3, 4 and 5 further explored the 
physiological implications of this finding in the context of metabolism of Aβ and 
production of postprandial lipoproteins derived from enterocytes. In this chapter, the 
findings will be considered principally in a physiological context; methodological 
considerations and possible future studies will also be discussed. Consideration of 
the findings in the broader context of AD risk will be considered and will include co-
authored papers where significant contributions were made. 
 
 
6.1 Enterocytic beta-amyloid homeostasis 
 
6.1.1 Summary of enterocytic beta-amyloid findings   
 
High fat feeding is associated with a number of metabolic diseases including 
cardiovascular disease, diabetes, hyperlipidemia, hypertension, stroke, obesity and 
cognitive decline. In recent years, fatty acids have been increasingly recognised in 
the modulation of appetite, hormone secretion, inflammatory, oxidative and insulin 
metabolic pathways (Ulven and Christiansen 2015). The effect of these pathways 
on intestinal Aβ is currently not known; however, since the intestines are the first to 
respond to the availability of fat from the intestines, it would be reasonable to 
assume that Aβ expression is a direct result of high fat intake. This is supported by 
cell culture studies which were mentioned in chapter 5 (Oksman et al. 2006, Amtul 
et al. 2011b, Patil et al. 2006, Lim et al. 2005). 
 
This thesis was the first article to show the presence of Aβ within 
enterocytes and explore the relative expressions of Aβ in response to intake of 
dietary fats in murine model. Given that enterocytic Aβ expression is responsive to 
the intake of dietary fat or the availability of exogenous lipid substrate, it is 
reasonable to assume that it has a role in the metabolism of lipids, possibly as an 





This thesis presents the finding that Aβ, a protein which may accumulate in 
the brain over long periods of time and cause irreversible brain changes commonly 
reported in AD, is found in the absorptive enterocytes of the small intestine (chapter 
2). Furthermore, the enterocytic expression of Aβ and apo B were sensitive to the 
exogenous availability of lipid substrate derived from dietary sources (chapters 3 
and 4). Chapter 3 found that small intestinal villi height and overall intestinal length 
may be affected by dietary fat content in a manner which favours absorption, 
increasing the number of enterocytes. Chapter 4 further investigated the co-
association of Aβ with apo B in the context of lipoprotein biogenesis and regulation 
by dietary fatty acids and CH. Contrary to the hypothesis indicated in the literature 
review, chapter 5 showed that enterocytic abundance of Aβ was not differentially 
regulated by SFA, MUFA and PUFA.  
 
Enterocytic Aβ was predominantly localized with apo B within the perinuclear 
location of Golgi and ER of enterocytes indicated by significant co-localised 
immunodetection of Aβ and apo B. Although the different compositions of fatty acids 
(SFA, MUFA and PUFA) did not appear to differentially modulate enterocytic Aβ 
abundance, the calorie or total amount of fatty acid intake rather than saturation and 
chain length may be of greater importance with respect to promoting the biogenesis 
of Aβ. Our results were consistent with previous publications of reports that SFA, 
MUFA and PUFA equally promote apo B biogenesis and CM production (van 
Greevenbroek et al. 1996). These findings collectively support the concept that 
within enterocytes, Aβ is associated with postprandial apo B-containing lipoproteins 
(nascent CMs).  
 
6.1.2 Role of small intestine adaptation in enterocytic beta-amyloid 
abundance  
 
The absorptive enterocytes in the small intestine are responsible for the 
delivery and transport of 95 % of exogenous fats to the body. These specialised 
columnar epithelial cells absorb emulsified fats through the apical surface and 
secrete them into the lacteals as intestinal lipoprotein CMs via the basolateral 
surface. Following synthesis, CMs are secreted into mesenteric lymph and 




vein. Circulating CMs are rapidly metabolised by lipoprotein lipase (LPL), which 
results in the formation of smaller TG-poor, CH and apo E rich CM remnants. These 
apo E-rich CM remnants are ordinarily rapidly cleared by the liver via receptor-
specific processes (Hussain et al. 1996). Variation in dietary fat consumption and 
duration of feeding are proposed to alter dietary lipid absorption (Degrace et al. 
1998) and enterocytic turnover (growth and proliferation) (Dauncey et al. 1983, King 
et al. 1983) as well as secretion rate and fatty acid composition of biliary CMs 
(Degrace et al. 1998). In addition, gastrointestinal transit time is increased after 14 d 
of HF feeding (Cunningham et al. 1991). Taken together, it is reasonable to assume 
the small intestine can play a significant role in the absorption dietary fats and 
secretion of plasma Aβ-apo B-lipoproteins.  
 
Chapter 3 found that small intestinal villi height and overall intestinal length is 
influenced by habitual intake of dietary fat. In a physiological context, this dietary fat-
induced adaptation in small intestinal physiology is favourable towards increasing 
absorption of dietary fat and secretion of Aβ-apo B-lipoproteins by increasing the 
total number of enterocytes. Pearson’s correlation coefficient (chapter 4) shows that 
the presence of Aβ and apo B occur independently of each other, but both can 
associate during maturation of lipoproteins and thereafter be secreted as a 
lipoprotein complex. It is conceivable that the diet derived fatty acids can modulate 
APP processing pathways which are separate from the pathway which fatty acids 
affects apo B abundance. The role of fatty acids in APP processing and apo B will 
be discussed separately in this chapter. 
 
6.1.3 Effect of fatty acids on amyloid precursor protein processing 
 
Proteolytic processing of APP by α-secretase prevents the production of Aβ 
whereas processing by β- secretase (or BACE) and γ-secretase produces Aβ. 
Modulation of selective processing by inhibiting β- or γ- secretase has been 
regarded as a possible therapeutic target for reduction of Aβ that is pathologically 
implicated in AD (Nishitomi et al. 2006, Elvang et al. 2009). Results from chapter 5 
showed no distinct changes in enterocytic Aβ in SFA, MUFA or PUFA diets. This 
however does not eliminate the possibility that enterocytic APP processing can be 
regulated by different fatty acid type in enterocytes and other cells. Although no 




processing per se, there are a number of studies in other cell types which offer 
insight into intracellular lipid regulation of  APP processing (Lim et al. 2005, Patil et 
al. 2006, Parsons et al. 2007). Lim et al. (2005) found in the cortex of 17-19 month 
old transgenic Alzheimer mice models (Tg2576) fed a diet containing 0.6 % DHA, 
reduced insoluble amyloid plaques and specifically a reduction of Aβ42 within 
guanidine-soluble extracts. Further analysis showed that DHA specifically regulated 
APP levels by modulating preferential proteolysis by α-secretase by reducing β-
secretase (Lim et al. 2005). These results are not consistent with our enterocytic 
data, which indirectly suggests a stimulatory effect of n-3 PUFA on APP processing. 
Moreover, in this study enterocytic isoforms of Aβ were not determined.  
 
Further insight into the modulating effects of fatty acids on APP processing 
was gained by Patil et al. (2006) who showed in a transgenic Alzheimer’s mouse 
model that palmitic acid treatment led to the accumulation of C-terminal fragment 
(CTF) in neurons via the upregulation of β-secretase within surrounding astrocytes 
(Patil et al. 2006). The function of β-secretase to cleave APP depends on its state of 
maturation. Indeed, Parsons et al. (2007) found inhibition of palmitoylation and 
farnesylation resulted in reduced dimerisation of β-secretase and lower levels of Aβ 
which indicates that β-secretase maturation is linked to intracellular modifications of 
fatty acids. Although β-secretase expression was not measured in this study, dietary 
fatty acids may differentially regulate enterocytic Aβ via altered β-secretase 
cleavage of APP.  
 
6.1.4 Apolipoprotein E role in enterocytic triglyceride and beta-
amyloid 
 
In addition to the role in receptor uptake of TRLs, apo E is also responsible 
for production of VLDL in the liver. Low levels of apo E were linked to increased 
plasma concentrations of TRL’s and cholesterol, which is due to inefficient 
clearance via apo E receptors (Quarfordt et al. 1995, Zhang et al. 1992, Kuipers et 
al. 1997). Studies also indicate that apo E deficiency also leads to significant 
hepatic accumulations in the liver on low-fat chow; more than halving TRL content 
in the liver. This was consistent with a more than trice reduction in rate of 
production of VLDL measured by triton WR 1339 intravenous injection 




significant decrease in intracellular TG in apo E KO mice; though a slight increase 
in TG was detected after 24 h incubation with 0.75 mM oleate. In addition, the rate 
of VLDL-TG production was directly proportional to the expression of apo E 
expression in the hepatocytes mRNA, leading to the conclusion that apo E 
associates with immature VLDL particles prior to secretion. In chapter 3, our results 
showed a slight but non-significant decrease in plasma TG in apo E KO mice either 
on low or high fat chow feed, but rather a significant increase in plasma CH. This is 
consistent with the plasma TG and CH levels measured in apo E KO mice by 
Mensenkamp et al. (1999).  
 
The genetic expression of apo E has been shown in the gastrointestinal tract 
including the small intestine in humans. In the small intestine, apo E was specifically 
isolated in the macrophages, dendrite cells, and in lymph follicles of the lamina 
propria of mucosal layer (Niemi et al. 2002). There is some evidence that suggests 
apo E has a role in differentiation, proliferation, adhesion, structure, polarity and 
positioning of cells (Vogel et al. 1994, Lewalle et al. 1997, Handelmann et al. 1992, 
Scott et al. 1998). However, the study presented in chapter 3 contradicts these 
findings; apo E null mice shows increased the length/height of intestinal villi under 
low fat diet (compared to wild-type mice on LF diet) and decreased cells under high 
fat diet (compared to wild-type mice on HF diet). The diet-gene regulation of 
intestinal villi height/length and enterocytic cell number may indirectly influence the 
overall intestinal production of CMs and Aβ. 
 
6.1.5 Enterocytic triglyceride and apolipoprotein B synthesis and 
secretion 
 
Chapter 4 showed that enterocytic abundance of Aβ can occur 
independently from apo B; however, several studies support the binding and 
secretion of Aβ with apo B-containing lipoproteins from lipogenic cells (Koudinov 
and Koudinova 1997, James et al. 2003). In addition, secretion of surrogate maker 
sAPPα for Aβ proteolysis occur post intake of oral fat loading test, possibly from 
enterocyte source (Boyt et al. 1999). In blood, Aβ has high affinity to lipoproteins 
and apolipoproteins binding to more than 90 % Aβ (Koudinov et al. 1994, Stratman 
et al. 2005, Tokuda et al. 2000, Kuo et al. 1999, James and Mamo 2005). Taken 




lipoproteins in enterocytes prior secretion. The co-association of Aβ with perinuclear 
organelles indicate that Aβ is likely incorporated into CMs during maturation or 
lipidation stages of synthesis (discussed in detail in chapter 2). In addition, fatty 
acids irrespective of chain length and saturation can promote lipidation of apo B and 
drive synthesis and secretion of CMs. Since secretion of enterocytic Aβ was not 
measured in this study, in-situ isolation of immune-positive Aβ would reflect the 
balance of production and secretion of Aβ in complex with apo B-containing 
lipoproteins. Confirmation of Aβ secreted as a lipoprotein complex could be 
considered by immunoprecipitation of lymph.  
 
The effect of fatty acids on secretion of apo B-lipoproteins can provide an 
indication of the effect of fatty acids on the secretion of Aβ-apo B-lipoproteins. 
Understanding the production and secretion dynamics of Aβ-apo B-lipoproteins 
within enterocytes is an important consideration in the interpretation of enterocytic 
Aβ results in chapters 2, 3, 4 and 5. A study of fatty acid effects in Caco-2 cells 
show that addition of high fat mixed-diet which contained predominantly either SFA, 
MUFA and n-6 PUFA for 24 h increased secretion of TG and apo B48 by 2-fold 
compared to controls, however there was no significant difference in secretion of 
apo B between different fatty acid groups (van Greevenbroek et al. 1996). Indeed 
one of our co-authored works also indicates that Aβ secretion remains unchanged 
between low fat and high fat feeding (Pallebage-Gamarallage et al. 2012). If indeed 
secretion rates are comparable across the different fatty acid groups and controls, 
this finding supports the observations made in chapters 2, 3, 4 and 5 that different 
fatty acids can indiscriminately drive greater Aβ production compared to a low fat 
diet within enterocytes.  
 
6.1.6 Enterocytic and hepatic contribution to plasma beta-amyloid  
 
Results in this thesis indicate that small intestinal enterocytes produce and 
secrete Aβ with apo B-lipoproteins. The pathological relevance and possibility that 
liver and small intestine can separately contribute Aβ-apo B48-lipoproteins and Aβ-
apo B100-lipoproteins towards brain AD pathology has been discussed (Takechi et 
al. 2009). In brief, the roles of apo B48 and apo B100 have been previously studied 
in atherosclerotic plaques. Although both apo B48 and apo B100 have been found in 




et al. 2002, Olofsson and Boren 2005), apo B48 was found to be present in greater 
abundance (Pal et al. 2003). In addition, the increase in affinity of apo B48 to arterial 
wall was specific and not dependent on plasma concentrations (Pal et al. 2003). 
Both apo B48 and apo B100 can bind heparin sulphate proteoglycans (HSPGs) 
(Proctor and Mamo 2003), increased arterial retention of apo B48-lipoproteins can 
also extended to greater retention by extracellular matrices of the brain as shown by 
our recent study (Lam et al. 2011). In brief, this study explored the possibility that 
HSPGs, specifically biglycan, decorin and perlecan (not agrin) can facilitate the 
bindings of apo B to cerebral amyloid plaques of the brain (Lam et al. 2011). 
Currently, evidence suggests that intestinally derived Aβ contributes to greater 
plasma levels of apo B-containing lipoproteins postprandially; however, liver derived 
lipoproteins are present in greater concentrations in blood throughout the majority of 
the day. Therefore it is possible there can be differential effects of apo B100 and 
apo B48 Aβ containing lipoproteins may be relevant to risk for AD.  
 
 
6.2 High fat diet and intestinally or hepatically derived beta-amyloid 
in Alzheimer’s disease pathology 
 
6.2.1 Dietary fat and blood-brain barrier damage: candidates 
contribution to co-authored manuscripts  
 
Takechi et al. (2009) identified that apo B of small intestine and/or liver origin 
is present in cerebrovasculature and amyloid plaques. This study addresses the 
latter part of my broad hypothesis (see thesis introduction for hypothesis) and 
examines the putative effects of SFAs and UFAs dietary regimen on BBB integrity. 
This study directly extends on the findings of chapter 5 that enterocytic Aβ is 
enhanced under high-fat feeding, but demonstrates that SFA diets, not MUFA or 
PUFA, causes damage to BBB. In the article by Takechi et al, I contributed to care 
of animals, design of dietary intervention, sample collection, sample analysis and 
appraisal of draft manuscript. Secretion of plasma Aβ-lipoproteins from enterocytes 
may not be transported into the brain without demonstrable BBB damage and thus 
increased capillary permeability. Hence, the findings reported by Takechi et al were 





The co-authored article titled “Dietary fats, cerebrovascular integrity and 
Alzheimer’s disease risk.” (Takechi et al. 2010a) addresses the broader hypothesis 
(Introduction and chapter structure section) in relation to the role of dietary SFA and 
lipoprotein-Aβ in cerebrovascular and amyloid plaque pathology. Beta-amyloid has 
“vasoactive” effects on the BBB including damage to endothelial cells (Thomas et al. 
1997) and glial cells (George et al. 2004) resulting in a more permeable BBB. 
Chronic increases in plasma Aβ-lipoproteins induced by high dietary SFA intake 
could therefore damage cerebral blood vessels. One of the author’s own 
publications (Takechi et al. 2010b), using wild-type C57BL6J mice maintained on 
SFA feeding, compared to MUFA, PUFA and low-fat control diets showed marked 
leakage of the BBB, resulting in an increase in bi-directional transport of proteins 
across the BBB. Specifically, SFA feeding decreased expression of junction protein 
occludin along with increased influx of plasma apo B/IgG and increased efflux of 
S100β (Takechi et al. 2010b). Although blood to brain influx of Aβ-lipoproteins was 
not explored, cerebrovascular presence of apo B co-localised with Aβ indicates a 
high likelihood of Aβ-lipoprotein influx into the brain. In addition, colocalization of Aβ-
apo B evident within cerebral blood vessels, proteoglycans of the cerebral matrices 
(Lam et al. 2011) and amyloid plaques suggests that intestinally or hepatically 
derived Aβ-lipoproteins can cross the BBB and bind to the brain via apo B binding 
ligands. 
 
6.2.2 Summary of enterocyte or hepatocyte derived beta-amyloid in 
Alzheimer’s disease pathology 
 
The results from chapter 5 did not indicate increased plasma Aβ as a result 
of dietary fat feeding (SFA, MUFA and PUFA). Based on these results it is unclear 
whether or not SFA-induced increases in Aβ-lipoprotein levels is causally associated 
with BBB dysfunction. Alternatively, SFA could damage BBB via other mechanisms 
such as lipotoxicity, oxidation, inflammation which has been summarized in detail 
elsewhere (see section 4 of the review article by Takechi et al. 2010a).  
 
Takechi et al. (2010a) focuses on one of the key proteins which influences 
risk of developing AD, apo E4 and discusses the implications of apo E isoforms on 
TRL metabolism and related toxic mechanisms. Briefly, compared to other isoforms, 




individual contains one or two alleles (Strittmatter and Roses 1996). Apolipoprotein 
E4 could be implicated in AD pathology via by facilitating the blood to brain transport 
and parenchyma deposition of Aβ-lipoproteins. Apo E4 patients report “leaky” BBB 
compared to E2 and E3 subjects and under such circumstances this can lead to an 
increase in the influx of plasma Aβ-lipoproteins (Deane et al. 2008). Physiologically, 
apo E influences the metabolism of lipoproteins by binding to remnants (Hatters et 
al. 2006, Mahley 1988) and LDL receptor (Heeren et al. 2002, Krapp et al. 1996, 
Mamo et al. 1991). Compared to apo E3 and apo E2 which associates primarily with 
hepatically derived lipoproteins, apo E4 preferentially binds to CMs (Saito et al. 
2003) and comprises up to 65 % of the protein component of CM-remnants 
(Campos et al. 1992). The presence of apo E on Aβ-apo B-lipoproteins can facilitate 
nucleation into brain matrices as apo E binds with high affinity to HSPGs. In 
addition, apo E is an important ligand for the binding of apo B-lipoprotein remnants 
to LRP1 which is implicated in cerebral Aβ efflux. However, cell culture studies 
indicate that the binding affinity of apo E isoforms to LRP is not different, indicating 
that efflux is relatively constant and may not be implicated in AD via this clearance 
route.   
 
Cerebral Aβ-apo B-lipoproteins can deposit into the brain by association of 
apo B and various proteoglycans found in extracellular matrices of the brain. 
Proteoglycans, the predominant component of extracellular matrices can bind to 
both apo B and apo E (Flood et al. 2002, Bame et al. 1997). Studies have found 
HSPG, a type of proteoglycan, to be involved in the formation of amyloid plaques 
(van Horssen et al. 2003). Agrin, perlecan, biglycan and decorin are all 
proteoglycans which are capable of binding to apo B/apo E and these have been 
implicated in retention of lipoprotein (Iozzo 1998, Small et al. 1996, O’Brien et al. 
1998, Olin et al. 2001). A recent co-authored in our laboratory (Lam et al. 2011), 
demonstrated using immune-based approach, the colocalization of Aβ-apo B with 
HSPGs in a transgenic (APP/PS1) mouse model of AD and found perlecan, biglycan 
and decorin to be co-localized with apo B and Aβ in amyloid plaques. This study 
provides a possible mechanism for the nucleation of CSF Aβ-apo B-lipoproteins to 
cerebral matrices.  
 
 





6.3.1 Immunohistochemistry and immunofluorescence for detection 
of beta-amyloid 
 
 As the detection of intestinal Aβ was crucial to our first article (chapter 2) “B-
amyloid or its precursor protein is found in epithelial cells of the small intestine and 
is stimulated by high fat feeding” the results were dependent on the sensitivity and 
specificity of IHC method and in particular the specificity of the Aβ antibody to 
recognise Aβ antigen without binding to unwanted epitopes. Specific immunological 
methods were developed and employed to determine in-situ location of Aβ. As a 
negative control, antibody absorption method was used, which briefly involves pre-
incubation of synthetic Aβ peptide with the primary Aβ antibody. Thereafter, the 
“absorbed” antibody was applied to the tissue as per IHC method and successful 
blocking or absence of staining signified that an antibody bound or absorbed Aβ. In 
addition to antibody pre-absorption, PBS was also used as a negative control with 
our experiments and transgenic mouse or human brain tissue with known amyloid 
plaques were used as positive controls. Antibody AB5076 was used for purposes of 
identification of intestinal Aβ in IHC and IF methods in subsequent experimental 
procedures (chapters 3, 4 and 5).    
 
Immunohistochemistry is a useful technique in determining in situ location of 
antigens of interest. Immunohistochemistry is an increasingly used method for 
clinical and research applications and the number of publications using IHC has 
increased 3-fold in the past 20 years (Matos et al. 2010). Briefly, IHC is a 
straightforward method which allows in-situ isolation of specific antigens by colour-
tagging which would otherwise remain undifferentiated by conventional histological 
techniques (Matos et al. 2010). By selective use of antibodies, IHC can be 
informative in recognising cellular or tissue responses in vivo by detecting changes 
in antigen expression (Brandtzaeg 1998). In addition, sensitivity of the methods can 
be adjusted by changing detection systems or decreasing antibody dilutions to 
enable recognition of very small amounts of antigen. 
 





The second methodological hurdle in this candidacy was to determine a 
method for quantification for Aβ determined by IHC and IF. First of all, it was 
important that the chromatin or fluorescence visualised with IHC and IF respectively 
was representative of the relative amount of Aβ. A number of research papers have 
found correlations between antigen amount and IHC signal (Matkowskyj et al. 2003, 
True 1988). It is also conceivable that quantification of IHC and IF uses similar 
antigen-antibody methods such as ELISA technique and Western blotting which are 
widely accepted as quantitative (Matos et al. 2010). 
 
Whilst IHC with semi-quantitative analysis were sufficient in determining the 
expression of intestinal Aβ, quantification of Aβ by IHC (chapter 2 and 3) was limited 
to manual methods of grading which is considered “semi-quantitative”. Although 
analysis by visual identification of “chromatin” intensity predetermined by 
parameters and can be limited by observer bias and subjectivity (Shi et al. 1991, Shi 
et al. 1993, Mikaelian et al. 2004), this method is an accepted method for semi-
quantification in IHC. Consideration of other factors in IHC, such as preservation of 
tissue and the ability of antibody to recognise the epitope, are vital to the process of 
quantification and has been discussed in detail by Walker (2006). In the 
methodologies used in this study, these conditions were tightly controlled between 
specimens that were prepared and treated under identical conditions of fixation, 
processing, cutting, staining and observed through identical optical chain.  
 
Immunofluorescence was developed based on its more direct method of 
quantification from measurement of fluorescent intensity. In addition, IF was 
employed for its advantage of 3D double labelling of two or more antigens (objective 
in chapter 4). Therefore, the IF method was introduced in chapter 4 for advantages 
of digital image analysis with software which can selectively recognise and quantify 
the immunostaining results by calculating the density of pixels allowing for both co-
localization and quantification. In chapter 4, the optical detectable “overlap” of two 
fluorescent intensities was used to determine the degree of co-association of cellular 
elements in-situ.  
 
The objective of chapter 4 was to determine whether Aβ co localizes with 
intestinal apo B. In order to achieve this within tissues, a dual-labelling method using 




technique successfully overcomes the barriers of using polyclonal antibodies raised 
in the same species by diluting the first antibody and by the use of different 
secondary detection systems. In brief, this method used a low dilution of rabbit 
polyclonal apo B antibody (1:4000) adding anti-rabbit IgG with biotin to bind and 
thus block most of the apo B antigen site. Subsequently, the second antibody rabbit 
polyclonal anti-Golgi at dilution 1:10 was used to attach to the Golgi protein of 
interest and finally, secondary anti-rabbit IgG conjugated with FITC and avidin 
conjugated with Alexa 546 was added. This method allows for double labelling of 2 
distinct polyclonal antibodies raised in the same species without cross-reactivity. 
Subsequent detection of Aβ was achieved without overlap of fluorescence emission 
from other fluorophores.  
 
6.3.3. Recommendations for future work 
 
Although the main objectives of the study have been thoroughly explored by 
the experiments conducted, there have been several limitations and therefore there 
expose possibilities for future studies. Extensions of this study may include 1) 
determining if different types of fats modulate the amyloidogenic processing of Aβ in 
hepatocytes and enterocytes; 2) modulate the binding or association of Aβ isoforms 
to chylomicrons and VLDL in response to fat intake; 3) Elucidate if absorption of 
triglycerides, and secretion, transport and clearance of CMs can be influenced by 
the presence of Aβ; 4) determine if intracellular Aβ interacts with fatty acids and play 
a role in incorporation into chylomicrons; and lastly, to explore further the kinetics 
(transport and clearance) of Aβ-lipoproteins, include liver derived lipoproteins and 
hepatocytes/liver involvement and contribution to plasma Aβ-lipoprotein pool. Serial 
ultracentrifugation can be used to isolate TRLs from IDL and HDLs at 229,190 g for 
24 h (Mamo et al. 2008). Thereafter, the lipoprotein-Aβ fractions can be 
immunoprecipitated using monoclonal Aβ antibodies and immunoblot. Analysis of 
Aβ-lipoprotein fractions can be achieved by semi-dry western blotting (Mamo et al. 
2008). For detection of intestinally derived CMs with Aβ, CMs can be isolated in 
Caco-2 cell culture or human plasma (Karpe and Hamsten 1994). This method 
could possibly be adapted to isolate CM fraction from VLDL and apply 
immunoprecipitation to quantify Aβ-CM in plasma or cell culture. The secretion of 
CM-Aβ can be measured in the future by collecting the conditioned medium of 




by SDS-PAGE and immunoblot with Aβ antibodies as described (Koudinov and 
Koudinova 1997). Once isolation of CM-Aβ has been established, dietary 
interventions with animal models, cell culture, kinetic tracer studies and clinical 
studies involving cognitive tests can be used to further investigate the role of CM-Aβ 
in AD.  
 
The effect of apo E genotype and apo B-lipoproteins and risk in AD can be 
either measured with respect to the isoform of apo E – 2, 3 and 4 and the 
association of CM with Aβ (measure by immunoprecipitation as mentioned above) 
using either transgenic apo E mouse models or in clinical studies with humans with 
different apo E genotypes. Measurement of postprandial levels and clearance of 
CM-Aβ should also be studied with respect to high fat diet. The permeability of BBB, 




6.4 Summary  
 
The findings presented in this thesis suggest that dietary fatty acids promote 
the expression of Aβ within enterocytes, possibly via greater synthesis from APP. 
Grant (2014) showed that in eight countries, increased consumption of animal fat 
(high SFA) and calories positively correlated with the increased prevalence of AD. In 
addition, several studies show that SFA specifically increases AD risk whereas 
PUFA and MUFA can reduce risk (Eskelinen et al. 2008, Kalmijn et al. 1997, 
Luchsinger et al. 2002, Molteni et al. 2002, Sofrizzi et al. 2005, Grant 1998, Grant 
2014). However, the equal increases in enterocytic Aβ by intake of SFA, MUFA and 
PUFA diets could mean that modulation of AD risk by dietary fats would likely occur 
via pathways other than enterocytic production and secretion of Aβ. As suggested 
by subsequent studies from our laboratory, SFA but not MUFA or PUFA might be 
harmful towards BBB structure and therefore compromise the bidirectional transport 
of Aβ between the blood and brain, favouring influx and contributing to cerebral 
plaque Aβ load (Takechi et al. 2009). Results in this study would support the notion 
that increased availability of enterocytic Aβ via diet can add to the peripheral Aβ-
lipoprotein pool which can enter the brain and over time contribute to cerebral 




ingestion of fat (all types) as it may increase enterocytic Aβ abundance, increased 
villi height and the length of the small intestine and therefore increase overall 
intestinal Aβ and plasma Aβ-apo B-lipoproteins (chapter 3). Based on our findings, 
increasing clearance or decreasing production of apo B-lipoproteins coupled with 
maintenance of BBB integrity may decrease cerebral Aβ load and therefore reduce 
risk of developing AD.  
 
Bateman et al. (2012) showed that cerebral amyloidosis can develop over 25 
years prior to the onset of cognitive decline symptoms. This study indicates that 
dietary fat can exacerbate the exposure of the BBB by increasing plasma and CSF 
Aβ-lipoproteins. Since the disease process in AD is a steady and progressive 
process, one can assume that chronic intake of fat will exacerbate the development 
of AD. This is supported by epidemiological studies that show high fat intake, 
especially SFA, is detrimental to cognitive state. Results from chapter 5 indicate that 
the abundance of intestinal Aβ increases in response to fatty acids irrespective of 
chain length and saturation which leads to the question as to whether unsaturated 
fats is protective towards AD via other mechanisms, possibly to do with increased 
rate of clearance and BBB integrity. Studies in our laboratory indicate that SFA is 
detrimental to the structure of the BBB which can lead to increase influx of Aβ-
lipoprotein into the brain.  
 
Future research would need to long term study involve human subjects, food 
frequency questionnaire, measurement of plasma Aβ-lipoproteins and BBB integrity 
to track development of AD in response to intestinally derived Aβ. It would be 
interesting to elucidate if chronic increase in dietary SFA, MUFA and PUFA mid-life 
leads to changes in plasma Aβ-lipoprotein and BBB disturbance that may eventuate 





Findings in this thesis are the first to explore the likelihood that small 
intestinal enterocytes may contribute Aβ-lipoproteins in response to increased intake 
of calories via dietary fat. Intake of SFA, MUFA and PUFA all increase enterocytic 




damage to BBB which indicates high intake of SFA alone can contribute over time to 
pathology of AD. I suspect that dietary SFA induced increases in enterocytic 
expression of Aβ and secretion of Aβ-apo B-lipoproteins can contribute over time 
and perhaps decades before the onset of cognitive symptoms to the eventual 
development of AD. This thesis presents a mechanistic link between two multi-





































Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, 
Dingwall C, De Strooper B & Dotti CG. (2004) Neuronal membrane 





Abbott NJ, Patabendige AA, Dolman DE, Yusof SR & Begley DJ. (2010) Structure 
and function of the blood-brain barrier. Neurobiol Dis. 37, 13-25. 
Abuznait AH, Qosa H, Busnena BA, El Sayed KA & Kaddoumi A. (2013) Olive-oil-
derived oleocanthal enhances beta-amyloid clearance as a potential 
neuroprotective mechanism against Alzheimer's disease: in vitro and in vivo 
studies. ACS Chem Neurosci. 4, 973-982. 
Adunsky A, Chesnin V, Davidson M, Gerber Y, Alexander K & Haratz D. (2002) A 
cross-sectional study of lipids and ApoC levels in Alzheimer's patients with 
and without cardiovascular disease. J Gerontol A Biol Sci Med Sci. 57, 757-
761. 
Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, 
Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin 
WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer 
PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel 
R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis 
R, Walker D, Webster S, Wegrzyniak B, Wenk G & Wyss-Coray T. (2000) 
Inflammation and Alzheimer's disease. Neurobiol Aging. 21, 383-421. 
Albanese E, Dangour AD, Uauy R, Acosta D, Guerra M, Guerra SS, Huang Y, 
Jacob KS, de Rodriguez JL, Noriega LH, Salas A, Sosa AL, Sousa RM, 
Williams J, Ferri CP & Prince MJ. (2009) Dietary fish and meat intake and 
dementia in Latin America, China, and India: a 10/66 Dementia Research 
Group population-based study. Am J Clin Nutr. 90, 392-400. 
Allsop D, Landon M & Kidd M. (1983) The isolation and amino acid composition of 
senile plaque core protein. Brain Res. 259, 348-352. 
Alonso AC, Grundke-Iqbal I & Iqbal K. (1996) Alzheimer's disease 
hyperphosphorylated tau sequesters normal tau into tangles of filaments and 
disassembles microtubules. Nat Med. 2, 783-787. 
Alsop DC, Detre JA & Grossman M. (2000) Assessment of cerebral blood flow in 
Alzheimer's disease by spin-labeled magnetic resonance imaging. Ann 
Neurol. 47, 93-100. 
Altman R & Rutledge JC. (2010) The vascular contribution to Alzheimer's disease. 
Clin Sci (Lond). 119, 407-421. 
Amtul Z, Uhrig M, Rozmahel RF & Beyreuther K. (2011a) Structural insight into the 
differential effects of omega-3 and omega-6 fatty acids on the production of 




Amtul Z, Uhrig M, Supino R & Beyreuther K. (2010) Phospholipids and a 
phospholipid-rich diet alter the in vitro amyloid-beta peptide levels and 
amyloid-beta 42/40 ratios. Neurosci Lett. 481, 73-77. 
Amtul Z, Westaway D, Cechetto DF & Rozmahel RF. (2011b) Oleic acid ameliorates 
amyloidosis in cellular and mouse models of Alzheimer's disease. Brain 
Pathol. 21, 321-329. 
Anderson GJ, Tso PS & Connor WE. (1994) Incorporation of chylomicron fatty acids 
into the developing rat brain. J Clin Invest. 93, 2764-2767. 
Andreasen N & Blennow K. (2002) Beta-amyloid (Abeta) protein in cerebrospinal 
fluid as a biomarker for Alzheimer's disease. Peptides. 23, 1205-1214. 
Arendash GW, Su GC, Crawford FC, Bjugstad KB & Mullan M. (1999) Intravascular 
beta-amyloid infusion increases blood pressure: implications for a vasoactive 
role of beta-amyloid in the pathogenesis of Alzheimer's disease. Neurosci 
Lett. 268, 17-20. 
Arendt T, Holzer M, Fruth R, Bruckner MK & Gartner U. (1998) Phosphorylation of 
tau, Abeta-formation, and apoptosis after in vivo inhibition of PP-1 and PP-
2A. Neurobiol Aging. 19, 3-13. 
Arrol S, Mackness MI & Durrington PN. (2000) The effects of fatty acids on 
apolipoprotein B secretion by human hepatoma cells (HEP G2). 
Atherosclerosis. 150, 255-264. 
Arsenault D, Julien C, Tremblay C & Calon F. (2011) DHA improves cognition and 
prevents dysfunction of entorhinal cortex neurons in 3xTg-AD mice. PLoS 
One. 6, 17397. 
Austin MA. (1999) Epidemiology of hypertriglyceridemia and cardiovascular disease. 
Am J Cardiol. 83, 13F-16F. 
Australian Bureau of Statistics. (2008) Population Projections, Australia, 2006 to 
2101. Cat no. 3222.0. ABS. Canberra. 
Australian Bureau of Statistics. (2012) Australian Demographic Statistics, Jun 2012. 
Cat no. 3101.0. ABS. Canberra. 
Australian Institute of Health and Welfare. (2012) Dementia in Australia. Cat no. 
AGE 90 AIHW, Canberra. 
Balabanov R & Dore-Duffy P. (1998) Role of the CNS microvascular pericyte in the 
blood-brain barrier. J Neurosci Res. 53, 637-644. 
Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLong 




essential for amyloid deposition in the APP(V717F) transgenic mouse model 
of Alzheimer's disease. Proc Natl Acad Sci U S A. 96, 15233-15238. 
Ballabh P, Braun A & Nedergaard M. (2004) The blood-brain barrier: an overview: 
structure, regulation, and clinical implications. Neurobiol Dis. 16, 1-13. 
Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D & Jones E. (2011) 
Alzheimer's disease. Lancet. 377, 1019-1031. 
Bame KJ, Danda J, Hassall A & Tumova S. (1997) Abeta(1-40) prevents 
heparanase-catalyzed degradation of heparan sulfate glycosaminoglycans 
and proteoglycans in vitro. A role for heparan sulfate proteoglycan turnover 
in Alzheimer's disease. J Biol Chem. 272, 17005-17011. 
Barberger-Gateau P, Letenneur L, Deschamps V, Peres K, Dartigues JF & Renaud 
S. (2002) Fish, meat, and risk of dementia: cohort study. BMJ. 325, 932-933. 
Barnham KJ, McKinstry WJ, Multhaup G, Galatis D, Morton CJ, Curtain CC, 
Williamson NA, White AR, Hinds MG, Norton RS, Beyreuther K, Masters CL, 
Parker MW & Cappai R. (2003) Structure of the Alzheimer's disease amyloid 
precursor protein copper binding domain. A regulator of neuronal copper 
homeostasis. J Biol Chem. 278, 17401-17407. 
Barrow CJ, Yasuda A, Kenny PT & Zagorski MG. (1992) Solution conformations and 
aggregational properties of synthetic amyloid beta-peptides of Alzheimer's 
disease. Analysis of circular dichroism spectra. J Mol Biol. 225, 1075-1093. 
Bateman PA, Jackson KG, Maitin V, Yaqoob P & Williams CM. (2007) Differences in 
cell morphology, lipid and apo B secretory capacity in caco-2 cells following 
long term treatment with saturated and monounsaturated fatty acids. Biochim 
Biophys Acta. 1771, 475-485. 
Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, 
Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver 
A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, 
Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling 
RA, Salloway S, Morris JC & Dominantly Inherited Alzheimer N. (2012) 
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. 
N Engl J Med. 367, 795-804. 
Beach TG, Wilson JR, Sue LI, Newell A, Poston M, Cisneros R, Pandya Y, Esh C, 
Connor DJ, Sabbagh M, Walker DG & Roher AE. (2007) Circle of Willis 
atherosclerosis: association with Alzheimer's disease, neuritic plaques and 




Bellosta S, Ferri N, Bernini F, Paoletti R & Corsini A. (2000) Non-lipid-related effects 
of statins. Ann Med. 32, 164-176. 
Beyreuther K, Pollwein P, Multhaup G, Monning U, Konig G, Dyrks T, Schubert W & 
Masters CL. (1993) Regulation and expression of the Alzheimer's beta/A4 
amyloid protein precursor in health, disease, and Down's syndrome. Ann N Y 
Acad Sci. 695, 91-102. 
Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE & Selkoe DJ. (1996) 
Amyloid beta-peptide is transported on lipoproteins and albumin in human 
plasma. J Biol Chem. 271, 32916-32922. 
Blessed G, Tomlinson BE & Roth M. (1968) The association between quantitative 
measures of dementia and of senile change in the cerebral grey matter of 
elderly subjects. Br J Psychiatry. 114, 797-811. 
Boyt AA, Taddei K, Hallmayer J, Mamo J, Helmerhorst E, Gandy SE & Martins RN. 
(1999) Relationship between lipid metabolism and amyloid precursor protein 
and apolipoprotein E. Alzheimer's Reports. 2, 339-346. 
Brandtzaeg P. (1998) The increasing power of immunohistochemistry and 
immunocytochemistry. J Immunol Methods. 216, 49-67. 
Brantley PJ, Myers VH & Roy HJ. (2005) Environmental and lifestyle influences on 
obesity. J La State Med Soc. 157 Spec No 1, S19-27. 
Breteler MM. (2000) Vascular risk factors for Alzheimer's disease: an epidemiologic 
perspective. Neurobiol Aging. 21, 153-160. 
Brookmeyer R, Johnson E, Ziegler-Graham K & Arrighi HM. (2007) Forecasting the 
global burden of Alzheimer's disease. Alzheimers Dement. 3, 186-191. 
Brownlow ML, Benner L, D'Agostino D, Gordon MN & Morgan D. (2013) Ketogenic 
diet improves motor performance but not cognition in two mouse models of 
Alzheimer's pathology. PLoS One. 8, e75713. 
Burgess BL, McIsaac SA, Naus KE, Chan JY, Tansley GH, Yang J, Miao F, Ross 
CJ, van Eck M, Hayden MR, van Nostrand W, St George-Hyslop P, 
Westaway D & Wellington CL. (2006) Elevated plasma triglyceride levels 
precede amyloid deposition in Alzheimer's disease mouse models with 
abundant A beta in plasma. Neurobiol Dis. 24, 114-127. 
Busciglio J, Gabuzda DH, Matsudaira P & Yankner BA. (1993) Generation of beta-
amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc 




Busciglio J, Lorenzo A, Yeh J & Yankner BA. (1995) beta-amyloid fibrils induce tau 
phosphorylation and loss of microtubule binding. Neuron. 14, 879-888. 
Calon F, Lim GP, Morihara T, Yang F, Ubeda O, Salem N, Jr., Frautschy SA & Cole 
GM. (2005) Dietary n-3 polyunsaturated fatty acid depletion activates 
caspases and decreases NMDA receptors in the brain of a transgenic mouse 
model of Alzheimer's disease. Eur J Neurosci. 22, 617-626. 
Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O, Rostaing P, Triller A, 
Salem N, Jr., Ashe KH, Frautschy SA & Cole GM. (2004) Docosahexaenoic 
acid protects from dendritic pathology in an Alzheimer's disease mouse 
model. Neuron. 43, 633-645. 
Campos E, Nakajima K, Tanaka A & Havel RJ. (1992) Properties of an 
apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated 
from human blood plasma with a monoclonal antibody to apolipoprotein B-
100. J Lipid Res. 33, 369-380. 
Caramelli P, Nitrini R, Maranhao R, Lourenco AC, Damasceno MC, Vinagre C & 
Caramelli B. (1999) Increased apolipoprotein B serum concentration in 
Alzheimer's disease. Acta Neurol Scand. 100, 61-63. 
Carpentier AC. (2008) Postprandial fatty acid metabolism in the development of 
lipotoxicity and type 2 diabetes. Diabetes Metab. 34, 97-107. 
Carter DB, Dunn E, McKinley DD, Stratman NC, Boyle TP, Kuiper SL, Oostveen JA, 
Weaver RJ, Boller JA & Gurney ME. (2001) Human apolipoprotein E4 
accelerates beta-amyloid deposition in APPsw transgenic mouse brain. Ann 
Neurol. 50, 468-475. 
Chan JC, Tong PC & Critchley JA. (2002) The insulin resistance syndrome: 
mechanisms of clustering of cardiovascular risk. Semin Vasc Med. 2, 45-57. 
Chandra V, Ganguli M, Pandav R, Johnston J, Belle S & DeKosky ST. (1998) 
Prevalence of Alzheimer's disease and other dementias in rural India: the 
Indo-US study. Neurology. 51, 1000-1008. 
Chen P, Ratcliff G, Belle SH, Cauley JA, DeKosky ST & Ganguli M. (2001) Patterns 
of cognitive decline in presymptomatic Alzheimer disease: a prospective 
community study. Arch Gen Psychiatry. 58, 853-858. 
Chu K, Miyazaki M, Man WC & Ntambi JM. (2006) Stearoyl-coenzyme A desaturase 
1 deficiency protects against hypertriglyceridemia and increases plasma 
high-density lipoprotein cholesterol induced by liver X receptor activation. 




Claassen JA & Zhang R. (2011) Cerebral autoregulation in Alzheimer's disease. J 
Cereb Blood Flow Metab. 31, 1572-1577. 
Clifford PM, Zarrabi S, Siu G, Kinsler KJ, Kosciuk MC, Venkataraman V, D'Andrea 
MR, Dinsmore S & Nagele RG. (2007) Abeta peptides can enter the brain 
through a defective blood-brain barrier and bind selectively to neurons. Brain 
Res. 1142, 223-236. 
Cnop M, Igoillo-Esteve M, Cunha DA, Ladriere L & Eizirik DL. (2008) An update on 
lipotoxic endoplasmic reticulum stress in pancreatic beta-cells. Biochem Soc 
Trans. 36, 909-915. 
Cole GM, Ma QL & Frautschy SA. (2010) Dietary fatty acids and the aging brain. 
Nutr Rev. 68 Suppl 2, 102-111. 
Cole SL & Vassar R. (2006) Isoprenoids and Alzheimer's disease: a complex 
relationship. Neurobiol Dis. 22, 209-222. 
Conquer JA, Tierney MC, Zecevic J, Bettger WJ & Fisher RH. (2000) Fatty acid 
analysis of blood plasma of patients with Alzheimer's disease, other types of 
dementia, and cognitive impairment. Lipids. 35, 1305-1312. 
Cook DG, Forman MS, Sung JC, Leight S, Kolson DL, Iwatsubo T, Lee VM & Doms 
RW. (1997) Alzheimer's A beta(1-42) is generated in the endoplasmic 
reticulum/intermediate compartment of NT2N cells. Nat Med. 3, 1021-1023. 
Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, 
Jr., Rimmler JB, Locke PA, Conneally PM, Schmader KE & et al. (1994) 
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer 
disease. Nat Genet. 7, 180-184. 
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, 
Roses AD, Haines JL & Pericak-Vance MA. (1993) Gene dose of 
apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late 
onset families. Science. 261, 921-923. 
Crawford F, Soto C, Suo Z, Fang C, Parker T, Sawar A, Frangione B & Mullan M. 
(1998) Alzheimer's beta-amyloid vasoactivity: identification of a novel beta-
amyloid conformational intermediate. FEBS Lett. 436, 445-448. 
Crawford F, Suo Z, Fang C, Sawar A, Su G, Arendash G & Mullan M. (1997) The 
vasoactivity of A beta peptides. Ann N Y Acad Sci. 826, 35-46. 
Cullen KM. (1997) Perivascular astrocytes within Alzheimer's disease plaques. 




Cunnane SC, Plourde M, Pifferi F, Begin M, Feart C & Barberger-Gateau P. (2009) 
Fish, docosahexaenoic acid and Alzheimer's disease. Prog Lipid Res. 48, 
239-256. 
Cunningham KM, Daly J, Horowitz M & Read NW. (1991) Gastrointestinal 
adaptation to diets of differing fat composition in human volunteers. Gut. 32, 
483-486. 
Dane-Stewart CA, Watts GF, Pal S, Chan D, Thompson P, Hung J & Mamo JC. 
(2003) Effect of atorvastatin on apolipoprotein B48 metabolism and low-
density lipoprotein receptor activity in normolipidemic patients with coronary 
artery disease. Metabolism. 52, 1279-1286. 
Dauncey MJ, Ingram DL, James PS & Smith MW. (1983) Modification by diet and 
environmental temperature of enterocyte function in piglet intestine. J 
Physiol. 341, 441-452. 
Davidson NO, Kollmer ME & Glickman RM. (1986) Apolipoprotein B synthesis in rat 
small intestine: regulation by dietary triglyceride and biliary lipid. J Lipid Res. 
27, 30-39. 
Davidson TL, Monnot A, Neal AU, Martin AA, Horton JJ & Zheng W. (2012) The 
effects of a high-energy diet on hippocampal-dependent discrimination 
performance and blood-brain barrier integrity differ for diet-induced obese 
and diet-resistant rats. Physiol Behav. 107, 26-33. 
Davis-Salinas J, Saporito-Irwin SM, Cotman CW & Van Nostrand WE. (1995) 
Amyloid beta-protein induces its own production in cultured degenerating 
cerebrovascular smooth muscle cells. J Neurochem. 65, 931-934. 
Davis HR, Jr., Zhu LJ, Hoos LM, Tetzloff G, Maguire M, Liu J, Yao X, Iyer SP, Lam 
MH, Lund EG, Detmers PA, Graziano MP & Altmann SW. (2004) Niemann-
Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol 
transporter and a key modulator of whole-body cholesterol homeostasis. J 
Biol Chem. 279, 33586-33592. 
Dawkins E & Small DH. (2014) Insights into the physiological function of the beta-
amyloid precursor protein: beyond Alzheimer's disease. J Neurochem. 129, 
756-769. 
de Bruin TW, Brouwer CB, van Linde-Sibenius Trip M, Jansen H & Erkelens DW. 
(1993) Different postprandial metabolism of olive oil and soybean oil: a 
possible mechanism of the high-density lipoprotein conserving effect of olive 




De Lorgeril M, Salen P, Martin JL, Mamelle N, Monjaud I, Touboul P & Delaye J. 
(1996) Effect of a mediterranean type of diet on the rate of cardiovascular 
complications in patients with coronary artery disease. Insights into the 
cardioprotective effect of certain nutriments. J Am Coll Cardiol. 28, 1103-
1108. 
de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J & Mamelle N. (1999) 
Mediterranean diet, traditional risk factors, and the rate of cardiovascular 
complications after myocardial infarction: final report of the Lyon Diet Heart 
Study. Circulation. 99, 779-785. 
Deane R, Bell RD, Sagare A & Zlokovic BV. (2009) Clearance of amyloid-beta 
peptide across the blood-brain barrier: implication for therapies in 
Alzheimer's disease. CNS Neurol Disord Drug Targets. 8, 16-30. 
Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, 
Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, 
Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern 
D & Zlokovic B. (2003) RAGE mediates amyloid-beta peptide transport 
across the blood-brain barrier and accumulation in brain. Nat Med. 9, 907-
913. 
Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM & Zlokovic 
BV. (2008) apoE isoform-specific disruption of amyloid beta peptide 
clearance from mouse brain. J Clin Invest. 118, 4002-4013. 
Deane R, Sagare A, Hamm K, Parisi M, LaRue B, Guo H, Wu Z, Holtzman DM & 
Zlokovic BV. (2005) IgG-assisted age-dependent clearance of Alzheimer's 
amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J 
Neurosci. 25, 11495-11503. 
Degrace P, Caselli C & Bernard A. (1998) Long-term adaptation to high-fat diets 
modifies the nature and output of postprandial intestinal lymph fatty acid in 
rats. J Nutr. 128, 185-192. 
DeMattos RB. (2004) Apolipoprotein E dose-dependent modulation of beta-amyloid 
deposition in a transgenic mouse model of Alzheimer's disease. J Mol 
Neurosci. 23, 255-262. 
Demuro A, Mina E, Kayed R, Milton SC, Parker I & Glabe CG. (2005) Calcium 
dysregulation and membrane disruption as a ubiquitous neurotoxic 




Devore EE, Grodstein F, van Rooij FJ, Hofman A, Rosner B, Stampfer MJ, 
Witteman JC & Breteler MM. (2009) Dietary intake of fish and omega-3 fatty 
acids in relation to long-term dementia risk. Am J Clin Nutr. 90, 170-176. 
Diakogiannaki E & Morgan NG. (2008) Differential regulation of the ER stress 
response by long-chain fatty acids in the pancreatic beta-cell. Biochem Soc 
Trans. 36, 959-962. 
Diaz O, Berquand A, Dubois M, Di Agostino S, Sette C, Bourgoin S, Lagarde M, 
Nemoz G & Prigent AF. (2002) The mechanism of docosahexaenoic acid-
induced phospholipase D activation in human lymphocytes involves 
exclusion of the enzyme from lipid rafts. J Biol Chem. 277, 39368-39378. 
Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, 
Wu S, Wu X, Holtzman DM & Paul SM. (2002) Immunization reverses 
memory deficits without reducing brain Abeta burden in Alzheimer's disease 
model. Nat Neurosci. 5, 452-457. 
Donahue JE, Flaherty SL, Johanson CE, Duncan JA, 3rd, Silverberg GD, Miller MC, 
Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V & Stopa EG. (2006) 
RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta 
Neuropathol. 112, 405-415. 
Donahue JE & Johanson CE. (2008) Apolipoprotein E, amyloid-beta, and blood-
brain barrier permeability in Alzheimer disease. J Neuropathol Exp Neurol. 
67, 261-270. 
Dosunmu R, Wu J, Basha MR & Zawia NH. (2007) Environmental and dietary risk 
factors in Alzheimer's disease. Expert Rev Neurother. 7, 887-900. 
Driscoll DM & Getz GS. (1984) Extrahepatic synthesis of apolipoprotein E. J Lipid 
Res. 25, 1368-1379. 
Dubois C, Armand M, Azais-Braesco V, Portugal H, Pauli AM, Bernard PM, Latge C, 
Lafont H, Borel P & Lairon D. (1994) Effects of moderate amounts of 
emulsified dietary fat on postprandial lipemia and lipoproteins in 
normolipidemic adults. Am J Clin Nutr. 60, 374-382. 
Dulubova I, Ho A, Huryeva I, Sudhof TC & Rizo J. (2004) Three-dimensional 
structure of an independently folded extracellular domain of human amyloid-
beta precursor protein. Biochemistry. 43, 9583-9588. 
Eckert GP, Wood WG & Muller WE. (2005) Statins: drugs for Alzheimer's disease? J 




Eikelenboom P, Veerhuis R, Scheper W, Rozemuller AJ, van Gool WA & 
Hoozemans JJ. (2006) The significance of neuroinflammation in 
understanding Alzheimer's disease. J Neural Transm. 113, 1685-1695. 
Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D & Heyman A. (1996) 
Cerebral amyloid angiopathy in the brains of patients with Alzheimer's 
disease: the CERAD experience, Part XV. Neurology. 46, 1592-1596. 
Elvang AB, Volbracht C, Pedersen LO, Jensen KG, Karlsson JJ, Larsen SA, Mork A, 
Stensbol TB & Bastlund JF. (2009) Differential effects of gamma-secretase 
and BACE1 inhibition on brain Abeta levels in vitro and in vivo. J Neurochem. 
110, 1377-1387. 
Emanuele E, Peros E, Tomaino C, Feudatari E, Bernardi L, Binetti G, Maletta R, 
D'Angelo A, Montagna L, Bruni AC & Geroldi D. (2004) Apolipoprotein(a) null 
phenotype is related to a delayed age at onset of Alzheimer's disease. 
Neurosci Lett. 357, 45-48. 
Engelhart MJ, Geerlings MI, Ruitenberg A, Van Swieten JC, Hofman A, Witteman 
JC & Breteler MM. (2002) Diet and risk of dementia: Does fat matter?: The 
Rotterdam Study. Neurology. 59, 1915-1921. 
Eskelinen MH, Ngandu T, Helkala EL, Tuomilehto J, Nissinen A, Soininen H & 
Kivipelto M. (2008) Fat intake at midlife and cognitive impairment later in life: 
a population-based CAIDE study. Int J Geriatr Psychiatry. 23, 741-747. 
Esler WP, Stimson ER, Ghilardi JR, Vinters HV, Lee JP, Mantyh PW & Maggio JE. 
(1996) In vitro growth of Alzheimer's disease beta-amyloid plaques displays 
first-order kinetics. Biochemistry. 35, 749-757. 
Esteban JA. (2004) Living with the enemy: a physiological role for the beta-amyloid 
peptide. Trends Neurosci. 27, 1-3. 
Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, 
Pericak-Vance MA, Risch N & van Duijn CM. (1997) Effects of age, sex, and 
ethnicity on the association between apolipoprotein E genotype and 
Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta 
Analysis Consortium. JAMA. 278, 1349-1356. 
Farrer LA, Friedland RP, Bowirrat A, Waraska K, Korczyn A & Baldwin CT. (2003) 
Genetic and environmental epidemiology of Alzheimer's disease in arabs 
residing in Israel. J Mol Neurosci. 20, 207-212. 
Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, 




T. (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta -
amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad 
Sci U S A. 98, 5856-5861. 
Feart C, Samieri C, Rondeau V, Amieva H, Portet F, Dartigues JF, Scarmeas N & 
Barberger-Gateau P. (2009) Adherence to a Mediterranean diet, cognitive 
decline, and risk of dementia. JAMA. 302, 638-648. 
Feng B, Yao PM, Li Y, Devlin CM, Zhang D, Harding HP, Sweeney M, Rong JX, 
Kuriakose G, Fisher EA, Marks AR, Ron D & Tabas I. (2003) The 
endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in 
macrophages. Nat Cell Biol. 5, 781-792. 
Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa 
K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, 
Scazufca M & Alzheimer's Disease I. (2005) Global prevalence of dementia: 
a Delphi consensus study. Lancet. 366, 2112-2117. 
Field FJ, Albright E & Mathur SN. (1988) Regulation of triglyceride-rich lipoprotein 
secretion by fatty acids in CaCo-2 cells. J Lipid Res. 29, 1427-1437. 
Flood C, Gustafsson M, Richardson PE, Harvey SC, Segrest JP & Boren J. (2002) 
Identification of the proteoglycan binding site in apolipoprotein B48. J Biol 
Chem. 277, 32228-32233. 
Fotuhi M, Mohassel P & Yaffe K. (2009) Fish consumption, long-chain omega-3 fatty 
acids and risk of cognitive decline or Alzheimer disease: a complex 
association. Nat Clin Pract Neurol. 5, 140-152. 
Frears ER, Stephens DJ, Walters CE, Davies H & Austen BM. (1999) The role of 
cholesterol in the biosynthesis of beta-amyloid. Neuroreport. 10, 1699-1705. 
Freeman LR & Granholm AC. (2012) Vascular changes in rat hippocampus 
following a high saturated fat and cholesterol diet. J Cereb Blood Flow 
Metab. 32, 643-653. 
Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, 
Garlind A, Vedin I, Vessby B, Wahlund LO & Palmblad J. (2006) Omega-3 
fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: 
OmegAD study: a randomized double-blind trial. Arch Neurol. 63, 1402-1408. 
Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM & Holtzman 
DM. (2005) Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and 
promotes the formation of cerebral amyloid angiopathy in an amyloid 




Galloway S, Jian L, Johnsen R, Chew S & Mamo JC. (2007) beta-amyloid or its 
precursor protein is found in epithelial cells of the small intestine and is 
stimulated by high-fat feeding. J Nutr Biochem. 18, 279-284. 
Galloway S, Pallebage-Gamarallage MM, Takechi R, Jian L, Johnsen RD, Dhaliwal 
SS & Mamo JC. (2008) Synergistic effects of high fat feeding and 
apolipoprotein E deletion on enterocytic amyloid-beta abundance. Lipids 
Health Dis. 7, 15. 
Galloway S, Takechi R, Pallebage-Gamarallage MM, Dhaliwal SS & Mamo JC. 
(2009) Amyloid-beta colocalizes with apolipoprotein B in absorptive cells of 
the small intestine. Lipids Health Dis. 8, 46. 
Gamoh S, Hashimoto M, Hossain S & Masumura S. (2001) Chronic administration 
of docosahexaenoic acid improves the performance of radial arm maze task 
in aged rats. Clin Exp Pharmacol Physiol. 28, 266-270. 
Gardener S, Gu Y, Rainey-Smith SR, Keogh JB, Clifton PM, Mathieson SL, Taddei 
K, Mondal A, Ward VK, Scarmeas N, Barnes M, Ellis KA, Head R, Masters 
CL, Ames D, Macaulay SL, Rowe CC, Szoeke C, Martins RN & Group AR. 
(2012) Adherence to a Mediterranean diet and Alzheimer's disease risk in an 
Australian population. Transl Psychiatry. 2, 164. 
Gearing M, Mori H & Mirra SS. (1996) Abeta-peptide length and apolipoprotein E 
genotype in Alzheimer's disease. Ann Neurol. 39, 395-399. 
George AJ, Holsinger RM, McLean CA, Laughton KM, Beyreuther K, Evin G, 
Masters CL & Li QX. (2004) APP intracellular domain is increased and 
soluble Abeta is reduced with diet-induced hypercholesterolemia in a 
transgenic mouse model of Alzheimer disease. Neurobiol Dis. 16, 124-132. 
Gershkovich P & Hoffman A. (2005) Uptake of lipophilic drugs by plasma derived 
isolated chylomicrons: linear correlation with intestinal lymphatic 
bioavailability. Eur J Pharm Sci. 26, 394-404. 
Ghersi-Egea JF, Gorevic PD, Ghiso J, Frangione B, Patlak CS & Fenstermacher JD. 
(1996) Fate of cerebrospinal fluid-borne amyloid beta-peptide: rapid 
clearance into blood and appreciable accumulation by cerebral arteries. J 
Neurochem. 67, 880-883. 
Ghiselli G, Schaefer EJ, Zech LA, Gregg RE & Brewer HB, Jr. (1982) Increased 





Ghiso J, Gardella JE, Liem L, Gorevic PD & Frangione B. (1994) Characterization of 
a novel processing pathway for Alzheimer's amyloid beta precursor protein. 
Neurosci Lett. 171, 213-216. 
Ghiso J, Matsubara E, Koudinov A, Choi-Miura NH, Tomita M, Wisniewski T & 
Frangione B. (1993) The cerebrospinal-fluid soluble form of Alzheimer's 
amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the 
complement membrane-attack complex. Biochem J. 293, 27-30. 
Ghribi O, Golovko MY, Larsen B, Schrag M & Murphy EJ. (2006) Deposition of iron 
and beta-amyloid plaques is associated with cortical cellular damage in 
rabbits fed with long-term cholesterol-enriched diets. J Neurochem. 99, 438-
449. 
Giubilei F, D'Antona R, Antonini R, Lenzi GL, Ricci G & Fieschi C. (1990) Serum 
lipoprotein pattern variations in dementia and ischemic stroke. Acta Neurol 
Scand. 81, 84-86. 
Glenner GG & Wong CW. (1984) Alzheimer's disease: initial report of the 
purification and characterization of a novel cerebrovascular amyloid protein. 
Biochem Biophys Res Commun. 120, 885-890. 
Golde TE & Eckman CB. (2001) Cholesterol modulation as an emerging strategy for 
the treatment of Alzheimer's disease. Drug Discov Today. 6, 1049-1055. 
Golde TE, Estus S, Usiak M, Younkin LH & Younkin SG. (1990) Expression of beta 
amyloid protein precursor mRNAs: recognition of a novel alternatively spliced 
form and quantitation in Alzheimer's disease using PCR. Neuron. 4, 253-267. 
Goldgaber D, Schwarzman AI, Bhasin R, Gregori L, Schmechel D, Saunders AM, 
Roses AD & Strittmatter WJ. (1993) Sequestration of amyloid beta-peptide. 
Ann N Y Acad Sci. 695, 139-143. 
Gonzalez S, Huerta JM, Fernandez S, Patterson AM & Lasheras C. (2010) The 
relationship between dietary lipids and cognitive performance in an elderly 
population. Int J Food Sci Nutr. 61, 217-225. 
Grant WB. (1998) The APOE-epsilon4 allele and Alzheimer disease among African 
Americans, Hispanics, and whites. JAMA. 280, 1662-1663; author reply 
1663. 
Grant WB (2014) Trends in diet and Alzheimer's disease during the nutrition 
transition in Japan and developing countries. J Alzheimers Dis. 38, 611-620. 
Graves AB, Rajaram L, Bowen JD, McCormick WC, McCurry SM & Larson EB. 




Americans in King County, WA: the Kame Project. J Gerontol B Psychol Sci 
Soc Sci. 54, S154-161. 
Green KN, Martinez-Coria H, Khashwji H, Hall EB, Yurko-Mauro KA, Ellis L & 
LaFerla FM. (2007) Dietary docosahexaenoic acid and docosapentaenoic 
acid ameliorate amyloid-beta and tau pathology via a mechanism involving 
presenilin 1 levels. J Neurosci. 27, 4385-4395. 
Green PH & Riley JW. (1981) Lipid absorption and intestinal lipoprotein formation. 
Aust N Z J Med. 11, 84-90. 
Greenwood CE & Winocur G. (1990) Learning and memory impairment in rats fed a 
high saturated fat diet. Behav Neural Biol. 53, 74-87. 
Greenwood CE & Winocur G. (2001) Glucose treatment reduces memory deficits in 
young adult rats fed high-fat diets. Neurobiol Learn Mem. 75, 179-189. 
Gregg RE, Zech LA, Schaefer EJ, Stark D, Wilson D & Brewer HB, Jr. (1986) 
Abnormal in vivo metabolism of apolipoprotein E4 in humans. J Clin Invest. 
78, 815-821. 
Gustafson D. (2008) A life course of adiposity and dementia. Eur J Pharmacol. 585, 
163-175. 
Haass C, Koo EH, Capell A, Teplow DB & Selkoe DJ. (1995) Polarized sorting of 
beta-amyloid precursor protein and its proteolytic products in MDCK cells is 
regulated by two independent signals. J Cell Biol. 128, 537-547. 
Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, 
Lieberburg I, Koo EH, Schenk D, Teplow DB & et al. (1992) Amyloid beta-
peptide is produced by cultured cells during normal metabolism. Nature. 359, 
322-325. 
Haass C & Selkoe DJ. (2007) Soluble protein oligomers in neurodegeneration: 
lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol. 8, 
101-112. 
Hamelin BA & Turgeon J. (1998) Hydrophilicity/lipophilicity: relevance for the 
pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends 
Pharmacol Sci. 19, 26-37. 
Hanson AJ, Bayer-Carter JL, Green PS, Montine TJ, Wilkinson CW, Baker LD, 
Watson GS, Bonner LM, Callaghan M, Leverenz JB, Tsai E, Postupna N, 
Zhang J, Lampe J & Craft S. (2013) Effect of apolipoprotein E genotype and 
diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical 




Hardy J, Duff K, Hardy KG, Perez-Tur J & Hutton M. (1998) Genetic dissection of 
Alzheimer's disease and related dementias: amyloid and its relationship to 
tau. Nat Neurosci. 1, 355-358. 
Harper JD & Lansbury PT, Jr. (1997) Models of amyloid seeding in Alzheimer's 
disease and scrapie: mechanistic truths and physiological consequences of 
the time-dependent solubility of amyloid proteins. Annu Rev Biochem. 66, 
385-407. 
Harper JD, Wong SS, Lieber CM & Lansbury PT, Jr. (1999) Assembly of A beta 
amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's 
disease. Biochemistry. 38, 8972-8980. 
Hashimoto M, Hossain S, Agdul H & Shido O. (2005) Docosahexaenoic acid-
induced amelioration on impairment of memory learning in amyloid beta-
infused rats relates to the decreases of amyloid beta and cholesterol levels in 
detergent-insoluble membrane fractions. Biochim Biophys Acta. 1738, 91-98. 
Hatters DM, Peters-Libeu CA & Weisgraber KH. (2006) Apolipoprotein E structure: 
insights into function. Trends Biochem Sci. 31, 445-454. 
Havlik RJ, Izmirlian G, Petrovitch H, Ross GW, Masaki K, Curb JD, Saunders AM, 
Foley DJ, Brock D, Launer LJ & White L. (2000) APOE-epsilon4 predicts 
incident AD in Japanese-American men: the honolulu-asia aging study. 
Neurology. 54, 1526-1529. 
Hawkins BT & Davis TP. (2005) The blood-brain barrier/neurovascular unit in health 
and disease. Pharmacol Rev. 57, 173-185. 
Hayes KC, Khosla P, Hajri T & Pronczuk A. (1997) Saturated fatty acids and LDL 
receptor modulation in humans and monkeys. Prostaglandins Leukot Essent 
Fatty Acids. 57, 411-418. 
Hedin HL, Nasman A & Fowler CJ. (1998) The secretion of soluble amyloid beta 
precursor protein (A beta PPs) by chick neurons in serum-free primary 
culture is not regulated by protein kinase C. Amyloid. 5, 227-237. 
Heeren J, Niemeier A, Merkel M & Beisiegel U. (2002) Endothelial-derived 
lipoprotein lipase is bound to postprandial triglyceride-rich lipoproteins and 
mediates their hepatic clearance in vivo. J Mol Med (Berl). 80, 576-584. 
Hendrie HC, Baiyewu O, Eldemire D & Prince C. (1996) Cross-cultural perspectives: 





Hendrie HC, Osuntokun BO, Hall KS, Ogunniyi AO, Hui SL, Unverzagt FW, Gureje 
O, Rodenberg CA, Baiyewu O & Musick BS. (1995) Prevalence of 
Alzheimer's disease and dementia in two communities: Nigerian Africans and 
African Americans. Am J Psychiatry. 152, 1485-1492. 
Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, Peng Y, Cambareri G, Rocher A, 
Mobbs CV, Hof PR & Pasinetti GM. (2004) Diet-induced insulin resistance 
promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. 
FASEB J. 18, 902-904. 
Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, Stern Y & Mayeux R. 
(2003) Stroke and the risk of Alzheimer disease. Arch Neurol. 60, 1707-
1712. 
Hooijmans CR, Van der Zee CE, Dederen PJ, Brouwer KM, Reijmer YD, van Groen 
T, Broersen LM, Lutjohann D, Heerschap A & Kiliaan AJ. (2009) DHA and 
cholesterol containing diets influence Alzheimer-like pathology, cognition and 
cerebral vasculature in APPswe/PS1dE9 mice. Neurobiol Dis. 33, 482-498. 
Hsiao KK, Borchelt DR, Olson K, Johannsdottir R, Kitt C, Yunis W, Xu S, Eckman C, 
Younkin S, Price D & et al. (1995) Age-related CNS disorder and early death 
in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor 
proteins. Neuron. 15, 1203-1218. 
Hui DY, Innerarity TL & Mahley RW. (1981) Lipoprotein binding to canine hepatic 
membranes. Metabolically distinct apo-E and apo-B,E receptors. J Biol 
Chem. 256, 5646-5655. 
Hultin M & Olivecrona T. (1998) Conversion of chylomicrons into remnants. 
Atherosclerosis. 141 Suppl 1, 25-29. 
Hussain MM. (2014) Intestinal lipid absorption and lipoprotein formation. Curr Opin 
Lipidol. 25, 200-206. 
Hussain MM, Kancha RK, Zhou Z, Luchoomun J, Zu H & Bakillah A. (1996) 
Chylomicron assembly and catabolism: role of apolipoproteins and receptors. 
Biochim Biophys Acta. 1300, 151-170. 
Hussain MM, Kedees MH, Singh K, Athar H & Jamali NZ. (2001) Signposts in the 
assembly of chylomicrons. Front Biosci. 6, 320-331. 
Ikeda K, Haga C & Kosaka K. (1990) Light and electron microscopic examination of 





Iozzo RV. (1998) Matrix proteoglycans: from molecular design to cellular function. 
Annu Rev Biochem. 67, 609-652. 
Irizarry MC, Deng A, Lleo A, Berezovska O, Von Arnim CA, Martin-Rehrmann M, 
Manelli A, LaDu MJ, Hyman BT & Rebeck GW. (2004) Apolipoprotein E 
modulates gamma-secretase cleavage of the amyloid precursor protein. J 
Neurochem. 90, 1132-1143. 
Isherwood SG, Williams CM & Gould BJ. (1997) Apolipoprotein B-48 as a marker for 
chylomicrons and their remnants: studies in the postprandial state. Proc Nutr 
Soc. 56, 497-505. 
Itagaki S, McGeer PL, Akiyama H, Zhu S & Selkoe D. (1989) Relationship of 
microglia and astrocytes to amyloid deposits of Alzheimer disease. J 
Neuroimmunol. 24, 173-182. 
Iwata H, Tomita T, Maruyama K & Iwatsubo T. (2001) Subcellular compartment and 
molecular subdomain of beta-amyloid precursor protein relevant to the Abeta 
42-promoting effects of Alzheimer mutant presenilin 2. J Biol Chem. 276, 
21678-21685. 
Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N & Ihara Y. (1994) 
Visualization of A beta 42(43) and A beta 40 in senile plaques with end-
specific A beta monoclonals: evidence that an initially deposited species is A 
beta 42(43). Neuron. 13, 45-53. 
Jackle S, Rinninger F, Greeve J, Greten H & Windler E. (1992) Regulation of the 
hepatic removal of chylomicron remnants and beta-very low density 
lipoproteins in the rat. J Lipid Res. 33, 419-429. 
Jackson KG, Maitin V, Leake DS, Yaqoob P & Williams CM. (2006) Saturated fat-
induced changes in Sf 60-400 particle composition reduces uptake of LDL by 
HepG2 cells. J Lipid Res. 47, 393-403. 
Jackson KG, Robertson MD, Fielding BA, Frayn KN & Williams CM. (2002) Olive oil 
increases the number of triacylglycerol-rich chylomicron particles compared 
with other oils: an effect retained when a second standard meal is fed. Am J 
Clin Nutr. 76, 942-949. 
Jackson KG, Wolstencroft EJ, Bateman PA, Yaqoob P & Williams CM. (2005) Acute 
effects of meal fatty acids on postprandial NEFA, glucose and apo E 
response: implications for insulin sensitivity and lipoprotein regulation? Br J 




James AP & Mamo JC. (2005) The immunodetection of lipoprotein-bound amyloid-
beta is attenuated because of the presence of lipids. Ann Clin Biochem. 42, 
70-72. 
James AP, Pal S, Gennat HC, Vine DF & Mamo JC. (2003) The incorporation and 
metabolism of amyloid-beta into chylomicron-like lipid emulsions. J 
Alzheimers Dis. 5, 179-188. 
Jancso G, Domoki F, Santha P, Varga J, Fischer J, Orosz K, Penke B, Becskei A, 
Dux M & Toth L. (1998) Beta-amyloid (1-42) peptide impairs blood-brain 
barrier function after intracarotid infusion in rats. Neurosci Lett. 253, 139-141. 
Jiao S, Moberly JB & Schonfeld G. (1990) Editing of apolipoprotein B messenger 
RNA in differentiated Caco-2 cells. J Lipid Res. 31, 695-700. 
Jick H, Zornberg GL, Jick SS, Seshadri S & Drachman DA. (2000) Statins and the 
risk of dementia. Lancet. 356, 1627-1631. 
Jofre-Monseny L, Minihane AM & Rimbach G. (2008) Impact of apoE genotype on 
oxidative stress, inflammation and disease risk. Mol Nutr Food Res. 52, 131-
145. 
Johnson NA, Jahng GH, Weiner MW, Miller BL, Chui HC, Jagust WJ, Gorno-
Tempini ML & Schuff N. (2005) Pattern of cerebral hypoperfusion in 
Alzheimer disease and mild cognitive impairment measured with arterial 
spin-labeling MR imaging: initial experience. Radiology. 234, 851-859. 
Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson 
H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, 
Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, 
Jonsson EG, Palotie A, Behrens TW, Magnusson OT, Kong A, 
Thorsteinsdottir U, Watts RJ & Stefansson K. (2012) A mutation in APP 
protects against Alzheimer's disease and age-related cognitive decline. 
Nature. 488, 96-99. 
Julien C, Tremblay C, Phivilay A, Berthiaume L, Emond V, Julien P & Calon F. 
(2010) High-fat diet aggravates amyloid-beta and tau pathologies in the 
3xTg-AD mouse model. Neurobiol Aging. 31, 1516-1531. 
Kalaria RN. (1992) The blood-brain barrier and cerebral microcirculation in 
Alzheimer disease. Cerebrovasc Brain Metab Rev. 4, 226-260. 
Kalaria RN, Akinyemi R & Ihara M. (2012) Does vascular pathology contribute to 




Kalback W, Esh C, Castano EM, Rahman A, Kokjohn T, Luehrs DC, Sue L, 
Cisneros R, Gerber F, Richardson C, Bohrmann B, Walker DG, Beach TG & 
Roher AE. (2004) Atherosclerosis, vascular amyloidosis and brain 
hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurol 
Res. 26, 525-539. 
Kalmijn S. (2000) Fatty acid intake and the risk of dementia and cognitive decline: a 
review of clinical and epidemiological studies. J Nutr Health Aging. 4, 202-
207. 
Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A & Breteler MM. (1997) Dietary 
fat intake and the risk of incident dementia in the Rotterdam Study. Ann 
Neurol. 42, 776-782. 
Kandimalla KK, Curran GL, Holasek SS, Gilles EJ, Wengenack TM & Poduslo JF. 
(2005) Pharmacokinetic analysis of the blood-brain barrier transport of 125I-
amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice 
(APP,PS1) and its implications for amyloid plaque formation. J Pharmacol 
Exp Ther. 313, 1370-1378. 
Kanemitsu N, Shimamoto C, Hiraike Y, Omae T, Iwakura K, Nakanishi Y & Katsu K. 
(2006) Fat Absorption and Morphological Changes in the Small Intestine in 
Model Mice with Hyperlipidemia (Apo E Deficiency). Bulletin of Osaka 
Medical College. 52, 59-67. 
Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, 
Multhaup G, Beyreuther K & Muller-Hill B. (1987) The precursor of 
Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. 
Nature. 325, 733-736. 
Kanoski SE & Davidson TL. (2011) Western diet consumption and cognitive 
impairment: links to hippocampal dysfunction and obesity. Physiol Behav. 
103, 59-68. 
Kaplan RJ & Greenwood CE. (1998) Dietary saturated fatty acids and brain function. 
Neurochem Res. 23, 615-626. 
Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, 
Deedwania P, Olsson AG, Boekholdt SM, Demicco DA, Szarek M, LaRosa 
JC, Pedersen TR, Grundy SM, Group TNTS & Group IS. (2008) Lipids, 
apolipoproteins, and their ratios in relation to cardiovascular events with 




Katsiardanis K, Diamantaras AA, Dessypris N, Michelakos T, Anastasiou A, 
Katsiardani KP, Kanavidis P, Papadopoulos FC, Stefanadis C, Panagiotakos 
DB & Petridou ET. (2013) Cognitive impairment and dietary habits among 
elders: the Velestino Study. J Med Food. 16, 343-350. 
Kesaniemi YA, Ehnholm C & Miettinen TA. (1987) Intestinal cholesterol absorption 
efficiency in man is related to apoprotein E phenotype. J Clin Invest. 80, 578-
581. 
King IS, Paterson JY, Peacock MA, Smith MW & Syme G. (1983) Effect of diet upon 
enterocyte differentiation in the rat jejunum. J Physiol. 344, 465-481. 
Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, 
Soininen H, Tuomilehto J & Nissinen A. (2001) Midlife vascular risk factors 
and Alzheimer's disease in later life: longitudinal, population based study. 
BMJ. 322, 1447-1451. 
Kivipelto M, Laakso MP, Tuomilehto J, Nissinen A & Soininen H. (2002) 
Hypertension and hypercholesterolaemia as risk factors for Alzheimer's 
disease: potential for pharmacological intervention. CNS Drugs. 16, 435-444. 
Klegeris A & McGeer PL. (2002) Cyclooxygenase and 5-lipoxygenase inhibitors 
protect against mononuclear phagocyte neurotoxicity. Neurobiol Aging. 23, 
787-794. 
Klein WL. (2002) Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) 
as new vaccine and drug targets. Neurochem Int. 41, 345-352. 
Kobayashi M, Ohno T, Tsuchiya T & Horio F. (2004) Characterization of diabetes-
related traits in MSM and JF1 mice on high-fat diet. J Nutr Biochem. 15, 614-
621. 
Kontush A. (2004) Apolipoprotein Abeta: black sheep in a good family. Brain Pathol. 
14, 433-447. 
Koudinov A, Matsubara E, Frangione B & Ghiso J. (1994) The soluble form of 
Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 
and very high density lipoprotein in normal human plasma. Biochem Biophys 
Res Commun. 205, 1164-1171. 
Koudinov AR & Koudinova NV. (1997) Alzheimer's soluble amyloid beta protein is 
secreted by HepG2 cells as an apolipoprotein. Cell Biol Int. 21, 265-271. 
Koudinov AR, Koudinova NV & Berezov TT. (1996a) Alzheimer's peptides A beta 1-
40 and A beta 1-28 inhibit the plasma cholesterol esterification rate. Biochem 




Koudinov AR, Koudinova NV, Kumar A, Beavis RC & Ghiso J. (1996b) Biochemical 
characterization of Alzheimer's soluble amyloid beta protein in human 
cerebrospinal fluid: association with high density lipoproteins. Biochem 
Biophys Res Commun. 223, 592-597. 
Koudinova NV, Berezov TT & Koudinov AR. (1996) Multiple inhibitory effects of 
Alzheimer's peptide Abeta1-40 on lipid biosynthesis in cultured human 
HepG2 cells. FEBS Lett. 395, 204-206. 
Krapp A, Ahle S, Kersting S, Hua Y, Kneser K, Nielsen M, Gliemann J & Beisiegel 
U. (1996) Hepatic lipase mediates the uptake of chylomicrons and beta-
VLDL into cells via the LDL receptor-related protein (LRP). J Lipid Res. 37, 
926-936. 
Kuehl FA, Jr. & Egan RW. (1980) Prostaglandins, arachidonic acid, and 
inflammation. Science. 210, 978-984. 
Kuipers F, Jong MC, Lin Y, Eck M, Havinga R, Bloks V, Verkade HJ, Hofker MH, 
Moshage H, Berkel TJ, Vonk RJ & Havekes LM. (1997) Impaired secretion of 
very low density lipoprotein-triglycerides by apolipoprotein E- deficient mouse 
hepatocytes. J Clin Invest. 100, 2915-2922. 
Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Drumm D & 
Roher AE. (1998) Elevated low-density lipoprotein in Alzheimer's disease 
correlates with brain abeta 1-42 levels. Biochem Biophys Res Commun. 252, 
711-715. 
Kuo YM, Emmerling MR, Lampert HC, Hempelman SR, Kokjohn TA, Woods AS, 
Cotter RJ & Roher AE. (1999) High levels of circulating Abeta42 are 
sequestered by plasma proteins in Alzheimer's disease. Biochem Biophys 
Res Commun. 257, 787-791. 
Kurokawa M, Hirano T, Furukawa S, Nagano S & Adachi M. (1995) Similar to oleic 
acid, eicosapentaenoic acid stimulates apolipoprotein B secretion by 
inhibiting its intracellular degradation in Hep G2 cells. Atherosclerosis. 112, 
59-68. 
LaDu MJ, Lukens JR, Reardon CA & Getz GS. (1997) Association of human, rat, 
and rabbit apolipoprotein E with beta-amyloid. J Neurosci Res. 49, 9-18. 
LaDu MJ, Pederson TM, Frail DE, Reardon CA, Getz GS & Falduto MT. (1995) 
Purification of apolipoprotein E attenuates isoform-specific binding to beta-




La Fata G, Weber P & Mohajeri MH. (2014) Effects of vitamin E on cognitive 
performance during ageing and in Alzheimer's disease. Nutrients. 6, 5453-
5472. 
Laitinen MH, Ngandu T, Rovio S, Helkala EL, Uusitalo U, Viitanen M, Nissinen A, 
Tuomilehto J, Soininen H & Kivipelto M. (2006) Fat intake at midlife and risk 
of dementia and Alzheimer's disease: a population-based study. Dement 
Geriatr Cogn Disord. 22, 99-107. 
Lam V, Takechi R, Pallebage-Gamarallage MM, Galloway S & Mamo JC. (2011) 
Colocalisation of plasma derived apo B lipoproteins with cerebral 
proteoglycans in a transgenic-amyloid model of Alzheimer's disease. 
Neurosci Lett. 492, 160-164. 
Lange KL, Bondi MW, Salmon DP, Galasko D, Delis DC, Thomas RG & Thal LJ. 
(2002) Decline in verbal memory during preclinical Alzheimer's disease: 
examination of the effect of APOE genotype. J Int Neuropsychol Soc. 8, 943-
955. 
LaRue B, Hogg E, Sagare A, Jovanovic S, Maness L, Maurer C, Deane R & 
Zlokovic BV. (2004) Method for measurement of the blood-brain barrier 
permeability in the perfused mouse brain: application to amyloid-beta peptide 
in wild type and Alzheimer's Tg2576 mice. J Neurosci Methods. 138, 233-
242. 
Laurin D, Verreault R, Lindsay J, Dewailly E & Holub BJ. (2003) Omega-3 fatty acids 
and risk of cognitive impairment and dementia. J Alzheimers Dis. 5, 315-322. 
Lazarczyk MJ, Hof PR, Bouras C & Giannakopoulos P. (2012) Preclinical Alzheimer 
disease: identification of cases at risk among cognitively intact older 
individuals. BMC Med. 10, 127. 
Lee DM & Singh S. (1988) Degradation of apolipoprotein B-100 in human 
chylomicrons. Biochim Biophys Acta. 960, 148-156. 
Leighton JK, Joyner J, Zamarripa J, Deines M & Davis RA. (1990) Fasting 
decreases apolipoprotein B mRNA editing and the secretion of small 
molecular weight apoB by rat hepatocytes: evidence that the total amount of 
apoB secreted is regulated post-transcriptionally. J Lipid Res. 31, 1663-1668. 
Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Burger K, 
Hampel H, Frolich L, Wolf S, Prinz B, Jahn H, Luckhaus C, Perneczky R, 
Hull M, Schroder J, Kessler H, Pantel J, Gertz HJ, Klafki HW, Kolsch H, 




(2010) Soluble amyloid precursor proteins in the cerebrospinal fluid as novel 
potential biomarkers of Alzheimer's disease: a multicenter study. Mol 
Psychiatry. 15, 138-145. 
Lewis RA, Austen KF & Soberman RJ. (1990) Leukotrienes and other products of 
the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in 
human diseases. N Engl J Med. 323, 645-655. 
Li M, Chen L, Lee DH, Yu LC & Zhang Y. (2007) The role of intracellular amyloid 
beta in Alzheimer's disease. Prog Neurobiol. 83, 131-139. 
Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, Salem N, Jr., Frautschy 
SA & Cole GM. (2005) A diet enriched with the omega-3 fatty acid 
docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse 
model. J Neurosci. 25, 3032-3040. 
Lim SY & Suzuki H. (2000) Intakes of dietary docosahexaenoic acid ethyl ester and 
egg phosphatidylcholine improve maze-learning ability in young and old 
mice. J Nutr. 130, 1629-1632. 
Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB & McDowell I. (2002) 
Risk factors for Alzheimer's disease: a prospective analysis from the 
Canadian Study of Health and Aging. Am J Epidemiol. 156, 445-453. 
Lippa CF, Nee LE, Mori H & St George-Hyslop P. (1998) Abeta-42 deposition 
precedes other changes in PS-1 Alzheimer's disease. Lancet. 352, 1117-
1118. 
Liu Y, Yang L, Conde-Knape K, Beher D, Shearman MS & Shachter NS. (2004) 
Fatty acids increase presenilin-1 levels and [gamma]-secretase activity in 
PSwt-1 cells. J Lipid Res. 45, 2368-2376. 
Lorenzo A & Yankner BA. (1994) Beta-amyloid neurotoxicity requires fibril formation 
and is inhibited by congo red. Proc Natl Acad Sci U S A. 91, 12243-12247. 
Luchoomun J & Hussain MM. (1999) Assembly and secretion of chylomicrons by 
differentiated Caco-2 cells. Nascent triglycerides and preformed 
phospholipids are preferentially used for lipoprotein assembly. J Biol Chem. 
274, 19565-19572. 
Luchsinger JA & Mayeux R. (2004) Cardiovascular risk factors and Alzheimer's 
disease. Curr Atheroscler Rep. 6, 261-266. 
Luchsinger JA, Tang MX, Shea S & Mayeux R. (2002) Caloric intake and the risk of 




Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel 
RE & Rogers J. (1999) Soluble amyloid beta peptide concentration as a 
predictor of synaptic change in Alzheimer's disease. Am J Pathol. 155, 853-
862. 
Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN & 
Bazan NG. (2005) A role for docosahexaenoic acid-derived neuroprotectin 
D1 in neural cell survival and Alzheimer disease. J Clin Invest. 115, 2774-
2783. 
Mackic JB, Bading J, Ghiso J, Walker L, Wisniewski T, Frangione B & Zlokovic BV. 
(2002) Circulating amyloid-beta peptide crosses the blood-brain barrier in 
aged monkeys and contributes to Alzheimer's disease lesions. Vascul 
Pharmacol. 38, 303-313. 
Mahley RW. (1988) Apolipoprotein E: cholesterol transport protein with expanding 
role in cell biology. Science. 240, 622-630. 
Mahley RW & Huang Y. (1999) Apolipoprotein E: from atherosclerosis to 
Alzheimer's disease and beyond. Curr Opin Lipidol. 10, 207-217. 
Mahley RW, Hui DY, Innerarity TL & Weisgraber KH. (1981) Two independent 
lipoprotein receptors on hepatic membranes of dog, swine, and man. Apo-
B,E and apo-E receptors. J Clin Invest. 68, 1197-1206. 
Mahley RW & Rall SC, Jr. (2000) Apolipoprotein E: far more than a lipid transport 
protein. Annu Rev Genomics Hum Genet. 1, 507-537. 
Mamo JC, Bowler A, Elsegood CL & Redgrave TG. (1991) Defective plasma 
clearance of chylomicron-like lipid emulsions in Watanabe heritable 
hyperlipidemic rabbits. Biochim Biophys Acta. 1081, 241-245. 
Mamo JC, Elsegood CL, Umeda Y, Hirano T & Redgrave TG. (1993) Effect of 
probucol on plasma clearance and organ uptake of chylomicrons and VLDLs 
in normal and diabetic rats. Arterioscler Thromb. 13, 231-239. 
Mamo JC, Jian L, James AP, Flicker L, Esselmann H & Wiltfang J. (2008) Plasma 
lipoprotein beta-amyloid in subjects with Alzheimer's disease or mild 
cognitive impairment. Ann Clin Biochem. 45, 395-403. 
Mamo JC, Smith D, Yu KC, Kawaguchi A, Harada-Shiba M, Yamamura T & 
Yamamoto A. (1998) Accumulation of chylomicron remnants in homozygous 




Mamo JC, Watts GF, Barrett PH, Smith D, James AP & Pal S. (2001) Postprandial 
dyslipidemia in men with visceral obesity: an effect of reduced LDL receptor 
expression? Am J Physiol Endocrinol Metab. 281, 626-632. 
Manders EMM, Verbeek FJ & Atenm JA. (1993) Measurement of co-localization of 
objects in dual-colour confocal images. J Microsc. 169, 375-382. 
Maness LM, Banks WA, Podlisny MB, Selkoe DJ & Kastin AJ. (1994) Passage of 
human amyloid beta-protein 1-40 across the murine blood-brain barrier. Life 
Sci. 55, 1643-1650. 
Martel CL, Mackic JB, Matsubara E, Governale S, Miguel C, Miao W, McComb JG, 
Frangione B, Ghiso J & Zlokovic BV. (1997) Isoform-specific effects of 
apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and 
blood-brain barrier transport of circulating Alzheimer's amyloid beta. J 
Neurochem. 69, 1995-2004. 
Martel CL, Mackic JB, McComb JG, Ghiso J & Zlokovic BV. (1996) Blood-brain 
barrier uptake of the 40 and 42 amino acid sequences of circulating 
Alzheimer's amyloid beta in guinea pigs. Neurosci Lett. 206, 157-160. 
Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN & Beyreuther K. 
(1985) Neuronal origin of a cerebral amyloid: neurofibrillary tangles of 
Alzheimer's disease contain the same protein as the amyloid of plaque cores 
and blood vessels. EMBO J. 4, 2757-2763. 
Matos LL, Trufelli DC, de Matos MG & da Silva Pinhal MA. (2010) 
Immunohistochemistry as an important tool in biomarkers detection and 
clinical practice. Biomark Insights. 5, 9-20. 
Matsubara E, Ghiso J, Frangione B, Amari M, Tomidokoro Y, Ikeda Y, Harigaya Y, 
Okamoto K & Shoji M. (1999) Lipoprotein-free amyloidogenic peptides in 
plasma are elevated in patients with sporadic Alzheimer's disease and 
Down's syndrome. Ann Neurol. 45, 537-541. 
Mattson MP. (2003a) Gene-diet interactions in brain aging and neurodegenerative 
disorders. Ann Intern Med. 139, 441-444. 
Mattson MP. (2004) Pathways towards and away from Alzheimer's disease. Nature. 
430, 631-639. 
Maugeais C, Tietge UJ, Tsukamoto K, Glick JM & Rader DJ. (2000) Hepatic 
apolipoprotein E expression promotes very low density lipoprotein-




Maurer K, Volk S & Gerbaldo H. (1997) Auguste D and Alzheimer's disease. Lancet. 
349, 1546-1549. 
Mayhan WG. (2001) Regulation of blood-brain barrier permeability. Microcirculation. 
8, 89-104. 
McGee CD & Greenwood CE. (1990) Protein and carbohydrate selection respond to 
changes in dietary saturated fatty acids but not to changes in essential fatty 
acids. Life Sci. 47, 67-76. 
Meel-van den Abeelen AS, van Beek AH, Slump CH, Panerai RB & Claassen JA. 
(2014) Transfer function analysis for the assessment of cerebral 
autoregulation using spontaneous oscillations in blood pressure and cerebral 
blood flow. Med Eng Phys. 36, 563-575. 
Menotti A, Kromhout D, Blackburn H, Fidanza F, Buzina R & Nissinen A. (1999) 
Food intake patterns and 25-year mortality from coronary heart disease: 
cross-cultural correlations in the Seven Countries Study. The Seven 
Countries Study Research Group. Eur J Epidemiol. 15, 507-515. 
Mensenkamp AR, Jong MC, van Goor H, van Luyn MJ, Bloks V, Havinga R, Voshol 
PJ, Hofker MH, van Dijk KW, Havekes LM & Kuipers F. (1999) 
Apolipoprotein E participates in the regulation of very low density lipoprotein-
triglyceride secretion by the liver. J Biol Chem. 274, 35711-35718. 
Mensenkamp AR, Van Luyn MJ, Havinga R, Teusink B, Waterman IJ, Mann CJ, 
Elzinga BM, Verkade HJ, Zammit VA, Havekes LM, Shoulders CC & Kuipers 
F. (2004) The transport of triglycerides through the secretory pathway of 
hepatocytes is impaired in apolipoprotein E deficient mice. J Hepatol. 40, 
599-606. 
Merched A, Xia Y, Visvikis S, Serot JM & Siest G. (2000) Decreased high-density 
lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly 
correlated with the severity of Alzheimer's disease. Neurobiol Aging. 21, 27-
30. 
Mikaelian I, Nanney LB, Parman KS, Kusewitt DF, Ward JM, Naf D, Krupke DM, 
Eppig JT, Bult CJ, Seymour R, Ichiki T & Sundberg JP. (2004) Antibodies 
that label paraffin-embedded mouse tissues: a collaborative endeavor. 
Toxicol Pathol. 32, 181-191. 
Molteni R, Barnard RJ, Ying Z, Roberts CK & Gomez-Pinilla F. (2002) A high-fat, 
refined sugar diet reduces hippocampal brain-derived neurotrophic factor, 




Molteni R, Wu A, Vaynman S, Ying Z, Barnard RJ & Gomez-Pinilla F. (2004) 
Exercise reverses the harmful effects of consumption of a high-fat diet on 
synaptic and behavioral plasticity associated to the action of brain-derived 
neurotrophic factor. Neuroscience. 123, 429-440. 
Morgan NG. (2009) Fatty acids and beta-cell toxicity. Curr Opin Clin Nutr Metab 
Care. 12, 117-122. 
Morris MC. (2004) Diet and Alzheimer's disease: what the evidence shows. 
MedGenMed. 6, 48. 
Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, 
Schneider J & Wilson RS. (2003) Dietary fats and the risk of incident 
Alzheimer disease. Arch Neurol. 60, 194-200. 
Morris MC, Evans DA, Tangney CC, Bienias JL, Schneider JA, Wilson RS & Scherr 
PA. (2006) Dietary copper and high saturated and trans fat intakes 
associated with cognitive decline. Arch Neurol. 63, 1085-1088. 
Nakashima Y, Plump AS, Raines EW, Breslow JL & Ross R. (1994) ApoE-deficient 
mice develop lesions of all phases of atherosclerosis throughout the arterial 
tree. Arterioscler Thromb. 14, 133-140. 
Namba Y, Tsuchiya H & Ikeda K. (1992) Apolipoprotein B immunoreactivity in senile 
plaque and vascular amyloids and neurofibrillary tangles in the brains of 
patients with Alzheimer's disease. Neurosci Lett. 134, 264-266. 
Naoumova RP, Dunn S, Rallidis L, Abu-Muhana O, Neuwirth C, Rendell NB, Taylor 
GW & Thompson GR. (1997) Prolonged inhibition of cholesterol synthesis 
explains the efficacy of atorvastatin. J Lipid Res. 38, 1496-1500. 
Naqvi AZ, Harty B, Mukamal KJ, Stoddard AM, Vitolins M & Dunn JE. (2011) 
Monounsaturated, trans, and saturated Fatty acids and cognitive decline in 
women. J Am Geriatr Soc. 59, 837-843. 
National Health and Medical Research Council, Australian Government Department 
of Health and Ageing, New Zealand Ministry of Health. Nutrient reference 
values for Australia and New Zealand including recommended dietary 
intakes. Canberra: Commonwealth of Australia; 2006. 
Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P & Buxbaum 
JD. (2000) Correlation between elevated levels of amyloid beta-peptide in 




Nedergaard M, Ransom B & Goldman SA. (2003) New roles for astrocytes: 
redefining the functional architecture of the brain. Trends Neurosci. 26, 523-
530. 
Nelson TJ & Alkon DL. (2007) Protection against beta-amyloid-induced apoptosis by 
peptides interacting with beta-amyloid. J Biol Chem. 282, 31238-31249. 
Neumann S, Coudreuse DY, van der Westhuyzen DR, Eckhardt ER, Korswagen 
HC, Schmitz G & Sprong H. (2009) Mammalian Wnt3a is released on 
lipoprotein particles. Traffic. 10, 334-343. 
Newman EA. (2003) New roles for astrocytes: regulation of synaptic transmission. 
Trends Neurosci. 26, 536-542. 
Nichols MR, Moss MA, Reed DK, Lin WL, Mukhopadhyay R, Hoh JH & Rosenberry 
TL. (2002) Growth of beta-amyloid(1-40) protofibrils by monomer elongation 
and lateral association. Characterization of distinct products by light 
scattering and atomic force microscopy. Biochemistry. 41, 6115-6127. 
Nishitomi K, Sakaguchi G, Horikoshi Y, Gray AJ, Maeda M, Hirata-Fukae C, Becker 
AG, Hosono M, Sakaguchi I, Minami SS, Nakajima Y, Li HF, Takeyama C, 
Kihara T, Ota A, Wong PC, Aisen PS, Kato A, Kinoshita N & Matsuoka Y. 
(2006) BACE1 inhibition reduces endogenous Abeta and alters APP 
processing in wild-type mice. J Neurochem. 99, 1555-1563. 
Nishitsuji K, Hosono T, Nakamura T, Bu G & Michikawa M. (2011) Apolipoprotein E 
regulates the integrity of tight junctions in an isoform-dependent manner in 
an in vitro blood-brain barrier model. J Biol Chem. 286, 17536-17542. 
Noutsou M & Georgopoulos A. (1999) Effects of simvastatin on fasting and 
postprandial triglyceride-rich lipoproteins in patients with type I diabetes 
mellitus. J Diabetes Complications. 13, 98-104. 
Ntambi JM & Miyazaki M. (2004) Regulation of stearoyl-CoA desaturases and role in 
metabolism. Prog Lipid Res. 43, 91-104. 
O'Brien KD, Olin KL, Alpers CE, Chiu W, Ferguson M, Hudkins K, Wight TN & Chait 
A. (1998) Comparison of apolipoprotein and proteoglycan deposits in human 
coronary atherosclerotic plaques: colocalization of biglycan with 
apolipoproteins. Circulation. 98, 519-527. 
Oba S, Nagata C, Nakamura K, Fujii K, Kawachi T, Takatsuka N & Shimizu H. 
(2009) Diet based on the Japanese Food Guide Spinning Top and 
subsequent mortality among men and women in a general Japanese 




Ogunniyi A & Osuntokun B. (1991) Relatively low prevalence of Alzheimer's disease 
in developing countries and the racial factor in dementia research. Ethn Dis. 
1, 394-395. 
Oksman M, Iivonen H, Hogyes E, Amtul Z, Penke B, Leenders I, Broersen L, 
Lutjohann D, Hartmann T & Tanila H. (2006) Impact of different saturated 
fatty acid, polyunsaturated fatty acid and cholesterol containing diets on 
beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis. 23, 
563-572. 
Olin KL, Potter-Perigo S, Barrett PH, Wight TN & Chait A. (2001) Biglycan, a 
vascular proteoglycan, binds differently to HDL2 and HDL3: role of apoE. 
Arterioscler Thromb Vasc Biol. 21, 129-135. 
Olofsson SO & Boren J. (2005) Apolipoprotein B: a clinically important 
apolipoprotein which assembles atherogenic lipoproteins and promotes the 
development of atherosclerosis. J Intern Med. 258, 395-410. 
Olsson A, Hoglund K, Sjogren M, Andreasen N, Minthon L, Lannfelt L, Buerger K, 
Moller HJ, Hampel H, Davidsson P & Blennow K. (2003) Measurement of 
alpha- and beta-secretase cleaved amyloid precursor protein in 
cerebrospinal fluid from Alzheimer patients. Exp Neurol. 183, 74-80. 
Osman I, Gaillard O, Meillet D, Bordas-Fonfrede M, Gervais A, Schuller E, Delattre J 
& Legrand A. (1995) A sensitive time-resolved immunofluorometric assay for 
the measurement of apolipoprotein B in cerebrospinal fluid. Application to 
multiple sclerosis and other neurological diseases. Eur J Clin Chem Clin 
Biochem. 33, 53-58. 
Osuntokun BO, Ogunniyi AO & Lekwauwa UG. (1992) Alzheimer's disease in 
Nigeria. Afr J Med Med Sci. 21, 71-77. 
Otsuka M, Yamaguchi K & Ueki A. (2002) Similarities and differences between 
Alzheimer's disease and vascular dementia from the viewpoint of nutrition. 
Ann N Y Acad Sci. 977, 155-161. 
Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A & Breteler MM. (1999) 
Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 
53, 1937-1942. 
Ott BR, Daiello LA, Dahabreh IJ, Springate BA, Bixby K, Murali M & Trikalinos TA. 
(2015) Do statins impair cognition? A systematic review and meta-analysis of 




Pageot LP, Perreault N, Basora N, Francoeur C, Magny P & Beaulieu JF. (2000) 
Human cell models to study small intestinal functions: recapitulation of the 
crypt-villus axis. Microsc Res Tech. 49, 394-406. 
Pal S, Semorine K, Watts GF & Mamo J. (2003) Identification of lipoproteins of 
intestinal origin in human atherosclerotic plaque. Clin Chem Lab Med. 41, 
792-795. 
Pallebage-Gamarallage MM, Galloway S, Johnsen R, Jian L, Dhaliwal S & Mamo 
JC. (2009) The effect of exogenous cholesterol and lipid-modulating agents 
on enterocytic amyloid-beta abundance. Br J Nutr. 101, 340-347. 
Pallebage-Gamarallage MM, Galloway S, Takechi R, Dhaliwal S & Mamo JC. (2012) 
Probucol suppresses enterocytic accumulation of amyloid-beta induced by 
saturated fat and cholesterol feeding. Lipids. 47, 27-34. 
Pallebage-Gamarallage MM, Takechi R, Lam V, Galloway S, Dhaliwal S & Mamo 
JC. (2010) Post-prandial lipid metabolism, lipid-modulating agents and 
cerebrovascular integrity: implications for dementia risk. Atheroscler Suppl. 
11, 49-54. 
Panza F, D'Introno A, Colacicco AM, Basile AM, Capurso C, Kehoe PG, Capurso A 
& Solfrizzi V. (2004) Vascular risk and genetics of sporadic late-onset 
Alzheimer's disease. J Neural Transm. 111, 69-89. 
Parhofer KG, Barrett PH & Schwandt P. (2000) Atorvastatin improves postprandial 
lipoprotein metabolism in normolipidemlic subjects. J Clin Endocrinol Metab. 
85, 4224-4230. 
Park IH, Hwang EM, Hong HS, Boo JH, Oh SS, Lee J, Jung MW, Bang OY, Kim SU 
& Mook-Jung I. (2003) Lovastatin enhances Abeta production and senile 
plaque deposition in female Tg2576 mice. Neurobiol Aging. 24, 637-643. 
Parsons RB, Farrant JK, Price GC, Subramaniam D & Austen BM. (2007) 
Regulation of the lipidation of beta-secretase by statins. Biochem Soc Trans. 
35, 577-582. 
Patil S, Sheng L, Masserang A & Chan C. (2006) Palmitic acid-treated astrocytes 
induce BACE1 upregulation and accumulation of C-terminal fragment of APP 
in primary cortical neurons. Neurosci Lett. 406, 55-59. 
Patterson E, Wall R, Fitzgerald GF, Ross RP & Stanton C. (2012) Health 
implications of high dietary omega-6 polyunsaturated Fatty acids. J Nutr 




Pawlosky RJ, Hibbeln JR, Novotny JA & Salem N, Jr. (2001) Physiological 
compartmental analysis of alpha-linolenic acid metabolism in adult humans. 
J Lipid Res. 42, 1257-1265. 
Peila R, Rodriguez BL, Launer LJ & Honolulu-Asia Aging S. (2002) Type 2 diabetes, 
APOE gene, and the risk for dementia and related pathologies: The 
Honolulu-Asia Aging Study. Diabetes. 51, 1256-1262. 
Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH & Perry RH. (1978) 
Correlation of cholinergic abnormalities with senile plaques and mental test 
scores in senile dementia. Br Med J. 2, 1457-1459. 
Perry RJ & Hodges JR. (1999) Attention and executive deficits in Alzheimer's 
disease. A critical review. Brain. 122, 383-404. 
Petanceska SS, Seeger M, Checler F & Gandy S. (2000) Mutant presenilin 1 
increases the levels of Alzheimer amyloid beta-peptide Abeta42 in late 
compartments of the constitutive secretory pathway. J Neurochem. 74, 1878-
1884. 
Petot GJ & Friedland RP. (2004) Lipids, diet and Alzheimer disease: an extended 
summary. J Neurol Sci. 226, 31-33. 
Pettersen JA, Sathiyamoorthy G, Gao FQ, Szilagyi G, Nadkarni NK, St George-
Hyslop P, Rogaeva E & Black SE. (2008) Microbleed topography, 
leukoaraiosis, and cognition in probable Alzheimer disease from the 
Sunnybrook dementia study. Arch Neurol. 65, 790-795. 
Pike CJ, Burdick D, Walencewicz AJ, Glabe CG & Cotman CW. (1993) 
Neurodegeneration induced by beta-amyloid peptides in vitro: the role of 
peptide assembly state. J Neurosci. 13, 1676-1687. 
Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM & 
Breslow JL. (1992) Severe hypercholesterolemia and atherosclerosis in 
apolipoprotein E-deficient mice created by homologous recombination in ES 
cells. Cell. 71, 343-353. 
Poduslo JF, Curran GL, Sanyal B & Selkoe DJ. (1999) Receptor-mediated transport 
of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier. 
Neurobiol Dis. 6, 190-199. 
Poduslo JF, Curran GL, Wengenack TM, Malester B & Duff K. (2001) Permeability 
of proteins at the blood-brain barrier in the normal adult mouse and double 




Poirier J. (2003) Apolipoprotein E and cholesterol metabolism in the pathogenesis 
and treatment of Alzheimer's disease. Trends Mol Med. 9, 94-101. 
Poirier J. (2005) Apolipoprotein E, cholesterol transport and synthesis in sporadic 
Alzheimer's disease. Neurobiol Aging. 26, 355-361. 
Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P & Gauthier S. (1993) 
Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. 342, 697-
699. 
Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, 
Nalbantoglu J, Gilfix BM & Gauthier S. (1995) Apolipoprotein E4 allele as a 
predictor of cholinergic deficits and treatment outcome in Alzheimer disease. 
Proc Natl Acad Sci U S A. 92, 12260-12264. 
Presecki P, Muck-Seler D, Mimica N, Pivac N, Mustapic M, Stipcevic T & Smalc VF. 
(2011) Serum lipid levels in patients with Alzheimer's disease. Coll Antropol. 
35 Suppl 1, 115-120. 
Prince M, Graham N, Brodaty H, Rimmer E, Varghese M, Chiu H, Acosta D & 
Scazufca M. (2004) Alzheimer Disease International's 10/66 Dementia 
Research Group - one model for action research in developing countries. Int 
J Geriatr Psychiatry. 19, 178-181. 
Proctor SD & Mamo JC. (2003) Intimal retention of cholesterol derived from 
apolipoprotein B100- and apolipoprotein B48-containing lipoproteins in 
carotid arteries of Watanabe heritable hyperlipidemic rabbits. Arterioscler 
Thromb Vasc Biol. 23, 1595-1600. 
Proctor SD, Vine DF & Mamo JC. (2002) Arterial retention of apolipoprotein B(48)- 
and B(100)-containing lipoproteins in atherogenesis. Curr Opin Lipidol. 13, 
461-470. 
Puskas LG, Kitajka K, Nyakas C, Barcelo-Coblijn G & Farkas T. (2003) Short-term 
administration of omega 3 fatty acids from fish oil results in increased 
transthyretin transcription in old rat hippocampus. Proc Natl Acad Sci U S A. 
100, 1580-1585. 
Quarfordt SH, Oswald B, Landis B, Xu HS, Zhang SH & Maeda N. (1995) In vivo 
cholesterol kinetics in apolipoprotein E-deficient and control mice. J Lipid 
Res. 36, 1227-1235. 
Rapoport M, Dawson HN, Binder LI, Vitek MP & Ferreira A. (2002) Tau is essential 





Refolo LM & Fillit HM. (2004) Apolipoprotein E4 as a target for developing new 
therapeutics for Alzheimer's disease. J Mol Neurosci. 23, 151-155. 
Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, 
Sambamurti K, Duff K & Pappolla MA. (2000) Hypercholesterolemia 
accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. 
Neurobiol Dis. 7, 321-331. 
Riserus U, Arnlov J & Berglund L. (2007) Long-term predictors of insulin resistance: 
role of lifestyle and metabolic factors in middle-aged men. Diabetes Care. 30, 
2928-2933. 
Risau W, Esser S & Engelhardt B. (1998) Differentiation of blood-brain barrier 
endothelial cells. Pathol Biol (Paris). 46, 171-175. 
Reitz C, Tang MX, Luchsinger J & Mayeux R. (2004) Relation of plasma lipids to 
Alzheimer disease and vascular dementia. Arch Neurol. 61, 705-714. 
Roberts CK, Barnard RJ, Liang KH & Vaziri ND. (2002) Effect of diet on adipose 
tissue and skeletal muscle VLDL receptor and LPL: implications for obesity 
and hyperlipidemia. Atherosclerosis. 161, 133-141. 
Roher AE, Esh C, Kokjohn TA, Kalback W, Luehrs DC, Seward JD, Sue LI & Beach 
TG. (2003) Circle of willis atherosclerosis is a risk factor for sporadic 
Alzheimer's disease. Arterioscler Thromb Vasc Biol. 23, 2055-2062. 
Ronti T, Lupattelli G & Mannarino E. (2006) The endocrine function of adipose 
tissue: an update. Clin Endocrinol (Oxf). 64, 355-365. 
Ross MH, Kanye GI & Pawlina W. (2003) Digestive system: II Esophagus and 
gastrointestinal tract. Histology: a text and atlas. Philadelphia: Lippincott 
Williams and Wilkins.Ruitenberg A, den Heijer T, Bakker SL, van Swieten 
JC, Koudstaal PJ, Hofman A & Breteler MM. (2005) Cerebral hypoperfusion 
and clinical onset of dementia: the Rotterdam Study. Ann Neurol. 57, 789-
794. 
Runz H, Rietdorf J, Tomic I, de Bernard M, Beyreuther K, Pepperkok R & Hartmann 
T. (2002) Inhibition of intracellular cholesterol transport alters presenilin 
localization and amyloid precursor protein processing in neuronal cells. J 
Neurosci. 22, 1679-1689. 
Sabbagh M, Zahiri HR, Ceimo J, Cooper K, Gaul W, Connor D & Sparks DL. (2004) 
Is there a characteristic lipid profile in Alzheimer's disease? J Alzheimers 




Sagare AP, Winkler EA, Bell RD, Deane R & Zlokovic BV. (2011) From the liver to 
the blood-brain barrier: an interconnected system regulating brain amyloid-
beta levels. J Neurosci Res. 89, 967-968. 
Saito H, Dhanasekaran P, Baldwin F, Weisgraber KH, Phillips MC & Lund-Katz S. 
(2003) Effects of polymorphism on the lipid interaction of human 
apolipoprotein E. J Biol Chem. 278, 40723-40729. 
Salminen A, Ojala J, Kauppinen A, Kaarniranta K & Suuronen T. (2009) 
Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate 
immunity defence via pattern recognition receptors. Prog Neurobiol. 87, 181-
194. 
Sanchez-Mejia RO, Newman JW, Toh S, Yu GQ, Zhou Y, Halabisky B, Cisse M, 
Scearce-Levie K, Cheng IH, Gan L, Palop JJ, Bonventre JV & Mucke L. 
(2008) Phospholipase A2 reduction ameliorates cognitive deficits in a mouse 
model of Alzheimer's disease. Nat Neurosci. 11, 1311-1318. 
Sartorius T, Ketterer C, Kullmann S, Balzer M, Rotermund C, Binder S, Hallschmid 
M, Machann J, Schick F, Somoza V, Preissl H, Fritsche A, Haring HU & 
Hennige AM. (2012) Monounsaturated fatty acids prevent the aversive 
effects of obesity on locomotion, brain activity, and sleep behavior. Diabetes. 
61, 1669-1679. 
Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance 
MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ & et 
al. (1993) Association of apolipoprotein E allele epsilon 4 with late-onset 
familial and sporadic Alzheimer's disease. Neurology. 43, 1467-1472. 
Scarmeas N, Luchsinger JA, Mayeux R & Stern Y. (2007) Mediterranean diet and 
Alzheimer disease mortality. Neurology. 69, 1084-1093. 
Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N & Luchsinger JA. (2009) 
Mediterranean diet and mild cognitive impairment. Arch Neurol. 66, 216-225. 
Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, Tucker KL, 
Kyle DJ, Wilson PW & Wolf PA. (2006) Plasma phosphatidylcholine 
docosahexaenoic acid content and risk of dementia and Alzheimer disease: 
the Framingham Heart Study. Arch Neurol. 63, 1545-1550. 
Schmidt ML, DiDario AG, Otvos L, Jr., Hoshi N, Kant JA, Lee VM & Trojanowski JQ. 
(1994) Plaque-associated neuronal proteins: a recurrent motif in neuritic 
amyloid deposits throughout diverse cortical areas of the Alzheimer's 




Selkoe DJ. (1989) Aging, amyloid, and Alzheimer's disease. N Engl J Med. 320, 
1484-1487. 
Selkoe DJ. (2001) Alzheimer's disease results from the cerebral accumulation and 
cytotoxicity of amyloid beta-protein. J Alzheimers Dis. 3, 75-80. 
Selkoe DJ, Yamazaki T, Citron M, Podlisny MB, Koo EH, Teplow DB & Haass C. 
(1996) The role of APP processing and trafficking pathways in the formation 
of amyloid beta-protein. Ann N Y Acad Sci. 777, 57-64. 
Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, 
Schlossmacher M, Whaley J, Swindlehurst C & et al. (1992) Isolation and 
quantification of soluble Alzheimer's beta-peptide from biological fluids. 
Nature. 359, 325-327. 
Shadlen MF, Larson EB & Yukawa M. (2000) The epidemiology of Alzheimer's 
disease and vascular dementia in Japanese and African-American 
populations: the search for etiological clues. Neurobiol Aging. 21, 171-181. 
Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, 
Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL & 
Selkoe DJ. (2008) Amyloid-beta protein dimers isolated directly from 
Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 14, 837-
842. 
Shao H, Jao S, Ma K & Zagorski MG. (1999) Solution structures of micelle-bound 
amyloid beta-(1-40) and beta-(1-42) peptides of Alzheimer's disease. J Mol 
Biol. 285, 755-773. 
Shen H, Howles P & Tso P. (2001) From interaction of lipidic vehicles with intestinal 
epithelial cell membranes to the formation and secretion of chylomicrons. 
Adv Drug Deliv Rev. 50 Suppl 1, 103-125. 
Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin 
C, Li G, Holman K, Tsuda T, Mar L, Foncin JF, Bruni AC, Montesi MP, Sorbi 
S, Rainero I, Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A, Sanseau 
P, Polinsky RJ, Wasco W, Da Silva HA, Haines JL, Perkicak-Vance MA, 
Tanzi RE, Roses AD, Fraser PE, Rommens JM & St George-Hyslop PH. 
(1995) Cloning of a gene bearing missense mutations in early-onset familial 
Alzheimer's disease. Nature. 375, 754-760. 
Shi SR, Chaiwun B, Young L, Cote RJ & Taylor CR. (1993) Antigen retrieval 




demonstration of androgen receptor in formalin-fixed paraffin sections. J 
Histochem Cytochem. 41, 1599-1604. 
Shi SR, Key ME & Kalra KL. (1991) Antigen retrieval in formalin-fixed, paraffin-
embedded tissues: an enhancement method for immunohistochemical 
staining based on microwave oven heating of tissue sections. J Histochem 
Cytochem. 39, 741-748.Shibata M, Yamada S, Kumar SR, Calero M, Bading 
J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J & Zlokovic 
BV. (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by 
LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 106, 
1489-1499. 
Shie FS, Jin LW, Cook DG, Leverenz JB & LeBoeuf RC. (2002) Diet-induced 
hypercholesterolemia enhances brain A beta accumulation in transgenic 
mice. Neuroreport. 13, 455-459. 
Shioi J, Pangalos MN, Ripellino JA, Vassilacopoulou D, Mytilineou C, Margolis RU & 
Robakis NK. (1995) The Alzheimer amyloid precursor proteoglycan (appican) 
is present in brain and is produced by astrocytes but not by neurons in 
primary neural cultures. J Biol Chem. 270, 11839-11844. 
Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, Cai XD, McKay DM, 
Tintner R, Frangione B & et al. (1992) Production of the Alzheimer amyloid 
beta protein by normal proteolytic processing. Science. 258, 126-129. 
Simons K & Ikonen E. (2000) How cells handle cholesterol. Science. 290, 1721-
1726. 
Singh RB, Dubnov G, Niaz MA, Ghosh S, Singh R, Rastogi SS, Manor O, Pella D & 
Berry EM. (2002) Effect of an Indo-Mediterranean diet on progression of 
coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart 
Study): a randomised single-blind trial. Lancet. 360, 1455-1461. 
Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey 
HF, Frigon N, Hong J, Jacobson-Croak K, Jewett N, Keim P, Knops J, 
Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, Seubert P, 
Suomensaari SM, Wang S, Walker D, Zhao J, McConlogue L & John V. 
(1999) Purification and cloning of amyloid precursor protein beta-secretase 
from human brain. Nature. 402, 537-540. 
Small BJ, Fratiglioni L, Viitanen M, Winblad B & Backman L. (2000) The course of 
cognitive impairment in preclinical Alzheimer disease: three- and 6-year 




Small DH, Mok SS, Williamson TG & Nurcombe V. (1996) Role of proteoglycans in 
neural development, regeneration, and the aging brain. J Neurochem. 67, 
889-899. 
Smith D, Watts GF, Dane-Stewart C & Mamo JC. (1999) Post-prandial chylomicron 
response may be predicted by a single measurement of plasma 
apolipoprotein B48 in the fasting state. Eur J Clin Invest. 29, 204-209. 
Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, 
Lombroso PJ, Gouras GK & Greengard P. (2005) Regulation of NMDA 
receptor trafficking by amyloid-beta. Nat Neurosci. 8, 1051-1058. 
Solfrizzi V, D'Introno A, Colacicco AM, Capurso C, Del Parigi A, Capurso S, 
Gadaleta A, Capurso A & Panza F. (2005) Dietary fatty acids intake: possible 
role in cognitive decline and dementia. Exp Gerontol. 40, 257-270. 
Solfrizzi V, Frisardi V, Capurso C, D'Introno A, Colacicco AM, Vendemiale G, 
Capurso A & Panza F. (2010) Dietary fatty acids in dementia and 
predementia syndromes: epidemiological evidence and possible underlying 
mechanisms. Ageing Res Rev. 9, 184-199. 
Solfrizzi V, Panza F, Torres F, Mastroianni F, Del Parigi A, Venezia A & Capurso A. 
(1999) High monounsaturated fatty acids intake protects against age-related 
cognitive decline. Neurology. 52, 1563-1569. 
Sparks DL. (1996) Intraneuronal beta-amyloid immunoreactivity in the CNS. 
Neurobiol Aging. 17, 291-299. 
Sparks DL, Scheff SW, Hunsaker JC, 3rd, Liu H, Landers T & Gross DR. (1994) 
Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of 
rabbits with dietary cholesterol. Exp Neurol. 126, 88-94. 
Sparks DL, Scheff SW, Liu H, Landers T, Danner F, Coyne CM & Hunsaker JC, 3rd. 
(1996) Increased density of senile plaques (SP), but not neurofibrillary 
tangles (NFT), in non-demented individuals with the apolipoprotein E4 allele: 
comparison to confirmed Alzheimer's disease patients. J Neurol Sci. 138, 97-
104. 
St George-Hyslop PH. (2000) Molecular genetics of Alzheimer's disease. Biol 
Psychiatry. 47, 183-199. 
Strachan MW. (2003) Insulin and cognitive function. Lancet. 362, 1253. 
Stafstrom CE & Rho JM. (2012) The ketogenic diet as a treatment paradigm for 




St-Onge MP, Bosarge A, Goree LL & Darnell B. (2008) Medium chain triglyceride oil 
consumption as part of a weight loss diet does not lead to an adverse 
metabolic profile when compared to olive oil. J Am Coll Nutr. 27, 547-552. 
Strassnig M & Ganguli M. (2005) About a peculiar disease of the cerebral cortex: 
Alzheimer's original case revisited. Psychiatry (Edgmont). 2, 30-33. 
Stratman NC, Castle CK, Taylor BM, Epps DE, Melchior GW & Carter DB. (2005) 
Isoform-specific interactions of human apolipoprotein E to an intermediate 
conformation of human Alzheimer amyloid-beta peptide. Chem Phys Lipids. 
137, 52-61. 
Strittmatter WJ & Roses AD. (1996) Apolipoprotein E and Alzheimer's disease. 
Annu Rev Neurosci. 19, 53-77. 
Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen 
GS & Roses AD. (1993a) Apolipoprotein E: high-avidity binding to beta-
amyloid and increased frequency of type 4 allele in late-onset familial 
Alzheimer disease. Proc Natl Acad Sci U S A. 90, 1977-1981. 
Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance 
M, Schmechel D, Saunders AM, Goldgaber D & Roses AD. (1993b) Binding 
of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific 
effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci 
U S A. 90, 8098-8102. 
Studzinski CM, Li F, Bruce-Keller AJ, Fernandez-Kim SO, Zhang L, Weidner AM, 
Markesbery WR, Murphy MP & Keller JN. (2009) Effects of short-term 
Western diet on cerebral oxidative stress and diabetes related factors in APP 
x PS1 knock-in mice. J Neurochem. 108, 860-866. 
Su GC, Arendash GW, Kalaria RN, Bjugstad KB & Mullan M. (1999) Intravascular 
infusions of soluble beta-amyloid compromise the blood-brain barrier, 
activate CNS glial cells and induce peripheral hemorrhage. Brain Res. 818, 
105-117. 
Subasinghe S, Unabia S, Barrow CJ, Mok SS, Aguilar MI & Small DH. (2003) 
Cholesterol is necessary both for the toxic effect of Abeta peptides on 
vascular smooth muscle cells and for Abeta binding to vascular smooth 
muscle cell membranes. J Neurochem. 84, 471-479. 
Suo Z, Humphrey J, Kundtz A, Sethi F, Placzek A, Crawford F & Mullan M. (1998) 
Soluble Alzheimers beta-amyloid constricts the cerebral vasculature in vivo. 




Suryadevara V, Storey SG, Aronow WS & Ahn C. (2003) Association of abnormal 
serum lipids in elderly persons with atherosclerotic vascular disease and 
dementia, atherosclerotic vascular disease without dementia, dementia 
without atherosclerotic vascular disease, and no dementia or atherosclerotic 
vascular disease. J Gerontol A Biol Sci Med Sci. 58, 859-861. 
Sutcliffe JG, Hedlund PB, Thomas EA, Bloom FE & Hilbush BS. (2011) Peripheral 
reduction of beta-amyloid is sufficient to reduce brain beta-amyloid: 
implications for Alzheimer's disease. J Neurosci Res. 89, 808-814. 
Tabaton M, Nunzi MG, Xue R, Usiak M, Autilio-Gambetti L & Gambetti P. (1994) 
Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but 
not in cerebrospinal fluid. Biochem Biophys Res Commun. 200, 1598-1603. 
Takamura A, Kawarabayashi T, Yokoseki T, Shibata M, Morishima-Kawashima M, 
Saito Y, Murayama S, Ihara Y, Abe K, Shoji M, Michikawa M & Matsubara E. 
(2011) Dissociation of beta-amyloid from lipoprotein in cerebrospinal fluid 
from Alzheimer's disease accelerates beta-amyloid-42 assembly. J Neurosci 
Res. 89, 815-821. 
Takechi R, Galloway S, Pallebage-Gamarallage MM & Mamo JC. (2008a) 
Chylomicron amyloid-beta in the aetiology of Alzheimer's disease. 
Atheroscler Suppl. 9, 19-25. 
Takechi R, Galloway S, Pallebage-Gamarallage MM, Johnsen RD & Mamo JC. 
(2008b) Three-dimensional immunofluorescent double labelling using 
polyclonal antibodies derived from the same species: enterocytic 
colocalization of chylomicrons with Golgi apparatus. Histochem Cell Biol. 
129, 779-784. 
Takechi R, Galloway S, Pallebage-Gamarallage M, Wellington C, Johnsen R & 
Mamo JC. (2009) Three-dimensional colocalization analysis of plasma-
derived apolipoprotein B with amyloid plaques in APP/PS1 transgenic mice. 
Histochem Cell Biol. 131, 661-666. 
Takechi R, Galloway S, Pallebage-Gamarallage MM, Lam V & Mamo JC. (2010a) 
Dietary fats, cerebrovasculature integrity and Alzheimer's disease risk. Prog 
Lipid Res. 49, 159-170. 
Takechi R, Galloway S, Pallebage-Gamarallage MM, Wellington CL, Johnsen RD, 
Dhaliwal SS & Mamo JC. (2010b) Differential effects of dietary fatty acids on 
the cerebral distribution of plasma-derived apo B lipoproteins with amyloid-




Tangney CC, Kwasny MJ, Li H, Wilson RS, Evans DA & Morris MC. (2011) 
Adherence to a Mediterranean-type dietary pattern and cognitive decline in a 
community population. Am J Clin Nutr. 93, 601-607. 
Tanzi RE & Bertram L. (2005) Twenty years of the Alzheimer's disease amyloid 
hypothesis: a genetic perspective. Cell. 120, 545-555. 
Teng B, Burant CF & Davidson NO. (1993) Molecular cloning of an apolipoprotein B 
messenger RNA editing protein. Science. 260, 1816-1819. 
Teplow DB. (1998) Structural and kinetic features of amyloid beta-protein 
fibrillogenesis. Amyloid. 5, 121-142. 
Thal DR, Griffin WS, de Vos RA & Ghebremedhin E. (2008) Cerebral amyloid 
angiopathy and its relationship to Alzheimer's disease. Acta Neuropathol. 
115, 599-609. 
Thomas T, McLendon C, Sutton ET & Thomas G. (1997) Cerebrovascular 
endothelial dysfunction mediated by beta-amyloid. Neuroreport. 8, 1387-
1391. 
Thomas T, Thomas G, McLendon C, Sutton T & Mullan M. (1996) beta-Amyloid-
mediated vasoactivity and vascular endothelial damage. Nature. 380, 168-
171. 
Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, Zlokovic B, 
Smith JD, Ladu MJ, Rostagno A, Frangione B & Ghiso J. (2000) Lipidation of 
apolipoprotein E influences its isoform-specific interaction with Alzheimer's 
amyloid beta peptides. Biochem J. 348 Pt 2, 359-365. 
Tomita T, Tokuhiro S, Hashimoto T, Aiba K, Saido TC, Maruyama K & Iwatsubo T. 
(1998) Molecular dissection of domains in mutant presenilin 2 that mediate 
overproduction of amyloidogenic forms of amyloid beta peptides. Inability of 
truncated forms of PS2 with familial Alzheimer's disease mutation to increase 
secretion of Abeta42. J Biol Chem. 273, 21153-21160. 
Treusch S, Cyr DM & Lindquist S. (2009) Amyloid deposits: protection against toxic 
protein species? Cell Cycle. 8, 1668-1674. 
Tschanz JT, Norton MC, Zandi PP & Lyketsos CG. (2013) The Cache County Study 
on Memory in Aging: factors affecting risk of Alzheimer's disease and its 
progression after onset. Int Rev Psychiatry. 25, 673-685. 
Uryu S, Tokuhiro S & Oda T. (2003) beta-Amyloid-specific upregulation of stearoyl 





Utermann G, Kindermann I, Kaffarnik H & Steinmetz A. (1984) Apolipoprotein E 
phenotypes and hyperlipidemia. Hum Genet. 65, 232-236. 
van Gelder BM, Tijhuis M, Kalmijn S & Kromhout D. (2007) Fish consumption, n-3 
fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen 
Elderly Study. Am J Clin Nutr. 85, 1142-1147. 
van Greevenbroek MM & de Bruin TW. (1998) Chylomicron synthesis by intestinal 
cells in vitro and in vivo. Atherosclerosis. 141 Suppl 1, 9-16. 
van Greevenbroek MM, van Meer G, Erkelens DW & de Bruin TW. (1996) Effects of 
saturated, mono-, and polyunsaturated fatty acids on the secretion of apo B 
containing lipoproteins by Caco-2 cells. Atherosclerosis. 121, 139-150. 
van Horssen J, Wesseling P, van den Heuvel LP, de Waal RM & Verbeek MM. 
(2003) Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-
related disorders. Lancet Neurol. 2, 482-492. 
van Oijen M, de Jong FJ, Witteman JC, Hofman A, Koudstaal PJ & Breteler MM. 
(2007) Atherosclerosis and risk for dementia. Ann Neurol. 61, 403-410. 
Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ & Breteler MM. 
(2003) Silent brain infarcts and the risk of dementia and cognitive decline. N 
Engl J Med. 348, 1215-1222. 
Vigna GB, Donega P, Passaro A, Zanca R, Cattin L, Fonda M, Pauciullo P, Marotta 
G, Fellin R, Gasparrini S & Piliego T. (1999) Post-prandial effects of 
gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline 
hypertriglyceridemia. Nutr Metab Cardiovasc Dis. 9, 234-243. 
Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I & Schenk DB. (1993) Characterization 
of beta-amyloid peptide from human cerebrospinal fluid. J Neurochem. 61, 
1965-1968. 
Vincent-Baudry S, Defoort C, Gerber M, Bernard MC, Verger P, Helal O, Portugal H, 
Planells R, Grolier P, Amiot-Carlin MJ, Vague P & Lairon D. (2005) The 
Medi-RIVAGE study: reduction of cardiovascular disease risk factors after a 
3-mo intervention with a Mediterranean-type diet or a low-fat diet. Am J Clin 
Nutr. 82, 964-971. 
Walker RA. (2006) Quantification of immunohistochemistry--issues concerning 
methods, utility and semiquantitative assessment I. Histopathology. 49, 406-
410. 
Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ & 




potently inhibit hippocampal long-term potentiation in vivo. Nature. 416, 535-
539. 
Walsh DM & Selkoe DJ. (2007) A beta oligomers - a decade of discovery. J 
Neurochem. 101, 1172-1184. 
Wang J, Dickson DW, Trojanowski JQ & Lee VM. (1999) The levels of soluble 
versus insoluble brain Abeta distinguish Alzheimer's disease from normal 
and pathologic aging. Exp Neurol. 158, 328-337. 
Wassall SR, Brzustowicz MR, Shaikh SR, Cherezov V, Caffrey M & Stillwell W. 
(2004) Order from disorder, corralling cholesterol with chaotic lipids. The role 
of polyunsaturated lipids in membrane raft formation. Chem Phys Lipids. 
132, 79-88. 
Wassall SR & Stillwell W. (2009) Polyunsaturated fatty acid-cholesterol interactions: 
domain formation in membranes. Biochim Biophys Acta. 1788, 24-32. 
Weisgraber KH. (1994) Apolipoprotein E: structure-function relationships. Adv 
Protein Chem. 45, 249-302. 
Weller RO, Massey A, Newman TA, Hutchings M, Kuo YM & Roher AE. (1998) 
Cerebral amyloid angiopathy: amyloid beta accumulates in putative 
interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol. 153, 
725-733. 
Wild-Bode C, Yamazaki T, Capell A, Leimer U, Steiner H, Ihara Y & Haass C. 
(1997) Intracellular generation and accumulation of amyloid beta-peptide 
terminating at amino acid 42. J Biol Chem. 272, 16085-16088. 
Williams CM. (1997) Postprandial lipid metabolism: effects of dietary fatty acids. 
Proc Nutr Soc. 56, 679-692. 
Williams CM, Bateman PA, Jackson KG & Yaqoob P. (2004) Dietary fatty acids and 
chylomicron synthesis and secretion. Biochem Soc Trans. 32, 55-58. 
Wilson PW, Schaefer EJ, Larson MG & Ordovas JM. (1996) Apolipoprotein E alleles 
and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc 
Biol. 16, 1250-1255. 
Wimo A & Prince M. 2010. World Alzheimer's Report 2010: The Global Economic 
Impact of Dementia. Alzheimer's Disease International. London. 
Winocur G & Greenwood CE. (1999) The effects of high fat diets and environmental 




Wisniewski HM, Vorbrodt AW & Wegiel J. (1997a) Amyloid angiopathy and blood-
brain barrier changes in Alzheimer's disease. Ann N Y Acad Sci. 826, 161-
172. 
Wisniewski HM & Wen GY. (1985) Substructures of paired helical filaments from 
Alzheimer's disease neurofibrillary tangles. Acta Neuropathol. 66, 173-176. 
Wisniewski T, Ghiso J & Frangione B. (1994) Alzheimer's disease and soluble A 
beta. Neurobiol Aging. 15, 143-152. 
Wisniewski T, Ghiso J & Frangione B. (1997b) Biology of A beta amyloid in 
Alzheimer's disease. Neurobiol Dis. 4, 313-328. 
Wisniewski T & Sadowski M. (2008) Preventing beta-amyloid fibrillization and 
deposition: beta-sheet breakers and pathological chaperone inhibitors. BMC 
Neurosci. 9 Suppl 2, 5. 
Wolozin B. (2004) Cholesterol, statins and dementia. Curr Opin Lipidol. 15, 667-672. 
Wolozin B, Kellman W, Ruosseau P, Celesia GG & Siegel G. (2000) Decreased 
prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl 
coenzyme A reductase inhibitors. Arch Neurol. 57, 1439-1443. 
Woods SC, D'Alessio DA, Tso P, Rushing PA, Clegg DJ, Benoit SC, Gotoh K, Liu M 
& Seeley RJ. (2004) Consumption of a high-fat diet alters the homeostatic 
regulation of energy balance. Physiol Behav. 83, 573-578. 
Woudstra TD, Drozdowski LA, Wild GE, Clandinin MT, Agellon LB & Thomson AB. 
(2004) An isocaloric PUFA diet enhances lipid uptake and weight gain in 
aging rats. Lipids. 39, 343-354. 
World Health Organization. (2008) The global burden of disease: 2004 update. 
WHO. Geneva. 
Wu A, Molteni R, Ying Z & Gomez-Pinilla F. (2003) A saturated-fat diet aggravates 
the outcome of traumatic brain injury on hippocampal plasticity and cognitive 
function by reducing brain-derived neurotrophic factor. Neuroscience. 119, 
365-375. 
Yamamoto K, Shimada H, Koh H, Ataka S & Miki T. (2014) Serum levels of albumin-
amyloid beta complexes are decreased in Alzheimer's disease. Geriatr 
Gerontol Int. 14, 716-723. 
Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, 
Morser J, Migheli A, Nawroth P, Stern D & Schmidt AM. (1996) RAGE and 





Yao PM & Tabas I. (2001) Free cholesterol loading of macrophages is associated 
with widespread mitochondrial dysfunction and activation of the 
mitochondrial apoptosis pathway. J Biol Chem. 276, 42468-42476. 
Yasojima K, McGeer EG & McGeer PL. (2001) Relationship between beta amyloid 
peptide generating molecules and neprilysin in Alzheimer disease and 
normal brain. Brain Res. 919, 115-121. 
Ye S, Huang Y, Mullendorff K, Dong L, Giedt G, Meng EC, Cohen FE, Kuntz ID, 
Weisgraber KH & Mahley RW. (2005) Apolipoprotein (apo) E4 enhances 
amyloid beta peptide production in cultured neuronal cells: apoE structure as 
a potential therapeutic target. Proc Natl Acad Sci U S A. 102, 18700-18705. 
Younkin SG. (1995) Evidence that A beta 42 is the real culprit in Alzheimer's 
disease. Ann Neurol. 37, 287-288. 
Yurko-Mauro K. (2010) Cognitive and cardiovascular benefits of docosahexaenoic 
acid in aging and cognitive decline. Curr Alzheimer Res. 7, 190-196. 
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, 
Pais P, Varigos J, Lisheng L & Investigators IS. (2004) Effect of potentially 
modifiable risk factors associated with myocardial infarction in 52 countries 
(the INTERHEART study): case-control study. Lancet. 364, 937-952. 
Zampelas A, Murphy M, Morgan LM & Williams CM. (1994) Postprandial lipoprotein 
lipase, insulin and gastric inhibitory polypeptide responses to test meals of 
different fatty acid composition: comparison of saturated, n-6 and n-3 
polyunsaturated fatty acids. Eur J Clin Nutr. 48, 849-858. 
Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson 
ME, Buchhave P, Londos E, Umek RM, Minthon L, Simon AJ & Blennow K. 
(2008) Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer 
disease. Arch Neurol. 65, 1102-1107. 
Zhang SH, Reddick RL, Piedrahita JA & Maeda N. (1992) Spontaneous 
hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. 
Science. 258, 468-471. 
Zhao Y, McCabe JB, Vance J & Berthiaume LG. (2000) Palmitoylation of 
apolipoprotein B is required for proper intracellular sorting and transport of 
cholesteroyl esters and triglycerides. Mol Biol Cell. 11, 721-734. 
Zlokovic BV. (2005) Neurovascular mechanisms of Alzheimer's neurodegeneration. 




Zlokovic BV, Ghiso J, Mackic JB, McComb JG, Weiss MH & Frangione B. (1993) 
Blood-brain barrier transport of circulating Alzheimer's amyloid beta. 
Biochem Biophys Res Commun. 197, 1034-1040. 
 
* Every reasonable effort has been made to acknowledge the owners of copyright 
material. I would be pleased to hear from any copyright holder who has been 


































This thesis consists of both original text and several research articles 
previously published in internationally recognised scientific journals. This thesis 
consists of 3 first authored articles and 5 second authored articles. All articles used 





Appendix A presents a statement of contribution towards each journal article 
as well as signature verification for these statements are provided by respective 
authors. Where necessary, copyright was obtained for re-production of journal 































Galloway S, Jian L, Johnsen RD, Chew S, Mamo JCL. (2007) Beta-amyloid or its 
precursor protein is found in epithelial cells of the small intestine and is stimulated 





Susan Galloway was responsible for experimental procedures, data analysis, 
generation of images, and writing of the manuscript. Le Jian contributed towards 
experiment design, tissue collection and interpretation of results. Russel D. Johnsen 
contributed towards design of methodology. Stewart Chew assisted in study design 
and manuscript appraisal. John C. Mamo contributed to study design, interpretation 




























TERMS AND CONDITIONS 




This is a License Agreement between Susan Galloway ("You") and Elsevier ("Elsevier") provided by 
Copyright Clearance Center ("CCC"). The license consists of your order details, the terms and 
conditions provided by Elsevier, and the payment terms and conditions.  
All payments must be made in full to CCC. For payment instructions, please see information 






The Boulevard,Langford Lane 
Kidlington,Oxford,OX5 1GB,UK 
Registered Company Number 1982084 
Customer name Susan Galloway 
Customer address 159 Elderberry Dr, 
 
Perth, None 6164 
License number 3461310991178 
License date Sep 03, 2014 
Licensed content publisher Elsevier 
Licensed content publication The Journal of Nutritional Biochemistry 
Licensed content title 
β-Amyloid or its precursor protein is found in epithelial cells of the 
small intestine and is stimulated by high-fat feeding 
Licensed content author 
Susan Galloway,Le Jian,Russell Johnsen,Stewart Chew,John 
C.L. Mamo 
Licensed content date April 2007 
Licensed content volume number 18 
Licensed content issue number 4 
Number of pages 6 
Start Page 279 
End Page 284 
Type of Use reuse in a thesis/dissertation 
 
Portion full article 
 
Format both print and electronic 
 




Will you be translating? No 
 
Title of your thesis/dissertation  
Enterocytic beta amyloid-lipoprotein homeostasis: Implications for 
Alzheimer's disease risk  
Expected completion date Oct 2014 
 
Estimated size (number of pages) 220 
 
Elsevier VAT number GB 494 6272 12 
Price 0.00 USD 
 
VAT/Local Sales Tax 0.00 USD / 0.00 GBP 
Total 0.00 USD 
  
Terms and Conditions 
  
INTRODUCTION 
1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with 
completing this licensing transaction, you agree that the following terms and conditions apply to this 
transaction (along with the Billing and Payment terms and conditions established by Copyright 
Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are 






2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the 
terms and conditions indicated. 
3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our 
publication with credit or acknowledgement to another source, permission must also be sought from 
that source. If such permission is not obtained then that material may not be included in your 
publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or in 
a reference list at the end of your publication, as follows: 
“Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages 
No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT 
OWNER].” Also Lancet special credit - “Reprinted from The Lancet, Vol. number, Author(s), Title of 
article, Pages No., Copyright (Year), with permission from Elsevier.” 
4. Reproduction of this material is confined to the purpose and/or media for which permission is 
hereby given. 
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be 
altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/or 
any other alterations shall be made only with prior written authorization of Elsevier Ltd. (Please 
contact Elsevier at permissions@elsevier.com)  
6. If the permission fee for the requested use of our material is waived in this instance, please be 
advised that your future requests for Elsevier materials may attract a fee. 
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of (i) 
the license details provided by you and accepted in the course of this licensing transaction, (ii) these 
terms and conditions and (iii) CCC's Billing and Payment terms and conditions. 
8. License Contingent Upon Payment: While you may exercise the rights licensed immediately upon 
issuance of the license at the end of the licensing process for the transaction, provided that you have 
disclosed complete and accurate details of your proposed use, no license is finally effective unless 
and until full payment is received from you (either by publisher or by CCC) as provided in CCC's 
Billing and Payment terms and conditions. If full payment is not received on a timely basis, then any 
license preliminarily granted shall be deemed automatically revoked and shall be void as if never 
granted. Further, in the event that you breach any of these terms and conditions or any of CCC's 
Billing and Payment terms and conditions, the license is automatically revoked and shall be void as if 
never granted. Use of materials as described in a revoked license, as well as any use of the 
materials beyond the scope of an unrevoked license, may constitute copyright infringement and 
publisher reserves the right to take any and all action to protect its copyright in the materials. 
9. Warranties: Publisher makes no representations or warranties with respect to the licensed 
material. 
10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and their 
respective officers, directors, employees and agents, from and against any and all claims arising out 
of your use of the licensed material other than as specifically authorized pursuant to this license. 




transferred by you to any other person without publisher's written permission. 
12. No Amendment Except in Writing: This license may not be amended except in a writing signed by 
both parties (or, in the case of publisher, by CCC on publisher's behalf). 
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any purchase 
order, acknowledgment, check endorsement or other writing prepared by you, which terms are 
inconsistent with these terms and conditions or CCC's Billing and Payment terms and conditions. 
These terms and conditions, together with CCC's Billing and Payment terms and conditions (which 
are incorporated herein), comprise the entire agreement between you and publisher (and CCC) 
concerning this licensing transaction. In the event of any conflict between your obligations 
established by these terms and conditions and those established by CCC's Billing and Payment 
terms and conditions, these terms and conditions shall control. 
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described in this 
License at their sole discretion, for any reason or no reason, with a full refund payable to you. Notice 
of such denial will be made using the contact information provided by you. Failure to receive such 
notice will not alter or invalidate the denial. In no event will Elsevier or Copyright Clearance Center be 
responsible or liable for any costs, expenses or damage incurred by you as a result of a denial of 
your permission request, other than a refund of the amount(s) paid by you to Elsevier and/or 
Copyright Clearance Center for denied permissions. 
LIMITED LICENSE 
The following terms and conditions apply only to specific license types: 
15. Translation: This permission is granted for non-exclusive world English rights only unless your 
license was granted for translation rights. If you licensed translation rights you may only translate this 
content into the languages you requested. A professional translator must perform all translations and 
reproduce the content word for word preserving the integrity of the article. If this license is to re-use 1 
or 2 figures then permission is granted for non-exclusive world rights in all languages. 
16. Posting licensed content on any Website: The following terms and conditions apply as follows: 
Licensing material from an Elsevier journal: All content posted to the web site must maintain the 
copyright information line on the bottom of each image; A hyper-text must be included to the 
Homepage of the journal from which you are licensing at 
http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at 
http://www.elsevier.com; Central Storage: This license does not include permission for a scanned 
version of the material to be stored in a central repository such as that provided by Heron/XanEdu. 
Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier 
homepage at http://www.elsevier.com . All content posted to the web site must maintain the copyright 
information line on the bottom of each image. 
 
Posting licensed content on Electronic reserve: In addition to the above the following clauses are 
applicable: The web site must be password-protected and made available only to bona fide students 
registered on a relevant course. This permission is granted for 1 year only. You may obtain a new 
license for future website posting.  




granted is limited to the author accepted manuscript version* of your paper.  
*Accepted Author Manuscript (AAM) Definition: An accepted author manuscript (AAM) is the 
author’s version of the manuscript of an article that has been accepted for publication and which may 
include any author-incorporated changes suggested through the processes of submission 
processing, peer review, and editor-author communications. AAMs do not include other publisher 
value-added contributions such as copy-editing, formatting, technical enhancements and (if relevant) 
pagination. 
You are not allowed to download and post the published journal article (whether PDF or HTML, proof 
or final version), nor may you scan the printed edition to create an electronic version. A hyper-text 
must be included to the Homepage of the journal from which you are licensing at 
http://www.sciencedirect.com/science/journal/xxxxx. As part of our normal production process, you 
will receive an e-mail notice when your article appears on Elsevier’s online service ScienceDirect 
(www.sciencedirect.com). That e-mail will include the article’s Digital Object Identifier (DOI). This 
number provides the electronic link to the published article and should be included in the posting of 
your personal version. We ask that you wait until you receive this e-mail and have the DOI to do any 
posting.  
Posting to a repository: Authors may post their AAM immediately to their employer’s institutional 
repository for internal use only and may make their manuscript publically available after the journal-
specific embargo period has ended. 
Please also refer to Elsevier's Article Posting Policy for further information. 
18. For book authors the following clauses are applicable in addition to the above: Authors are 
permitted to place a brief summary of their work online only.. You are not allowed to download and 
post the published electronic version of your chapter, nor may you scan the printed edition to create 
an electronic version. Posting to a repository: Authors are permitted to post a summary of their 
chapter only in their institution’s repository. 
20. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be 
submitted to your institution in either print or electronic form. Should your thesis be published 
commercially, please reapply for permission. These requirements include permission for the Library 
and Archives of Canada to supply single copies, on demand, of the complete thesis and include 
permission for UMI to supply single copies, on demand, of the complete thesis. Should your thesis be 
published commercially, please reapply for permission.  
Elsevier Open Access Terms and Conditions 
Elsevier publishes Open Access articles in both its Open Access journals and via its Open Access 
articles option in subscription journals. 
Authors publishing in an Open Access journal or who choose to make their article Open Access in an 
Elsevier subscription journal select one of the following Creative Commons user licenses, which 
define how a reader may reuse their work: Creative Commons Attribution License (CC BY), Creative 
Commons Attribution – Non Commercial - ShareAlike (CC BY NC SA) and Creative Commons 
Attribution – Non Commercial – No Derivatives (CC BY NC ND) 




Any reuse of the article must not represent the author as endorsing the adaptation of the article nor 
should the article be modified in such a way as to damage the author’s honour or reputation. 
The author(s) must be appropriately credited. 
If any part of the material to be used (for example, figures) has appeared in our publication with credit 
or acknowledgement to another source it is the responsibility of the user to ensure their reuse 
complies with the terms and conditions determined by the rights holder. 
Additional Terms & Conditions applicable to each Creative Commons user license: 
CC BY: You may distribute and copy the article, create extracts, abstracts, and other revised 
versions, adaptations or derivative works of or from an article (such as a translation), to include in a 
collective work (such as an anthology), to text or data mine the article, including for commercial 
purposes without permission from Elsevier 
CC BY NC SA: For non-commercial purposes you may distribute and copy the article, create 
extracts, abstracts and other revised versions, adaptations or derivative works of or from an article 
(such as a translation), to include in a collective work (such as an anthology), to text and data mine 
the article and license new adaptations or creations under identical terms without permission from 
Elsevier 
CC BY NC ND: For non-commercial purposes you may distribute and copy the article and include it 
in a collective work (such as an anthology), provided you do not alter or modify the article, without 
permission from Elsevier 
Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY NC ND 
license requires permission from Elsevier and will be subject to a fee.  
Commercial reuse includes: 
· Promotional purposes (advertising or marketing) 
· Commercial exploitation ( e.g. a product for sale or loan) 
· Systematic distribution (for a fee or free of charge) 
Please refer to Elsevier's Open Access Policy for further information. 
21. Other Conditions:  
v1.6 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-
646-2777.   
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable license 
for your reference. No payment is required.   
 



































Galloway S, Pallebage-Gamarallage MM, Takechi R, Jian L, Johnsen RD, Dhaliwal 
SS, Mamo JC. (2008) Synergistic effects of high fat feeding and apolipoprotein E 





Susan Galloway carried out experiments, animal maintenance, collection, 
analysis and interpretation of data, and writing of the manuscript. Menuka M. 
Pallebage-Gamarallage and Ryusuke Takechi assisted in data collection and 
analysis. Le Jian and Satvinder S. Dhaliwal provided advice regarding statistical 
analysis of data. Russell D. Johnsen provided advice and assisted in method 
development. John C, Mamo contributed to study design, interpretation of data and 




*Copyright © 2008 Susan Galloway et al.; licensee BioMed Central Ltd. This 
is an Open Access article distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original 















Galloway S, Takechi R, Pallebage-Gamarallage MM, Dhaliwal SS, Mamo JC. 
(2009) Amyloid-beta colocalizes with apolipoprotein B in absorptive cells of the small 





Susan Galloway was responsible for study design, collection of samples, 
experimental protocols and writing of the manuscript. Ryusuke Takechi contributed 
to development of methodology and data interpretation. Ryusuke Takechi and 
Menuka M. Pallebage-Gamarallage were both involved in data collection and 
appraisal of the draft manuscript. Satvinder S. Dhaliwal gave advice on data 
interpretation and statistical analysis. John C. Mamo was involved in study design, 




*Copyright © 2009 Susan Galloway et al.; licensee BioMed Central Ltd. This 
is an Open Access article distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original 

















Takechi R, Galloway S, Pallebage-Gamarallage MM, Wellington C, Mamo JC. 
(2008) Chylomicron amyloid-beta in the aetiology of Alzheimer’s disease. 





Ryusuke Takechi was responsible for the review of literature, preparation 
and collection of data, presentation of figures and drafting of the review article. 
Susan Galloway and Menuka M. Pallebage-Gamarallage assisted in the 
presentation of data and figures and the review of manuscript. Cheryl L. Wellington 
supplied specimen samples for analysis and was involved in the appraisal of the 















TERMS AND CONDITIONS 




This is a License Agreement between Susan Galloway ("You") and Elsevier ("Elsevier") provided by 
Copyright Clearance Center ("CCC"). The license consists of your order details, the terms and 
conditions provided by Elsevier, and the payment terms and conditions.  




listed at the bottom of this form. 
Supplier 
Elsevier Limited 
The Boulevard,Langford Lane 
Kidlington,Oxford,OX5 1GB,UK 
Registered Company Number 1982084 
Customer name Susan Galloway 
Customer address 159 Elderberry Dr, 
 
Perth, None 6164 
License number 3461960877190 
License date Sep 04, 2014 
Licensed content publisher Elsevier 
Licensed content publication Atherosclerosis Supplements 
Licensed content title 
Chylomicron amyloid-beta in the aetiology of Alzheimer's 
disease 
Licensed content author 
R. Takechi,S. Galloway,M.M.S. Pallebage-
Gamarallage,J.C.L. Mamo 
Licensed content date September 2008 
Licensed content volume number 9 
Licensed content issue number 2 
Number of pages 7 
Start Page 19 
End Page 25 
Type of Use reuse in a thesis/dissertation 
 
Intended publisher of new work other 
 
Portion full article 
 
Format both print and electronic 
 




Will you be translating? No 
 
Title of your thesis/dissertation  
Enterocytic beta amyloid-lipoprotein homeostasis: 
Implications for Alzheimer's disease risk  
Expected completion date Oct 2014 
 
Estimated size (number of pages) 220 
 
Elsevier VAT number GB 494 6272 12 
Price 0.00 USD 
 
VAT/Local Sales Tax 0.00 USD / 0.00 GBP 
Total 0.00 USD 
  
Terms and Conditions 
  
INTRODUCTION 
1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with 
completing this licensing transaction, you agree that the following terms and conditions apply to this 
transaction (along with the Billing and Payment terms and conditions established by Copyright 





available at any time at http://myaccount.copyright.com).  
GENERAL TERMS 
2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the 
terms and conditions indicated. 
3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our 
publication with credit or acknowledgement to another source, permission must also be sought from 
that source. If such permission is not obtained then that material may not be included in your 
publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or in 
a reference list at the end of your publication, as follows: 
“Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages 
No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT 
OWNER].” Also Lancet special credit - “Reprinted from The Lancet, Vol. number, Author(s), Title of 
article, Pages No., Copyright (Year), with permission from Elsevier.” 
4. Reproduction of this material is confined to the purpose and/or media for which permission is 
hereby given. 
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be 
altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/or 
any other alterations shall be made only with prior written authorization of Elsevier Ltd. (Please 
contact Elsevier at permissions@elsevier.com)  
6. If the permission fee for the requested use of our material is waived in this instance, please be 
advised that your future requests for Elsevier materials may attract a fee. 
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of (i) 
the license details provided by you and accepted in the course of this licensing transaction, (ii) these 
terms and conditions and (iii) CCC's Billing and Payment terms and conditions. 
8. License Contingent Upon Payment: While you may exercise the rights licensed immediately upon 
issuance of the license at the end of the licensing process for the transaction, provided that you have 
disclosed complete and accurate details of your proposed use, no license is finally effective unless 
and until full payment is received from you (either by publisher or by CCC) as provided in CCC's 
Billing and Payment terms and conditions. If full payment is not received on a timely basis, then any 
license preliminarily granted shall be deemed automatically revoked and shall be void as if never 
granted. Further, in the event that you breach any of these terms and conditions or any of CCC's 
Billing and Payment terms and conditions, the license is automatically revoked and shall be void as if 
never granted. Use of materials as described in a revoked license, as well as any use of the 
materials beyond the scope of an unrevoked license, may constitute copyright infringement and 
publisher reserves the right to take any and all action to protect its copyright in the materials. 
9. Warranties: Publisher makes no representations or warranties with respect to the licensed 
material. 
10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and their 




of your use of the licensed material other than as specifically authorized pursuant to this license. 
11. No Transfer of License: This license is personal to you and may not be sublicensed, assigned, or 
transferred by you to any other person without publisher's written permission. 
12. No Amendment Except in Writing: This license may not be amended except in a writing signed by 
both parties (or, in the case of publisher, by CCC on publisher's behalf). 
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any purchase 
order, acknowledgment, check endorsement or other writing prepared by you, which terms are 
inconsistent with these terms and conditions or CCC's Billing and Payment terms and conditions. 
These terms and conditions, together with CCC's Billing and Payment terms and conditions (which 
are incorporated herein), comprise the entire agreement between you and publisher (and CCC) 
concerning this licensing transaction. In the event of any conflict between your obligations 
established by these terms and conditions and those established by CCC's Billing and Payment 
terms and conditions, these terms and conditions shall control. 
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described in this 
License at their sole discretion, for any reason or no reason, with a full refund payable to you. Notice 
of such denial will be made using the contact information provided by you. Failure to receive such 
notice will not alter or invalidate the denial. In no event will Elsevier or Copyright Clearance Center be 
responsible or liable for any costs, expenses or damage incurred by you as a result of a denial of 
your permission request, other than a refund of the amount(s) paid by you to Elsevier and/or 
Copyright Clearance Center for denied permissions. 
LIMITED LICENSE 
The following terms and conditions apply only to specific license types: 
15. Translation: This permission is granted for non-exclusive world English rights only unless your 
license was granted for translation rights. If you licensed translation rights you may only translate this 
content into the languages you requested. A professional translator must perform all translations and 
reproduce the content word for word preserving the integrity of the article. If this license is to re-use 1 
or 2 figures then permission is granted for non-exclusive world rights in all languages. 
16. Posting licensed content on any Website: The following terms and conditions apply as follows: 
Licensing material from an Elsevier journal: All content posted to the web site must maintain the 
copyright information line on the bottom of each image; A hyper-text must be included to the 
Homepage of the journal from which you are licensing at 
http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at 
http://www.elsevier.com; Central Storage: This license does not include permission for a scanned 
version of the material to be stored in a central repository such as that provided by Heron/XanEdu. 
Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier 
homepage at http://www.elsevier.com . All content posted to the web site must maintain the copyright 
information line on the bottom of each image. 
Posting licensed content on Electronic reserve: In addition to the above the following clauses are 
applicable: The web site must be password-protected and made available only to bona fide students 




license for future website posting.  
For journal authors: the following clauses are applicable in addition to the above: Permission 
granted is limited to the author accepted manuscript version* of your paper.  
*Accepted Author Manuscript (AAM) Definition: An accepted author manuscript (AAM) is the 
author’s version of the manuscript of an article that has been accepted for publication and which may 
include any author-incorporated changes suggested through the processes of submission 
processing, peer review, and editor-author communications. AAMs do not include other publisher 
value-added contributions such as copy-editing, formatting, technical enhancements and (if relevant) 
pagination. 
You are not allowed to download and post the published journal article (whether PDF or HTML, proof 
or final version), nor may you scan the printed edition to create an electronic version. A hyper-text 
must be included to the Homepage of the journal from which you are licensing at 
http://www.sciencedirect.com/science/journal/xxxxx. As part of our normal production process, you 
will receive an e-mail notice when your article appears on Elsevier’s online service ScienceDirect 
(www.sciencedirect.com). That e-mail will include the article’s Digital Object Identifier (DOI). This 
number provides the electronic link to the published article and should be included in the posting of 
your personal version. We ask that you wait until you receive this e-mail and have the DOI to do any 
posting.  
Posting to a repository: Authors may post their AAM immediately to their employer’s institutional 
repository for internal use only and may make their manuscript publically available after the journal-
specific embargo period has ended. 
Please also refer to Elsevier's Article Posting Policy for further information. 
18. For book authors the following clauses are applicable in addition to the above: Authors are 
permitted to place a brief summary of their work online only.. You are not allowed to download and 
post the published electronic version of your chapter, nor may you scan the printed edition to create 
an electronic version. Posting to a repository: Authors are permitted to post a summary of their 
chapter only in their institution’s repository. 
20. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be 
submitted to your institution in either print or electronic form. Should your thesis be published 
commercially, please reapply for permission. These requirements include permission for the Library 
and Archives of Canada to supply single copies, on demand, of the complete thesis and include 
permission for UMI to supply single copies, on demand, of the complete thesis. Should your thesis be 
published commercially, please reapply for permission.  
Elsevier Open Access Terms and Conditions 
Elsevier publishes Open Access articles in both its Open Access journals and via its Open Access 
articles option in subscription journals. 
Authors publishing in an Open Access journal or who choose to make their article Open Access in an 
Elsevier subscription journal select one of the following Creative Commons user licenses, which 
define how a reader may reuse their work: Creative Commons Attribution License (CC BY), Creative 




Attribution – Non Commercial – No Derivatives (CC BY NC ND) 
Terms & Conditions applicable to all Elsevier Open Access articles:  
Any reuse of the article must not represent the author as endorsing the adaptation of the article nor 
should the article be modified in such a way as to damage the author’s honour or reputation. 
The author(s) must be appropriately credited. 
If any part of the material to be used (for example, figures) has appeared in our publication with credit 
or acknowledgement to another source it is the responsibility of the user to ensure their reuse 
complies with the terms and conditions determined by the rights holder. 
Additional Terms & Conditions applicable to each Creative Commons user license: 
CC BY: You may distribute and copy the article, create extracts, abstracts, and other revised 
versions, adaptations or derivative works of or from an article (such as a translation), to include in a 
collective work (such as an anthology), to text or data mine the article, including for commercial 
purposes without permission from Elsevier 
CC BY NC SA: For non-commercial purposes you may distribute and copy the article, create 
extracts, abstracts and other revised versions, adaptations or derivative works of or from an article 
(such as a translation), to include in a collective work (such as an anthology), to text and data mine 
the article and license new adaptations or creations under identical terms without permission from 
Elsevier 
CC BY NC ND: For non-commercial purposes you may distribute and copy the article and include it 
in a collective work (such as an anthology), provided you do not alter or modify the article, without 
permission from Elsevier 
Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY NC ND 
license requires permission from Elsevier and will be subject to a fee.  
Commercial reuse includes: 
· Promotional purposes (advertising or marketing) 
· Commercial exploitation ( e.g. a product for sale or loan) 
· Systematic distribution (for a fee or free of charge) 
Please refer to Elsevier's Open Access Policy for further information. 
21. Other Conditions:  
v1.6 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-
646-2777.   
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable license 























Article 2:  
 
Pallebage-Gamarallage, M. M., S. Galloway, R. Johnsen, L. Jian, S. Dhaliwal, and 




Enterocytic Amyloid-Beta Abundance." [In eng]. Br J Nutr 101, no. 3 (Feb 2009): 
340-7. 
 
Menuka M. Pallebage-Gamarallage contributed to experimental protocols, 
data collection and drafting of the manuscript. Susan Galloway assisted in data 
collection and appraisal of the manuscript. Russell D. Johnsen assisted in method 
development and the review of the manuscript. Le Jian contributed to appraisal of 
the manuscript. Satvinder Dhaliwal provided statistical analysis of results and 
assisted in study design. John C. Mamo was instrumental in the design and funding 


























Pallebage-Gamarallage, M. M., S. Galloway, R. Takechi, S. Dhaliwal, and J. C. 
Mamo. "Probucol Suppresses Enterocytic Accumulation of Amyloid-Beta Induced by 
Saturated Fat and Cholesterol Feeding." [In eng]. Lipids 47, no. 1 (Jan 2012): 27-34. 
 
Menuka M. Pallebage-Gamarallage designed and undertook the experimental 
protocols including tissue collection, collating data, analysis of data, and preparation 
of the research article. Susan Galloway and Ryusuke Takechi contributed to tissue 
collection and Satvinder Dhaliwal assisted in statistical interpretation of data.  John 
C. Mamo assisted in study design and interpretation of data and contributed to the 


















TERMS AND CONDITIONS 




This is a License Agreement between Susan Galloway ("You") and Springer ("Springer") provided by 
Copyright Clearance Center ("CCC"). The license consists of your order details, the terms and 
conditions provided by Springer, and the payment terms and conditions.  
All payments must be made in full to CCC. For payment instructions, please see information 
listed at the bottom of this form. 
License Number 3462980247772 
License date Sep 06, 2014 
Order Content Publisher Springer 
Order Content Publication Lipids 
Order Content Title 
Probucol Suppresses Enterocytic Accumulation of Amyloid-β Induced by 
Saturated Fat and Cholesterol Feeding 
Order Content Author Menuka M. Pallebage-Gamarallage 
Order Content Date Jan 1, 2011 
Volume number 47 
Issue number 1 
Type of Use Thesis/Dissertation 
 
Portion Full text 
Number of copies 5 
Author of this Springer 
article 
No 
Order reference number None 
Title of your thesis / 
dissertation  
Enterocytic beta amyloid-lipoprotein homeostasis: Implications for 
Alzheimer's disease risk 
Expected completion date  Oct 2014 
Estimated size(pages) 220 
Total 0.00 USD 
 
Terms and Conditions 
 
Introduction 
The publisher for this copyrighted material is Springer Science + Business Media. By clicking "accept" 
in connection with completing this licensing transaction, you agree that the following terms and 
conditions apply to this transaction (along with the Billing and Payment terms and conditions 
established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink 
account and that are available at any time at http://myaccount.copyright.com).  
Limited License 
With reference to your request to reprint in your thesis material on which Springer Science and 
Business Media control the copyright, permission is granted, free of charge, for the use indicated in 





Licenses are for one-time use only with a maximum distribution equal to the number that you identified 
in the licensing process. 
This License includes use in an electronic form, provided its password protected or on the university’s 
intranet or repository, including UMI (according to the definition at the Sherpa website: 
http://www.sherpa.ac.uk/romeo/). For any other electronic use, please contact Springer at 
(permissions.dordrecht@springer.com or permissions.heidelberg@springer.com).  
The material can only be used for the purpose of defending your thesis limited to university-use only. 
If the thesis is going to be published, permission needs to be re-obtained (selecting "book/textbook" 
as the type of use).  
Although Springer holds copyright to the material and is entitled to negotiate on rights, this license is 
only valid, subject to a courtesy information to the author (address is given with the article/chapter) 
and provided it concerns original material which does not carry references to other sources (if material 
in question appears with credit to another source, authorization from that source is required as well).  
Permission free of charge on this occasion does not prejudice any rights we might have to charge for 
reproduction of our copyrighted material in the future.  
Altering/Modifying Material: Not Permitted 
You may not alter or modify the material in any manner. Abbreviations, additions, deletions and/or any 
other alterations shall be made only with prior written authorization of the author(s) and/or Springer 
Science + Business Media. (Please contact Springer at (permissions.dordrecht@springer.com or 
permissions.heidelberg@springer.com)  
Reservation of Rights 
Springer Science + Business Media reserves all rights not specifically granted in the combination of (i) 
the license details provided by you and accepted in the course of this licensing transaction, (ii) these 
terms and conditions and (iii) CCC's Billing and Payment terms and conditions.  
Copyright Notice:Disclaimer 
You must include the following copyright and permission notice in connection with any reproduction of 
the licensed material: "Springer and the original publisher /journal title, volume, year of publication, 
page, chapter/article title, name(s) of author(s), figure number(s), original copyright notice) is given to 
the publication in which the material was originally published, by adding; with kind permission from 
Springer Science and Business Media"  
Warranties: None  
Example 1: Springer Science + Business Media makes no representations or warranties with respect 
to the licensed material.  
Example 2: Springer Science + Business Media makes no representations or warranties with respect 
to the licensed material and adopts on its own behalf the limitations and disclaimers established by 
CCC on its behalf in its Billing and Payment terms and conditions for this licensing transaction.  
Indemnity 
You hereby indemnify and agree to hold harmless Springer Science + Business Media and CCC, and 




out of your use of the licensed material other than as specifically authorized pursuant to this license.  
No Transfer of License 
This license is personal to you and may not be sublicensed, assigned, or transferred by you to any 
other person without Springer Science + Business Media's written permission.  
No Amendment Except in Writing 
This license may not be amended except in a writing signed by both parties (or, in the case of 
Springer Science + Business Media, by CCC on Springer Science + Business Media's behalf).  
Objection to Contrary Terms 
Springer Science + Business Media hereby objects to any terms contained in any purchase order, 
acknowledgment, check endorsement or other writing prepared by you, which terms are inconsistent 
with these terms and conditions or CCC's Billing and Payment terms and conditions. These terms and 
conditions, together with CCC's Billing and Payment terms and conditions (which are incorporated 
herein), comprise the entire agreement between you and Springer Science + Business Media (and 
CCC) concerning this licensing transaction. In the event of any conflict between your obligations 
established by these terms and conditions and those established by CCC's Billing and Payment terms 
and conditions, these terms and conditions shall control.  
Jurisdiction 
All disputes that may arise in connection with this present License, or the breach thereof, shall be 
settled exclusively by arbitration, to be held in The Netherlands, in accordance with Dutch law, and to 
be conducted under the Rules of the 'Netherlands Arbitrage Instituut' (Netherlands Institute of 
Arbitration).OR:  
All disputes that may arise in connection with this present License, or the breach thereof, shall 
be settled exclusively by arbitration, to be held in the Federal Republic of Germany, in 
accordance with German law.  
Other terms and conditions: 
v1.3 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-
646-2777.  
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable license 













Takechi, R., S. Galloway, M. M. Pallebage-Gamarallage, C. L. Wellington, R. D. 
Johnsen, S. S. Dhaliwal, and J. C. Mamo. "Differential Effects of Dietary Fatty Acids 
on the Cerebral Distribution of Plasma-Derived Apo B Lipoproteins with Amyloid-
Beta." [In eng]. Br J Nutr 103, no. 5 (Mar 2010): 652-62. 
 
Takechi Ryusuke led the experiments and was responsible for the study 
design, methodology, data collection and interpretation and drafting of the 
manuscript. Susan Galloway contributed to study design, maintenance of animals, 
tissue collection and manuscript appraisal. Menuka M. Pallebage-Gamarallage 
assisted with animal maintenance, data collection and manuscript appraisal. Cheryl 
L. Wellington provided tissue samples as well as reviewing the draft manuscript. 
Russell D. Johnsen provided assistance with development of methods. Satvinder S. 
Dhaliwal assisted with statistical analysis of results. John C. Mamo contributed to 















Takechi R, Galloway S, Pallebage-Gamarallage MM, Lam V, Mamo JCL. (2009) 
Dietary fats, cerebrovascular integrity and Alzheimer’s disease risk. Prog Lipid Res. 
49, 159-170 
 
Ryusuke Takechi was responsible for the review and interpretation of 
literature, and writing of the manuscript. Susan Galloway, Menuka M. Pallebage-
Gamarallage and Virginie Lam assisted in the generation of images and review of 
the draft manuscript. John C. Mamo was involved in discussion of ideas and 


































TERMS AND CONDITIONS 




This is a License Agreement between Susan Galloway ("You") and Elsevier ("Elsevier") provided by 
Copyright Clearance Center ("CCC"). The license consists of your order details, the terms and 
conditions provided by Elsevier, and the payment terms and conditions.  
All payments must be made in full to CCC. For payment instructions, please see information 
listed at the bottom of this form. 
Supplier 
Elsevier Limited 
The Boulevard,Langford Lane 
Kidlington,Oxford,OX5 1GB,UK 
Registered Company Number 1982084 
Customer name Susan Galloway 
Customer address 159 Elderberry Dr, 
 
Perth, None 6164 
License number 3461960727925 
License date Sep 04, 2014 
Licensed content publisher Elsevier 
Licensed content publication Progress in Lipid Research 
Licensed content title 
Dietary fats, cerebrovasculature integrity and Alzheimer’s 
disease risk 
Licensed content author 
R. Takechi,S. Galloway,M.M.S. Pallebage-Gamarallage,V. 
Lam,J.C.L. Mamo 
Licensed content date April 2010 
Licensed content volume number 49 
Licensed content issue number 2 
Number of pages 12 
Start Page 159 
End Page 170 
Type of Use reuse in a thesis/dissertation 
 
Intended publisher of new work other 
 
Portion full article 
 
Format both print and electronic 
 




Will you be translating? No 
 
Title of your thesis/dissertation  
Enterocytic beta amyloid-lipoprotein homeostasis: 
Implications for Alzheimer's disease risk  
Expected completion date Oct 2014 
 
Estimated size (number of pages) 220 
 




Price 0.00 USD 
 
VAT/Local Sales Tax 0.00 USD / 0.00 GBP 
Total 0.00 USD 
  
Terms and Conditions 
  
INTRODUCTION 
1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection with 
completing this licensing transaction, you agree that the following terms and conditions apply to this 
transaction (along with the Billing and Payment terms and conditions established by Copyright 
Clearance Center, Inc. ("CCC"), at the time that you opened your Rightslink account and that are 
available at any time at http://myaccount.copyright.com).  
GENERAL TERMS 
2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the 
terms and conditions indicated. 
3. Acknowledgement: If any part of the material to be used (for example, figures) has appeared in our 
publication with credit or acknowledgement to another source, permission must also be sought from 
that source. If such permission is not obtained then that material may not be included in your 
publication/copies. Suitable acknowledgement to the source must be made, either as a footnote or in 
a reference list at the end of your publication, as follows: 
“Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of chapter, Pages 
No., Copyright (Year), with permission from Elsevier [OR APPLICABLE SOCIETY COPYRIGHT 
OWNER].” Also Lancet special credit - “Reprinted from The Lancet, Vol. number, Author(s), Title of 
article, Pages No., Copyright (Year), with permission from Elsevier.” 
4. Reproduction of this material is confined to the purpose and/or media for which permission is 
hereby given. 
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be 
altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/or 
any other alterations shall be made only with prior written authorization of Elsevier Ltd. (Please 
contact Elsevier at permissions@elsevier.com)  
6. If the permission fee for the requested use of our material is waived in this instance, please be 
advised that your future requests for Elsevier materials may attract a fee. 
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the combination of (i) 
the license details provided by you and accepted in the course of this licensing transaction, (ii) these 
terms and conditions and (iii) CCC's Billing and Payment terms and conditions. 
8. License Contingent Upon Payment: While you may exercise the rights licensed immediately upon 
issuance of the license at the end of the licensing process for the transaction, provided that you have 
disclosed complete and accurate details of your proposed use, no license is finally effective unless 
and until full payment is received from you (either by publisher or by CCC) as provided in CCC's 
Billing and Payment terms and conditions. If full payment is not received on a timely basis, then any 
license preliminarily granted shall be deemed automatically revoked and shall be void as if never 





Billing and Payment terms and conditions, the license is automatically revoked and shall be void as if 
never granted. Use of materials as described in a revoked license, as well as any use of the 
materials beyond the scope of an unrevoked license, may constitute copyright infringement and 
publisher reserves the right to take any and all action to protect its copyright in the materials. 
9. Warranties: Publisher makes no representations or warranties with respect to the licensed 
material. 
10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and their 
respective officers, directors, employees and agents, from and against any and all claims arising out 
of your use of the licensed material other than as specifically authorized pursuant to this license. 
11. No Transfer of License: This license is personal to you and may not be sublicensed, assigned, or 
transferred by you to any other person without publisher's written permission. 
12. No Amendment Except in Writing: This license may not be amended except in a writing signed by 
both parties (or, in the case of publisher, by CCC on publisher's behalf). 
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any purchase 
order, acknowledgment, check endorsement or other writing prepared by you, which terms are 
inconsistent with these terms and conditions or CCC's Billing and Payment terms and conditions. 
These terms and conditions, together with CCC's Billing and Payment terms and conditions (which 
are incorporated herein), comprise the entire agreement between you and publisher (and CCC) 
concerning this licensing transaction. In the event of any conflict between your obligations 
established by these terms and conditions and those established by CCC's Billing and Payment 
terms and conditions, these terms and conditions shall control. 
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described in this 
License at their sole discretion, for any reason or no reason, with a full refund payable to you. Notice 
of such denial will be made using the contact information provided by you. Failure to receive such 
notice will not alter or invalidate the denial. In no event will Elsevier or Copyright Clearance Center be 
responsible or liable for any costs, expenses or damage incurred by you as a result of a denial of 
your permission request, other than a refund of the amount(s) paid by you to Elsevier and/or 
Copyright Clearance Center for denied permissions. 
LIMITED LICENSE 
The following terms and conditions apply only to specific license types: 
15. Translation: This permission is granted for non-exclusive world English rights only unless your 
license was granted for translation rights. If you licensed translation rights you may only translate this 
content into the languages you requested. A professional translator must perform all translations and 
reproduce the content word for word preserving the integrity of the article. If this license is to re-use 1 
or 2 figures then permission is granted for non-exclusive world rights in all languages. 
16. Posting licensed content on any Website: The following terms and conditions apply as follows: 
Licensing material from an Elsevier journal: All content posted to the web site must maintain the 
copyright information line on the bottom of each image; A hyper-text must be included to the 
Homepage of the journal from which you are licensing at 
http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at 




version of the material to be stored in a central repository such as that provided by Heron/XanEdu. 
Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier 
homepage at http://www.elsevier.com . All content posted to the web site must maintain the copyright 
information line on the bottom of each image. 
Posting licensed content on Electronic reserve: In addition to the above the following clauses are 
applicable: The web site must be password-protected and made available only to bona fide students 
registered on a relevant course. This permission is granted for 1 year only. You may obtain a new 
license for future website posting.  
For journal authors: the following clauses are applicable in addition to the above: Permission 
granted is limited to the author accepted manuscript version* of your paper.  
*Accepted Author Manuscript (AAM) Definition: An accepted author manuscript (AAM) is the 
author’s version of the manuscript of an article that has been accepted for publication and which may 
include any author-incorporated changes suggested through the processes of submission 
processing, peer review, and editor-author communications. AAMs do not include other publisher 
value-added contributions such as copy-editing, formatting, technical enhancements and (if relevant) 
pagination. 
You are not allowed to download and post the published journal article (whether PDF or HTML, proof 
or final version), nor may you scan the printed edition to create an electronic version. A hyper-text 
must be included to the Homepage of the journal from which you are licensing at 
http://www.sciencedirect.com/science/journal/xxxxx. As part of our normal production process, you 
will receive an e-mail notice when your article appears on Elsevier’s online service ScienceDirect 
(www.sciencedirect.com). That e-mail will include the article’s Digital Object Identifier (DOI). This 
number provides the electronic link to the published article and should be included in the posting of 
your personal version. We ask that you wait until you receive this e-mail and have the DOI to do any 
posting.  
Posting to a repository: Authors may post their AAM immediately to their employer’s institutional 
repository for internal use only and may make their manuscript publically available after the journal-
specific embargo period has ended. 
Please also refer to Elsevier's Article Posting Policy for further information. 
18. For book authors the following clauses are applicable in addition to the above: Authors are 
permitted to place a brief summary of their work online only.. You are not allowed to download and 
post the published electronic version of your chapter, nor may you scan the printed edition to create 
an electronic version. Posting to a repository: Authors are permitted to post a summary of their 
chapter only in their institution’s repository. 
20. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be 
submitted to your institution in either print or electronic form. Should your thesis be published 
commercially, please reapply for permission. These requirements include permission for the Library 
and Archives of Canada to supply single copies, on demand, of the complete thesis and include 
permission for UMI to supply single copies, on demand, of the complete thesis. Should your thesis be 
published commercially, please reapply for permission.  




Elsevier publishes Open Access articles in both its Open Access journals and via its Open Access 
articles option in subscription journals. 
Authors publishing in an Open Access journal or who choose to make their article Open Access in an 
Elsevier subscription journal select one of the following Creative Commons user licenses, which 
define how a reader may reuse their work: Creative Commons Attribution License (CC BY), Creative 
Commons Attribution – Non Commercial - ShareAlike (CC BY NC SA) and Creative Commons 
Attribution – Non Commercial – No Derivatives (CC BY NC ND) 
Terms & Conditions applicable to all Elsevier Open Access articles:  
Any reuse of the article must not represent the author as endorsing the adaptation of the article nor 
should the article be modified in such a way as to damage the author’s honour or reputation. 
The author(s) must be appropriately credited. 
If any part of the material to be used (for example, figures) has appeared in our publication with credit 
or acknowledgement to another source it is the responsibility of the user to ensure their reuse 
complies with the terms and conditions determined by the rights holder. 
Additional Terms & Conditions applicable to each Creative Commons user license: 
CC BY: You may distribute and copy the article, create extracts, abstracts, and other revised 
versions, adaptations or derivative works of or from an article (such as a translation), to include in a 
collective work (such as an anthology), to text or data mine the article, including for commercial 
purposes without permission from Elsevier 
CC BY NC SA: For non-commercial purposes you may distribute and copy the article, create 
extracts, abstracts and other revised versions, adaptations or derivative works of or from an article 
(such as a translation), to include in a collective work (such as an anthology), to text and data mine 
the article and license new adaptations or creations under identical terms without permission from 
Elsevier 
CC BY NC ND: For non-commercial purposes you may distribute and copy the article and include it 
in a collective work (such as an anthology), provided you do not alter or modify the article, without 
permission from Elsevier 
Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY NC ND 
license requires permission from Elsevier and will be subject to a fee.  
Commercial reuse includes: 
· Promotional purposes (advertising or marketing) 
· Commercial exploitation ( e.g. a product for sale or loan) 
· Systematic distribution (for a fee or free of charge) 




21. Other Conditions:  
v1.6 
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or +1-978-
646-2777.   
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable license 

































I, Susan Galloway here confirm that I made the contributions to the publications 





I, Ryusuke Takechi, here confirm that I made the contributions to the publications 
included in this thesis as stated above and agreed to give permission to use these 





I, Menuka Pallebage-Gamarallage, here confirm that I made the contributions to the 
publications included in this thesis as stated above. I agree to give permission to 





I, Russell Johnsen, here confirm that I made the contributions to the publications 
included in this thesis as stated above and agreed to give permission to use these 




I, Le Jian, here confirm that I made the contributions to the publications included in 
this thesis as stated above and agreed to give permission to use these publications 







I, Satvinder Dhaliwal, here confirm that I made the contributions to the publications 
included in this thesis as stated above and agreed to give permission to use these 





I, Stewart Chew, here confirm that I made the contributions to the publications 
included in this thesis as stated above and agreed to give permission to use these 






I, Cheryl Wellington, here confirm that I made the contributions to the publications 
included in this thesis as stated above and agreed to give permission to use these 





I, Virginie Lam, here confirm that I made the contributions to the publications 
included in this thesis as stated above and agreed to give permission to use these 





I, John Mamo, here confirm that I made the contributions to the publications 
included in this thesis as stated above. I agree to give permission to use these 







Appendix B: Additional co-authored manuscripts 
 
This thesis contains additional publications which are not a part of the main 
body and main ideas of the thesis. These articles do however, support the broad 
hypothesis and provide additional insights from alternative perspective. The results 
of findings are published in internationally recognised journals.  
 
This thesis is supported by the following co-authored journal articles: 
 
Article 1:  
Takechi R, Galloway S, Pallebage-Gamarallage MM, Wellington C, Mamo JC. 
(2008) Chylomicron amyloid-beta in the aetiology of Alzheimer’s disease. 
Atheroscler Suppl. 9, 19-25. 
Article 2: 
Pallebage-Gamarallage, M. M., S. Galloway, R. Johnsen, L. Jian, S. Dhaliwal, and 
J. C. Mamo. "The Effect of Exogenous Cholesterol and Lipid-Modulating Agents on 
Enterocytic Amyloid-Beta Abundance." [In eng]. Br J Nutr 101, no. 3 (Feb 2009): 
340-7. 
Article 3: 
Pallebage-Gamarallage, M. M., S. Galloway, R. Takechi, S. Dhaliwal, and J. C. 
Mamo. "Probucol Suppresses Enterocytic Accumulation of Amyloid-Beta Induced by 
Saturated Fat and Cholesterol Feeding." [In eng]. Lipids 47, no. 1 (Jan 2012): 27-34. 
Article 4: 
Takechi, R., S. Galloway, M. M. Pallebage-Gamarallage, C. L. Wellington, R. D. 
Johnsen, S. S. Dhaliwal, and J. C. Mamo. "Differential Effects of Dietary Fatty Acids 
on the Cerebral Distribution of Plasma-Derived Apo B Lipoproteins with Amyloid-





Takechi R, Galloway S, Pallebage-Gamarallage MM, Lam V, Mamo JCL. (2009) 





































Article 1:  
 
 
Takechi R, Galloway S, Pallebage-Gamarallage MM, Wellington C, Mamo JC. 
(2008) Chylomicron amyloid-beta in the aetiology of Alzheimer’s disease. 




This review article presents current research regarding dietary fats and AD 
and provides an alternate novel perspective on pathological mechanisms involved.  
 
A number of epidemiological and animal studies show high intake of fats and 
cholesterol correlates with increased risk of developing AD via mechanisms related 
to the metabolism of Aβ (Kalmijn et al. 1997, Petot et al. 2004, Refolo et al. 2000, 
Sparks et al. 1994), however, the exact mechanisms remain unclear. Although Aβ, 
the derivative of precursor APP, has been shown to specifically cause a pathological 
cascade of events leading to AD, the origin of this crucial protein remains a subject 
of debate.  
 
One pathological feature that is common amongst AD-affected individuals is 
the presence of Aβ within the blood vessels of the brain and in many cases, damage 
to the BBB (Kalaria 1992, Wisniewski et al. 1997). The transport of Aβ across the 
BBB has been implicated and plasma Aβ can contribute to significant cerebral load 
(Deane et al. 2005) however currently, research into peripherally derived Aβ is 
limited. In this study we reported the expression of Aβ within small intestine 
enterocytes, which are responsible for absorption and transport of dietary fats. In 
addition, expression of Aβ was significantly enhanced by high fat feeding and 
abolished by fasting (Galloway et al. 2007). These findings provide an alternative 
view in understanding the possible pathological influence of dietary fats on the 
development of AD. Although cerebral amyloidosis was not observed in wild type 
mice involved in this study, LaRue et al. (2004) showed high-fat feeding induced an 





A number of studies have shown that acute and chronic exposure of 
cerebrovasculature to Aβ can result in damage to endothelial cells of the tunica 
intima (Thomas et al. 1997). In this study, peripheral administration of Aβ resulted in 
entrapment of Aβ within blood vessels and transportation into brain (Maness et al. 
1994, Martel et al. 1996, Zlokovic et al. 1993) and chronic exposure to peripheral Aβ 
was shown to damage blood vessels and activate the brain’s immune response (Su 
et al. 1999). Pathological consequences of damaged BBB could be increased 
transport of Aβ into the brain and/or decreased efflux of Aβ from the brain.   
 
Section 3 and 4 of the article discusses the production and association of 
enterocytic Aβ with CMs. Our study in wild-type C57/BL6J mice shows the distinct 
presence of Aβ proteins within the perinuclear location of enterocytes and other 
studies indicate Aβ co-localises with enterocytic apo B and Golgi apparatus. 
Saturated fatty acids and UFAs feeding in animals show substantial expression of 
Aβ with apo B. The association of Aβ with apo B is presently unclear; however, the 
cysteine-rich motif of APP/Aβ shares homology with some lipoprotein receptors. As 
these domains can bind to apo E-containing lipoproteins with substantial affinity, it is 
reasonable to assume that endogenously produced Aβ can bind and associate with 
apo E-containing CMs. The presence of Aβ within ER/Golgi region suggests 
association of Aβ during lipidation of apo B; a process which produces primordial 
lipoproteins. Lipid substrate availability is crucial for lipidation of apo B and formation 
of CM molecules and high fat induced increases in enterocytic Aβ suggests 
involvement and secretion of Aβ in complex with lipoproteins (James et al. 2003).  
 
Several lines of evidence support the binding and association of Aβ with 
intestinally derived lipoproteins. Clinical studies show increases in APP processing 
following ingestion of fatty meal and increased secretion of intestinal Aβ-lipoproteins 
into blood (Boyt et al. 1999). Analysis of plasma from probable AD subjects (Mamo 
et al. 2008) shows that the majority of plasma Aβ is associated with TRL fraction 
including CMs and their remnants. This study determined that Aβ40 was 
significantly increased in TRL fraction of AD subjects compared to cognitively intact 
controls. In addition, although the subjects analysed were normolipidemic, there 
were significant decreases in the rate of clearance of postprandial lipoproteins 




dyslipidemia, a condition where increases in dietary induced secretions of CMs are 
not sufficiently cleared (Smith et al. 1999). 
 
In section 5, A transgenic mouse (APP/PS1) model of AD (mirrors cerebral 
AD pathology by over-expression of APP) shows significant increases in plasma Aβ 
with increases in plasma TGs, as well as TRLs. Interestingly, these observations 
were made prior to the onset of cerebral and cerebrovascular accumulation of Aβ. 
Further analysis of brain samples from APP/PS1 mice showed higher levels of IgG 
in plaques and increased occludin which indicates increased permeability of the 
BBB in these animals.      
 
Section 6 links the role of apo E isoforms with current findings/knowledge in 
CM-Aβ metabolism. Interestingly, apo E4 present in 50 % of AD individuals and 
influences kinetics of CMs. Apolipoprotein E4 preferentially binds to CMs and VLDL 
remnants which indicate a possibly greater plasma concentration of Aβ not 
associated with apo E. Apolipoprotein E4-containing individuals contains more 
permeable BBB which makes them at greater risk towards increased influx of 
plasma Aβ.  
 
Lastly, section 7 summarises the current understanding surrounding dietary 
fat induced intestinal production of Aβ-lipoprotein and BBB integrity. High SFA 
induced exacerbation of cerebral amyloid deposition could be linked to a build-up of 
CM-Aβ and with increased permeability of the BBB can result in accumulation of 
these toxic peptides in the brain. Finally, this article recommends prevention and 










































Article 2:  
 
 
Pallebage-Gamarallage, M. M., S. Galloway, R. Johnsen, L. Jian, S. Dhaliwal, and 
J. C. Mamo. "The Effect of Exogenous Cholesterol and Lipid-Modulating Agents on 





The manuscript titled "The Effect of Exogenous Cholesterol and Lipid-
Modulating Agents on Enterocytic Amyloid-Beta Abundance" is complementary to 
my PhD candidacy by directly supporting my objectives. This research article 
investigates the regulation of enterocyte Aβ by cholesterol and cholesterol 
modulating agents and considers the role of statins as a therapeutic intervention to 
counter balance dietary induced enterocyte Aβ. Results presented here confirm that 
endogenous or exogenous (dietary) cholesterol plays a role in addition to dietary fat 
in relation to Aβ abundance. Saturated fat feeding was used as a positive control 
and expression of enterocytic Aβ was significantly greater than cholesterol fed diet, 
indicating that the SFA component of the diet alone was sufficient enough to obtain 
a response. I contributed to this study by appraisal of manuscript and by assisting in 




Several studies in animals show cholesterol feeding promotes deposition of 
Aβ in brain. In rabbits fed 2 % (w/w) cholesterol, there was an increase in neuronal 
accumulation of Aβ which was increased with feeding time (Sparks et al. 1994). 
Interestingly, removal of cholesterol content from the diet reversed the observation 
(Sparks 1996). Similarly, dietary cholesterol increased cerebral amyloid plaques in 
transgenic APPsw and PS1 mice (Refolo et al. 2000). Intracellular (neuronal) 
abundance of Aβ correlated positively with increased cholesterol (Sparks et al. 
1994). Consistent with this notion, statin treatment induced reduction of intracellular 
cholesterol reduced Aβ (Fassbender et al. 2001, Wolozin 2004). Ezetimibe 




(ATOR) inhibits endogenous cholesterol biogenesis by inhibiting 3-hydroxyl-3-
methylglutaryl CoA reductase inhibitor (Naoumova et al. 1997). Both ezetimibe and 
atorvastatin were incorporated separately into low-fat 2 % (w/w) cholesterol feed to 




Wild-type C57BL/6J mice were place on either low-fat and cholesterol-free 
diet (LF) or low-fat and 2 % cholesterol diet (HC). Another group fed a saturated fat 
diet was used as a comparison. Both LF and HC diets incorporated ezetimibe or 
atorvastatin within the diet making 6 groups of animals in total (4 statin + 2 control 
groups). Samples of the small intestine were collected for immunohistochemistry 
analysis and results were graded via semi-quantitative methods according to 




Enterocytic Aβ was found within the perinuclear location of enterocytes, the 
site of Golgi and rER. In comparison to LF feeding, HC diet significantly (P < 0.000) 
decreased enterocytic abundance of Aβ. Inhibition of cholesterol absorption by 
ezetimibe in LF group reversed the suppressive effects (P < 0.000) of cholesterol 
whilst atorvastatin in LF group enhanced enterocytic Aβ (P = 0.016). Results 
obtained from HC + EZE was comparative to LF alone, implying EZE treatment did 
not have other unknown effects on enterocytic Aβ. Furthermore the increased 
enterocytic Aβ was observed in LF group not HC; the latter group displayed Aβ 
abundance not different from HC + ATOR indicating that ATOR did not have 
pleiotropic effects on enterocyte Aβ. Saturated fat feeding increased enterocytic Aβ 




The presence of Aβ within enterocytes and attenuating effects of cholesterol 
inhibiting agents can translate to changes in the balance of production and secretion 
of Aβ. Plasma cholesterol was not significantly different between LF, HC diets and 




to be unchanged. Rather, modulation of enterocytic Aβ by cholesterol and statins 
could affect synthesis of Aβ with lipoproteins. Findings by Park et al. (2003) support 
the results of this study, and show that cholesterol inhibition by lovastatin increased 
production of Aβ in transgenic AD mice. Studies indicate that intracellular presence 
of both exogenous (absorbed) and endogenous cholesterol is suppressive towards 
enterocytic Aβ abundance, possibly via production pathways. Beta-amyloid 
homeostasis can be regulated by distribution of membrane non-esterified 
cholesterol and intracellular cholesteryl esters (Abad-Rodriguez et al. 2004). 
Cholesterol trafficking in neurons lowered β-secretase and increased γ-secretase 
which increased intracellular Aβ (Runz et al. 2002). These cholesterol esters are 
also implicated in genesis and secretion of chylomicrons (Shen et al. 2001, Simons 
and Ikonen 2000). The present study was not designed to assess the risk of 
intestinal Aβ and its modulation by cholesterol towards development of AD. 
However, this study suggests that modulation of enterocyte Aβ production and 
secretion may reduce risk of developing AD via downstream events involving 




































Article 3:  
 
 
Pallebage-Gamarallage, M. M., S. Galloway, R. Takechi, S. Dhaliwal, and J. C. 
Mamo. "Probucol Suppresses Enterocytic Accumulation of Amyloid-Beta Induced by 




The manuscript titled "Probucol Suppresses Enterocytic Accumulation of 
Amyloid-Beta Induced by Saturated Fat and Cholesterol Feeding." explores the 
putative effects of saturated fat and probucol on small intestine derived Aβ. The 
article directly reinforced my findings and also puts forward a possible therapeutic 
drug, probucol, that when incorporated into a SFA diet, significantly attenuates 
enterocytic Aβ. Dietary fat and drugs which facilitate apo B-lipoprotein production, 
secretion and plasma kinetics can also modulate enterocytic Aβ production and 
secretion and therefore contribute toward AD risk. I contributed to the article by 




Co-localisation of apo B with amyloid plaques in post mortem brain samples 
from AD humans (Namba et al. 1992) and transgenic mouse models (Takechi et al. 
2010b) presents direct evidence that peripheral Aβ-apo B contributes to cerebral 
amyloid deposits in the presence of BBB damage. In AD subjects (Mamo et al. 
2008), the plasma concentration of Aβ-lipoprotein is increased and transgenic 
animal research suggests that increased secretion of Aβ-lipoprotein may occur early 
during the pathological process in AD (Burgess et al. 2006). Probucol is a 
cholesterol lowering agent and has lipid-lowering properties which have been 
attributed to its influence on secretion and clearance of apo B-lipoproteins (Mamo et 
al. 1993, Gershkovich and Hoffman 2005). Probucol becomes incorporated into 
nascent lipoprotein molecules and has been effective in lowering the rate of 
cognitive decline in clinical studies (Poirier 2003, Poirier 2005) as well as reducing 
the rate of cerebral amyloid deposits in transgenic mice (Poirier 2003); although 




probucol were extended or were directly influenced by modulation of abundance and 




Intestinal Aβ-lipoprotein homeostasis was explored using wild-type 
C57BL/6J mice fed HF diet (15 % w/w as saturated fat with 1 % cholesterol) and LF 
diet (<4 % fat as unsaturated fat and no cholesterol) for 1 month. Probucol was 
incorporated into both LF and HF diets at 1 % (w/w). Double immunofluorescence 
using two polyclonal antibodies was performed as previously described (Takechi et 
al. 2008). Three-dimensional quantitative analysis and co-localization of enterocytic 
Aβ and apo B signal was performed by Automatic Measurement Program (AxiVision 




Apo B and Aβ were found within the perinuclear location of enterocytes as 
well as within the lacteals of the mucosa layer of the small intestine. This staining 
pattern was observed for all groups and the net abundance (perinuclear + lacteal) 
was not significantly different between groups; however, enterocytic abundance and 
secretion modulation effects were present. Compared with the HF group, the HF + 
probucol treatment group showed attenuated enterocytic Aβ which paralleled an 
increase in lacteal staining of apo B. The location of intestinal Aβ and apo B 
appeared to be qualitatively comparable indicating that Aβ-apo B binding and 
secretion occurs in complex. Although this is the case, there was about 70-80 % 
more Aβ in the perinuclear location of enterocytes in contrast to approximately 80 % 
of apo B within the lacteals. Compared to LF feeding, HF feeding induced a 2-fold 
increase in Aβ which was predominantly observed within the perinuclear location 
whilst secretion of Aβ remained relatively unchanged. Probucol did not influence Aβ 
abundance under LF feeding but caused a significant decrease in cellular Aβ under 
HF feeding with no change observed in lacteal Aβ abundance. In both LF and HF 
groups, probucol decreased enterocytic Aβ and increased lacteal Aβ ind icating 
stimulatory effects on secretion of apo B; HF feeding had greater stimulatory effect 
as probucol. In addition, 1% probucol supplementation was sufficient to lower 






High fat feeding consistently increases enterocytic abundance of Aβ, which 
is greater than the suppressive effects of cholesterol. SFA can influence the 
metabolism of Aβ via increased Aβ production and association with apo B 
containing lipoproteins and/or its cellular degradation. This study suggests that 
probucol can lower enterocytic Aβ; a mechanism which could translate to reduced 
plasma Aβ levels and reduced risk of cerebral accumulations. Probucol may also 
benefit AD sufferers by protecting the BBB from oxidative damage and by reducing 





































Article 4:  
 
 
Takechi R, Galloway S, Pallebage-Gamarallage MM, Lam V, Mamo JCL. (2009) 





This study addresses the latter part of the broad hypothesis and examines 
the putative effects of saturated and unsaturated feeding on BBB integrity. The 
primary finding of chapter 5 was that enterocytic Aβ is enhanced under high-fat 
feeding. Secretion of plasma Aβ-lipoproteins from enterocytes may not be 
transported into the brain without demonstrable BBB damage and thus increased 
“leakage” and contribution to pathology of AD was questionable. This study directly 
extends on the findings of chapter 5 and demonstrates that saturated fat diets, not 
MUFA or PUFA, causes damage to BBB. I contributed to care of animals, design of 




Alzheimer’s disease patients exhibit cerebrovascular disturbances such as 
sequestration of Aβ within the blood vessels of the brain, proliferation of vascular 
cells (Ellis et al. 1996) and inflammation (Cullen 1997, Itagaki et al. 1989). 
Moreover, increases in identification of plasma-derived proteins are found in AD 
brains (Kalaria 1992, Wisniewski et al. 1997b). These observations are consistent 
with the notion of damaged BBB and underlying manifestation of vascular pathology 
in AD. Increases in plasma Aβ transport to the brain coupled with inadequate 
clearance of Aβ from brain (Donahue et al. 2006) can cause accumulation of Aβ and 
a pathological cascade of events leading to synaptic toxicity and neuronal cell death.   
 
Plasma Aβ can be derived from lipogenic organs and the liver and small 
intestines can be a significant source of Aβ (Galloway et al. 2007, Takechi et al. 
2008a, Koudinov and Koudinova 1997). Hepatocytes and enterocytes secrete Aβ in 




previously found Aβ production is regulated by intake of dietary fats (Galloway et al. 
2007, Koudinov and Koudinova 1997, James et al. 2003). Consistent in the 
literature, SFA intake significantly increases enterocytic abundance of Aβ which 
associates with enterocytic lipoprotein-apo B prior to secretion into plasma. 
Increases in postprandial lipoproteins derived from enterocytes were previously 
observed in cognitively impaired and AD patients compared to age-matched controls 
(Mamo et al. 2008). 
 
The relationship between vascular disturbances present in AD and dietary 
induced increases in enterocytic and plasma Aβ lead to the current study examining 




Female C57BL6/J mice were fed HF diet (20.3 % w/w as fat) containing 
predominantly SFA, PUFA or MUFA fats and a LF (4 % w/w as fat) control diet for 3 
and 6 months. Plasma Aβ and S100β was analysed using ELISA methods as per 
manufacturer’s instructions. Cerebral cryosections were immunostained for IgG, apo 
B, occludin and von Willebrand factor (vWF) and signal was determined using semi-
quantitative immunofluorescent microscopy. Co-localisation of perivascular Aβ with 
apo B and occludin with vWF were determined by dual-labelling using two polyclonal 
antibodies as previously described (Takechi et al. 2008b). Co-localisation of apo B 
and amyloid plaques were also determined in separately provided APP/PS1 brain 




Extravasation of plasma IgG and apo B was significantly increased in the 
cerebral cortex and brain stem of SFA fed mice compared to other groups (Figure 
2). This increase in IgG and apo B was also observed in transgenic mice in the 
same brain regions as well as the hippocampus (Figure 5). Co-localization of 
perivascular Aβ with apo B was present in-situ indicating the transport of Aβ-apo B 
occurring as a result of SFA diet (Figure 3). Blood-brain-barrier integrity was 
assessed by measurement of occludin relative to vWF, which was significantly 




marker of brain to blood efflux, was significantly increased in SFA fed mice (>80%) 




Both influx and efflux functions of BBB were shown to be exacerbated under 
SFA feeding and in APP/PS1 mice. Compared to MUFA and PUFA groups, SFA 
feeding for 3 months was sufficient to induce cell junction changes within BBB and 
increased extravasation of plasma proteins, IgG and apo B into the brain. In 
addition, colocalization of Aβ and apo B within cerebral blood vessels and amyloid 
plaques suggests that intestinally or hepatically derived Aβ-apo B-lipoproteins can 
cross the BBB. Diets were well tolerated and there was no difference in weight gain, 
plasma triglycerides or plasma cholesterol indicating no pleiotropic effects of diets. 
Changes physiological function of BBB can therefore be regarded as a direct result 
of SFA feeding. Although the direct modes of action of SFA are currently unclear, 
several plausible mechanisms exist. Blood-brain barrier can be compromised via 
vasoactive properties of the plasma Aβ-lipoprotein entity alone or via induction of 
reactive oxygen species, changes in intracellular calcium homeostasis, increased 
stress on the endoplasmic reticulum (Morgan 2009, Carpentier 2008, Cnop et al. 
2008, Solfrizzi et al. 2010) or broader toxic effects of dietary fatty acids on BBB. This 
study extends previous findings and provides new insight in relation to mechanisms 
surrounding SFA diet induced increases to AD risk. Reduced AD risk associated 






























































Article 5:  
 
 
Takechi R, Galloway S, Pallebage-Gamarallage MM, Lam V, Mamo JCL. (2009) 
Dietary fats, cerebrovascular integrity and Alzheimer’s disease risk. Prog Lipid Res. 




A collection of epidemiological, animal and cell studies has led to the notion 
that AD pathology is strongly linked to the metabolism of dietary fats. Although the 
exact mechanisms remain unclear it is thought that dietary fat plays a role in the 
modulation of Aβ, the main protein implicated in AD. This candidacy examines in 
detail the effects of dietary fat upon regulation of intestinal Aβ-apo B-lipoproteins. In 
the context of my candidacy, this review provides references for downstream 
pathological events and specifically explores pleiotropic effects of dietary fat and 
cholesterol on the various physiological and pathological mechanisms shown to 
exacerbate the onset and progression of AD. I have contributed intellectually to the 
content of this article as well as appraising the manuscript.  
 
Section 1 (introduction) introduces the role of Aβ in AD pathology and 
describes the possible mechanisms behind elevated cerebral Aβ including over 
production of local Aβ, increased transport of peripheral Aβ into the brain and/or 
decreased Aβ clearance/degradation. Of these possible mechanisms, the author 
describes decreased Aβ clearance and increased Aβ production is less likely to be 
the case in sporadic AD cases. Increased BBB permeability and increased 
extravasation of plasma proteins within AD brains has been reported (Ellis et al. 
1996, Wisniewski et al. 1997a) and this article suggests that dietary fat is possibly 
implicated. Saturated fat and cholesterol have both been previously implicated with 
greater risk of developing AD (Oba et al. 2009, Yusuf et al. 2004, Menotti et al. 
1999, Singh et al. 2002, Vincent-Baudry et al. 2005, De Lorgeril et al. 1996, de 
Lorgeril et al. 1999) and animal models show aggressive cerebral pathology in 
response to increased SFA and cholesterol feeding (Sparks et al. 1994, Oksman et 





Section 2 provides a summary of epidemiological studies into the effects of 
dietary fatty acids (SFA, MUFA and n3/n6 PUFA) on cognitive decline and AD (See 
Chapter 1 Literature Review) as well as the effects of SFA diet on enterocyte 
derived Aβ. In brief, epidemiological studies have found intake of SFA to increase 
risk and unsaturated fat to decrease risk of cognitive decline and developing AD 
(Laitinen et al. 2006). The Mediterranean diet which is low in SFA and cholesterol 
and high in MUFA (predominantly through olive oil) has been shown to be beneficial 
towards chronic disease, cognitive decline and AD (Oba et al. 2009, Vincent-Baudry 
et al. 2005, Scarmeas et al. 2009, Petot et al. 2004). Polyunsaturated fats have 
been of particular interest in relation to mental health as about 50% of brain fatty 
acids are composed of n3s, DHA and EPA. Supplementation of diet with fish oil high 
in n-3 DHA has been shown to be beneficial in reducing cognitive decline (Kalmijn 
2000, Scarmeas et al. 2009, Cunnane et al. 2009).  
 
Consistent with previous epidemiological studies laboratory research shows 
that Aβ, the primary protein implicated in AD associates with lipoproteins in liver 
cells (Koudinov and Koudinova 1997) and in plasma, binds primarily to lipoproteins 
enriched with triglycerides (Mamo et al. 2008). The small intestine has also been 
shown to contribute to the plasma pool of Aβ and small intestinal enterocytes can 
express Aβ within the perinuclear location of the CM assembly. In addition, 
intracellular Aβ expression has been found to co-localize with apo B, the obligatory 
component of primordial CM molecules (Galloway et al. 2007, Galloway et al. 2008, 
Pallebage-Gamarallage et al. 2009). Production, secretion and transport of Aβ 
parallel those of a CM molecule and Aβ may be physiologically involved in 
metabolism of these lipoproteins. Accumulation of CMs after a high-fat meal (post 
prandial) has been shown to be increased in subjects with AD and cognitive decline 
(Boyt et al. 1999). Increased abundance of enterocytic Aβ induced by SFA and 
cholesterol feeding can translate into accumulation of Aβ-lipoproteins as a result of  
suppressive effects of SFA on the clearance of apo B-containing lipoproteins via 
reduced receptor expression (Jackson et al. 2006, Roberts et al. 2002, Hayes et al. 
1997). Collectively these studies suggest that a diet high in SFA may induce an 
increase in enterocytic Aβ production and secretion into blood and a lowered 
postprandial Aβ clearance rate leading to increased plasma Aβ-apo B-lipoproteins 
(TRL-Aβ). Increased plasma levels of Aβ-apo B-lipoproteins can translate into 




pathway of AD progression. The presence of apo B within amyloid plaques of 
human brain specimens (Namba et al. 1992) strongly supports this hypothesis.  
 
Section 3 explores the currently known mechanisms for Aβ transport across 
the BBB and examines the effects of SFA and cholesterol feeding on BBB integrity. 
Receptor mediated mechanisms for Aβ-TRL are currently unclear but may include 
transport via advanced glycosylation end products (RAGE) (Deane et al. 2003, 
Donhaue et al. 2006) and low-density-receptor related protein-1 (LRP1) (Deane et 
al. 2005, Deane et al. 2009, Donahue et al. 2006). In addition, the balance of RAGE 
relative to LRP1 may be important in regard to cerebral homeostasis as RAGE 
determines influx and LRP1 is more implicated in efflux of Aβ from the brain (Deane 
et al. 2009, Donahue et al. 2006, Deane et al. 2008, Ye et al. 2005).  
 
Indeed, the transport of plasma Aβ-TRL across the brain could also be 
severely affected if the BBB is compromised, allowing increased influx due to 
aberrations in endothelial cell and astrocyte functions Aβ has shown to have 
“vasoactive” effects on the BBB including damage to endothelial cells (Thomas et al. 
1997) and glial cells (George et al. 2004) resulting in a more permeable BBB. 
Chronic increases in plasma Aβ-TRL induced by high dietary SFA intake could 
therefore notionally damage cerebral blood vessels. One of the author’s own 
publications (described in article 4), shows that SFA feeding, compared to MUFA, 
PUFA and low-fat control diets showed marked leakage of the BBB, resulting in an 
increase in bi-directional transport of proteins across the BBB. Saturated fat feeding 
specifically decreased expression of junction protein occludin along with increases 
in influx of plasma apo B/IgG and increased efflux of S100β (Takechi et al. 2009). 
Although specific blood to brain influx of Aβ-TRL was not explored, cerebrovascular 
presence of apo B co-localised with Aβ indicates a high likelihood of Aβ-TRL 
transport. 
 
Section 4 explores other mechanisms by which SFA and cholesterol can 
contribute to BBB damage. As plasma Aβ results were not conclusive, the 
significance of SFA induced increased Aβ-TRL towards BBB integrity remains 
unclear at this point. In addition, SFA could damage BBB via other mechanisms. 
Increased exposure of BBB to fatty acids may induce greater levels of “lipotoxicity” 




MUFA and PUFA (Morgan 2009). Saturated fatty acids causes cell damage by 
altering endoplasmic reticulum processes including stress pathways (Diakogiannaki 
and Morgan 2008) and apoptosis (Morgan 2009). In addition, dietary fat induced 
lipid and protein oxidation has been reported (Studzinski et al. 2009, Ronti et al. 
2006). Membrane lipid composition has also been reported to be influenced by 
dietary fats via alteration of phospholipid levels and lipid rafts of neurons (Wassall 
and Stillwell 2009, Wassall et al. 2004, Diaz et al. 2002). Dietary fat may also 
influence changes in genetic expression of key Aβ regulatory proteins (Puskas et al. 
2003). In addition, SFA can dilate blood vessels and increased blood flow to the 
brain could foresee increased influx of Aβ into the brain. The effect of exogenous 
(dietary) cholesterol on BBB integrity was also reported (Ghribi et al. 2006). 
Research from our laboratory confirms that similar to SFA feeding, cholesterol 
feeding resulted in an increase in extravasation of apo B from blood to brain 
(Takechi et al. 2010b). Like SFA, intracellular cholesterol in higher than 
physiological concentrations, can also cause apoptosis by inducing ER and 
mitochondrial stress (Feng et al. 2003, Yao and Tabas 2001). However, cholesterol 
can also cause damage through different mechanisms to SFA including by reduction 
of Aβ production (Abad-Rodriguez et al. 2004, Pallebage-Gamarallage et al. 2009), 
increased secretion (Frears et al. 1999), increased binding to cell membrane and 
accelerated oligomerization (Subasinghe et al. 2003).  
 
In section 5, the author discusses one of the key proteins which influences 
risk of developing AD, apo E4, and discusses the implications of apo E isoforms on 
TRL metabolism and related toxic mechanisms. Compared to other isoforms, apo 
E4 increases risk of developing AD by 17 % or 43 % dependant on whether an 
individual contains one or two alleles (Strittmatter and Roses 1996). The 
involvement of Apo E4 in relation to AD has been reported (Boyt et al. 1999, 
Donahue and Johanson 2008, Fryer et al. 2005, Irizarry et al. 2004, LaDu et al. 
1997, Mahley and Huang 1999, Poirier et al. 1993, Strittmatter et al. 1993a, Refolo 
and Fillit 2004, Jofre-Monseny et al. 2008) and specifically in relation to Aβ 
metabolism, inflammation and oxidation, cholesterol homeostasis (see above), 
maintenance of BBB integrity and neuron function. Apolipoprotein E4 could be 
implicated in AD pathology via by facilitating the blood to brain transport and 
parenchyma deposition of Aβ-TRL. Apo E4 patients report “leaky” BBB compared to 




the influx of plasma Aβ-TRL (Deane et al. 2008). Physiologically, apo E influences 
the metabolism of TRL by binding to remnants (Mahley 1988, Hatters et al. 2006) 
and LDL receptor (Heeren et al. 2002, Krapp et al. 1996, Mamo et al. 1991). 
Compared to apo E3 and apo E2 which associates primarily with hepatically derived 
lipoproteins, apo E4 preferentially binds to TRL namely CMs (Saito et al. 2003) and 
comprises up to 65 % (total mass) of lipoproteins (Campos et al. 1992). The 
presence of apo E on Aβ-TRL can facilitate nucleation into brain matrices as apo E 
binds with high affinity to HSPG. In addition, apo E is an important ligand for the 
binding of TRL remnants to LRP1 which is implicated in cerebral Aβ efflux. 
However, cell culture studies indicate that the binding affinity of apo E isoforms to 
LRP is not different, indicating that efflux is relatively constant and efflux 
mechanisms may not be implicated in AD via this clearance route.   
 
Section 6 concludes important questions as to how cerebral Aβ-TRL can 
deposit into the brain by exploring the possible association between apo B and 
various proteoglycans found in extracellular matrices of the brain. Proteoglycans, 
the predominant component of extracellular matrices can bind to both apo B and 
apo E (Flood et al. 2002, Bame et al. 1997). Studies have found HSPG, a type of 
proteoglycan, to be involved in the formation of amyloid plaques (van Horssen et al. 
2003). Agrin, perlecan, biglycan and decorin are all proteoglycans which are 
capable of binding to apo B/apo E and these have been implicated in retention of 
lipoprotein (Iozzo 1998, Small et al. 1996, O’Brien et al. 1998, Olin et al. 2001). 
Recently, using immune-based approach, Lam V et al has recently studied the 
colocalization of Aβ-apo B with agrin, perlecan, biglycan and decorin in a transgenic 
(APP/PS1) mouse model of AD and found perlecan, biglycan and decorin to be co-
localized with apo B and Aβ in amyloid plaques (Fig 3) (Lam unpublished data). 
[Note the “unpublished data” was published in Neuroscience letters (Lam et al. 
2011)].  
 
Section 6 shows that apo B derived from the small intestine and/or liver is 
present in the brain and amyloid plaques, which leads to the question as to whether 
small intestine or liver derived Aβ-apo B contributes primarily to BBB damage. 
 
 Section 7 investigates the role of the small intestine and liver on apo B-




intestine produce apo B48 whereas in humans apo B48 is exclusively present on 
CMs (Isherwood et al. 1997, van Greevenbroek and de Bruin 1998) and also 
exclusively produced by enterocytes; apo B100 is produced mainly in hepatocytes. 
Apolipoprotein B48 is 48 % of the amino acid sequence of apo B100 and may 
influence differences in CM metabolism compared to apo B100-containing 
lipoproteins. Production and secretion of VLDL from hepatocytes is a constant 
process, whereas production and secretion of CMs from enterocytes is largely 
dependent on the availability of triglycerides and cholesterol from dietary sources. In 
clinical studies of AD subjects, post-prandial (or CM) clearance was reduced 
compared to controls, whereas fasting levels of apo B were not significantly 
changed (Mamo et al. 2008, Caramelli et al. 1999). The post absorptive state 
primarily indicates an increase in secretion of apo B48-CMs (small intestinal origin) 
whereas fasting apo B levels reflect liver-derived lipoproteins. Our studies have 
found that enterocytic Aβ is highly responsive to the availability of substrate from 
diet; fasting led to abolishment of expression, LF diet led to consistent Aβ 
expression and HF feeding led to significant increases in perinuclear Aβ expression. 
These observations are consistent with dietary fat influences on production of Aβ 
from APP with apo B. Saturated fat feeding induced increase in intestinal 
abundance of Aβ is indicative that intestinal apo B48 is more significantly influenced 
by diet than apo B48 of liver origin. However, this does not rule out hepatic 
contribution per se. The secretion of Aβ-lipoproteins from enterocytes represents the 
majority of the post-absorptive pool of plasma lipoproteins compared to greater apo 
B100/apo B48 when post-absorptive state is not reached. In addition, hydrolysis of 
apo B48-lipoproteins is carried out at a greater rate compared to hepatic-apo B100 
lipoproteins; CM remnants are cleared in about half the time compared to VLDL 
remnant clearance.  
 
The roles of apo B48 and apo B100 have been previously studied in 
atherosclerotic plaques. Although both apo B48 and apo B100 have been found to 
penetrate endothelial cells and reside in the tunica intima/media of vessels (Proctor 
et al. 2002, Olofsson and Boren 2005), apo B48 was substantially more invasive 
and was present in greater abundance (Pal et al. 2003). The increase in affinity of 
apo B48 to arterial wall was found to be specific and not dependent on plasma 
concentrations (Pal et al. 2003). Notionally the extent of BBB damage due to 




derived lipoproteins. Both apo B48 and apo B100 can bind HSPGs (Proctor and 
Mamo 2003), however it is not known if increased arterial retention of apo B48-
lipoproteins are also extended to greater retention by extracellular matrices of the 
brain. Currently, evidence suggests that intestinally derived Aβ contributes to 
greater plasma levels of apo B-containing lipoproteins postprandially, however liver 
derived lipoproteins are present in greater concentrations in blood throughout the 
majority of the day and therefore, their pathological contribution towards AD cannot 
be excluded. 
 
In summary, this review examines current research on AD and lipids and 
dietary fat metabolism and proposes a novel insight into the pathology of AD in 
relation to dietary fats. Dietary SFA can specifically increase risk of developing AD 
by increasing production and secretion of Aβ-lipoprotein. SFA induced damage to 
BBB integrity can lead to an increase in extravasation of plasma Aβ-apo B-
lipoproteins which have high affinity to brain HSPGs. Understanding the 
mechanisms underlying dietary fatty acids (and cholesterol) involvement in AD 
pathology could be of importance when considering strategies for the future 
prevention and maintenance of AD and cognitive decline and therapeutic 
interventions in AD, whether pharmacological, nutritional or lifestyle based should 
espouse both lipid metabolism and cerebrovascular integrity as key considerations 
in disease prevention and/or maintenance.  
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